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The frontal cortex serves as a crucial structure in the vertebrate CNS for the execution 
of certain forms of attention and memory. Of the various neurotransmitter pathways that 
innervate this area, it is the specific loss of cholinergic innervation that is detrimental to 
frontal cortex function, as demonstrated by the cognitive deficits observed in 
neurological disorders such as Alzheimers and schizophrenia.
Nicotinic acetylcholine receptors are activated by the endogenous ligand acetylcholine 
(ACh) and the major psychoactive component of tobacco, nicotine, and accordingly, the 
loss of cholinergic innervation to the frontal cortex and other regions of the CNS are the 
basis to which ‘nicotinic1 therapy may be beneficial to those neurological disorders 
where cholinergic function is compromised.
In order to examine nAChR function in the frontal cortex, pharmacological studies in 
Chapter 3 demonstrated that superfused frontal cortex synaptosomes (presynaptic 
terminals) could release [3H]D-aspartate (used as a surrogate for glutamate; see 
Chapter 3 section 1) when evoked by application of nAChR agonists. The nAChR- 
evoked release of [3H]D-aspartate described in Chapter 3 (section 3) was calcium- 
dependent, consistent with an exocytotic mechanism of release and could be blocked 
by both a7 and p2* nAChR specific antagonists, implying that the release of excitatory 
amino acids (EAA) is modulated by more than one subtype of nAChR. This work 
supersedes previous demonstrations of nAChR modulation of EAA release, which could 
only be observed when synaptosomes were stimulated with a combined depolarising 
and nicotinic stimulus (emulated in Chapter 3 section 2).
To corroborate the functional data described in Chapter 3, an immunocytochemical 
investigation (see Chapter 4) ascertained nAChR association with glutamatergic 
terminals and cell bodies of the frontal cortex. This investigation successfully described 
the co-association of a7 and P2* nAChRs with glutamatergic terminals as well as cell
bodies and provided a preliminary insight into the distribution of a7 nAChR within 
specific regions of the rat frontal cortex.
These studies provide a novel assessment of nAChR function and location with 
excitatory neurotransmitter systems in the frontal cortex by utilising direct methods of 
analysis.
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1.1. General introduction: Nicotinic receptors and memory
The major compound in tobacco that causes addiction to cigarette smoking is 
nicotine. With approximately 560 deaths recorded per hour worldwide, attributed to 
smoking related diseases, constant public awareness drives such as the recent 
increase in size of health warnings on tobacco product packaging (see Fig. 1.1), are 
intended to curb the general public from smoking.
Figure 1.1 Representative 
health warnings displayed on 
tobacco product packaging.
Implemented early in 2002, the 
UK government ruled that 
tobacco companies must conform 
to increasing the size of health 
warnings on tobacco products in 
a drive to increase social 
awareness of the high health 
risks associated with smoking.
However, the behavioural response to these public awareness initiatives are actually 
mediated by our ability to learn and memorise this information, a physiological 
mechanism that can actually be augmented by the very receptor that nicotine 
targets, the neuronal nicotinic acetycholine receptor (nAChR).
An overwhelming body of evidence supports the cognitive enhancing effects of 
nicotine in both acute and chronic treatment paradigms, displayed in both rat and 
human models (for review see Levin & Simon, 1998; Perry etal., 2001; Levin, 2002). 
In the clinical environment, inhibitors of acetylcholinesterase (e.g. donezepil, 
galantamine) that prevent the breakdown of the endogenous ligand for the nAChR, 
acetylcholine (ACh), are currently the only approved drugs for the treatment of 
cognitive dysfunction in patients diagnosed with Alzheimer’s disease (AD).
The development of a better understanding of the molecular interaction of nicotine or 
ACh with the nAChR and the observed behavioural responses requires an
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integration of studies that examine nAChR function at the gross anatomical level as 
well as at the cellular level. For instance, on the anatomical level it is a well-known 
assumption that the formation and storage of memory does not rely on a single 
entity within the brain, and instead relies on complex circuits that collect, distribute 
and retain information between certain regions of the brain. The distribution of 
nAChRs that have been implicated in memory are also subject to variation in 
location across the brain, yet further complicated by the ability to assemble into 
multiple subtypes and locate on various positions along a neuron.
In light of these challenging problems, investigations of the nAChR in the 
hippocampus, long known for its role in attention and memory (serving cognitive 
functions such as spatial memory and long term memory; For review see Jarrard, 
1995) have revealed evidence for nAChR receptor location, subtype specificity, cell 
type specificity and functional consequences of its activation, such as the induction 
of LTP; a cellular model of ‘memory’ where synapses are modified (synaptic 
plasticity) in either a strengthened (long term potentiation; LTP) or weakened (long 
term depression; LTD) manner, dependant upon the level of external stimulation, 
thereby increasing or decreasing the likelihood of conveying information through 
neuronal circuits respectively.
Few studies have examined the role of nAChR in the frontal cortex to the same 
degree as that of the hippocampus, perhaps hindered by the complex synaptic 
circuitry in this region compared to the well defined anatomical structure of the 
hippocampus. However, the frontal cortex is a critically important brain structure 
associated with attention and a crucial form of memory, working memory. This is a 
form of short-term memory that integrates moment-to-moment perceptions across 
time with that of archival information about past experiences, actions or knowledge.
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Therefore, the study of nAChRs in the frontal cortex, incorporating both anatomical 
and functional assessments, will contribute to the understanding of nAChR in certain 
aspects of cognition, extending to possible treatment strategies for complex 
cognitive deficits that accompany disorders such as AD, schizophrenia and 
Parkinson’s disease (PD).
1.1.2 nAChR and memory: Behavioural and Clinical observations
Behavioural and clinical studies that examine the effects of nAChR agonists in 
humans and experimental animals have clearly demonstrated improvements in 
particular cognitive tasks (for reviews see Newhouse et al., 1997; Levin & Simon, 
1998; Rusted etal., 2000; Levin, 2002).
1.1.3 Behavioural observations implicating nAChR function
One of the major challenges in assessing the function of nAChR with particular 
cognitive tasks using experimental animals is the discrimination between different 
forms of memory. As a general overview there are two types of memory, explicit and 
implicit memory, which are classified on the basis of how information is stored and 
recalled; explicit memory is a memory of facts or events that require a conscious 
effort for recollection whereas implicit memory is a memory that is recalled 
unconsciously, typically utilised in training reflexive motor or perceptual skills 
(Kandel, 2000). Of these two main forms of long-term memory (which can be divided 
into further classifications), explicit memory is exploited in cognitive tasks using 
experimental animals to differentiate between reference memory and working 
memory. Reference memory is utilised in tasks that present the same information 
(spatial or external cues) from previous tasks in order to carry out a repeated
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performance, whereas working memory is utilised on a short-term basis within a 
task. In a radial arm maze, nAChR agonists applied either acutely or chronically to 
rodents have been shown to effectively improve working memory and not reference 
memory, for example, in a 16-arm radial maze with 12 arms baited and 4 not, 
nAChR agonist treated rodents correctly entered baited arms only once (because 
arms were only baited once) throughout repeated tasks (working memory), whereas 
they failed to recall the same positioned unbaited arms between tasks (reference 
memory) (Levin eta l., 1996 & 1997). Application of nAChR antagonists was shown 
to inhibit this nAChR agonist induced improvement (Levin etal., 1997).
Studies have revealed that nAChR induced improvements to working memory 
involve the hippocampal formation; small ibotenic lesions of the hippocampus 
blocked nAChR improvements in working memory (Levin eta!., 1999). As well as 
this, nAChR antagonists injected into the prelimbic regions of the frontal cortex also 
reduced working memory tasks in rodents (Granon etal., 1995; For review see Levin 
& Simon, 1998). Indeed, prefrontal and frontal cortex association areas appear 
critical for the execution of working memory (For review see Fuster, 2001) and the 
ability for it to be processed through to higher modalities for long-term storage 
(Buckner et al., 1999). Three component systems are crucial to the execution and 
functioning of working memory in humans: an attentional system that collects and 
regulates the information flow in the environment to the other two component 
systems that contain memory on a temporary basis; the articulatory loop for 
language and auditory events and the visuospatial sketch pad for vision and action.
Attempts have been made to ascertain the nAChR subtypes that mediate nicotinic 
effects on memory in rodents. However, these assessments are limited in both the
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availability of sub-type specific ligands for the array of nAChR subtypes, as well as 
consideration of spatial concentration gradients generated from general or local 
injection of nAChR ligands; depending on the concentration of ligand applied, 
determination of specific or non-specific effects may be compromised. Nonetheless, 
such studies have inferred that a7 and a4B2* nAChR are involved with working 
memory function (for review see Levin, 2002), particularly when examined in the 
hippocampus. In the frontal cortex however, behavioural pharmacological evidence 
for subtype specific nAChR involvement with working memory is less clear, with to 
date only one behavioural study that implicated a4p2* nAChR (Granon etal., 1995). 
Instead, much of the information for the determination of nAChR subtypes in the 
frontal cortex has been obtained from other investigative approaches, such as 
nAChR ligand binding studies or electrophysiological assessment of nAChR 
function. These studies have aimed to relate the integration of nAChR function in 
frontal cortex synaptic circuitry to the gross behavioural functions of nAChR, such as 
working memory.
1.1.4 Clinical observations Implicating nAChR function
With respect to clinical observations, nAChR have been implicated in the altered 
state of cognitive function in neurological disorders such as AD, Parkinson’s disease 
(PD) and schizophrenia. As well as this, evidence also exists for their possible 
involvement in neurological diseases such as attention deficit hyperactivity disorder 
(ADHD) and Tourette’s syndrome.
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1.1.4.1 Alzheimers disease and nAChRs
Of persons over 65 years of age, AD is the cause for almost 60% of different forms 
of mental deterioration in elderly people, affecting 15 million people worldwide 
(Francis et al., 1999). A number of neurochemical deficits have been described in 
AD, in particular, the decreased function of the cholinergic system in AD patients, 
contributing to the ‘Cholinergic hypothesis’ of AD. It was proposed that degeneration 
of cholinergic neurons in the basal forebrain and the associated loss of cholinergic 
neurotransmission in the cerebral cortex and other areas of the brain, contributed 
significantly to the deterioration of cognitive function seen in patients with AD (Bartus 
etal., 1982).
The majority of evidence associating nAChR with AD involves the loss of cortical 
nAChR binding in AD subjects compared to age-matched controls (Nordberg & 
Windblad, 1986; Nordberg etal., 1988; Whitehouse etal., 1986 & 1988; Warpman et 
al., 1995; For review see Perry et al., 2001). The hippocampus, entorhinal cortex 
and frontal cortex are particularly vulnerable to loss of nAChR, particularly a7 and 
cx4 subunit containing nAChR. Interestingly, reduced nAChR ligand binding patterns 
but not mRNA levels for a7 and a4 subunit containing nAChR in AD brain indicate a 
presynaptic locus for loss of nAChR in the frontal cortex, hippocampus and other 
regions of the temporal cortex (for review see Nordberg, 2001). Presynaptic loss of 
nAChRs is likely to be a direct consequence from the loss of cholinergic terminals in 
the forebrain areas in AD as well as the loss of non-cholinergic cholinoceptive 
terminals such as glutamatergic terminals of pyramidal cells, cells that are primarily 
affected in the neuropathology of AD. nAChRs located at presynaptic terminals of 
pyramidal cells can modulate the release of EAA (see section 1.7 below) and 
therefore it is possible that cholinomimetic drugs may provide an additional
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therapeutic advantage, in addition to increasing ACh levels, (i.e. improvement of 
glutamatergic transmission, compromised in AD subjects, via nAChR mediated 
release of EAA from glutamatergic terminals).
Improvements in attentional and cognitive tasks have been demonstrated in patients 
clinically diagnosed with AD who have received nicotine by specific injection regimes 
(Newhouse et al., 1988, 1996) or transdermal nicotine-infused patches (Wilson et 
al., 1995; Levin & Rezvani, 2002; For review see Newhouse & Kelton, 2000). 
However, it is of concern whether the cognitive improvements are a manifestation of 
improved attentional aspects to specific tasks (see Lawrence & Sahakian, 1995). 
Other nAChR ligands have been assessed (e.g. ABT-418; Potter et al., 1999) for 
their effects on cognitive function but to date no selective nAChR subtype ligands or 
indeed nAChR ligands alone have been used in the treatment of AD.
1.1.4.2 Schizophrenia and nAChRs
The most prominent clinical observation supportive of nAChR association with 
schizophrenia is that of the prevalence of smoking in schizophrenic patients; 
epidemiological studies have shown that approximately 90% of the schizophrenic 
population smoke compared to the 30% of the ‘general’ population (Picciotto et al., 
2000). The major hypothesis for such a high prevalence of smoking in 
schizophrenics is believed to be a form of ‘self medication’, which may ameliorate 
attentional and psychological affects of the condition or arising from anti-psychotic 
drug therapy. Indeed, smoking in schizophrenics improves abnormal smooth pursuit 
eye movements (Olincy et al., 1998) as well as normalise P50 auditory evoked 
responses; a measure of brain wave responses when patients are exposed to 
auditory stimuli, which lack inhibitory control in schizophrenics but not normal
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patients (Waldo et al., 1991). In this latter behavioural observation, a7 nAChR 
located on hippocampal interneurons are believed to be implicated: (1) These 
neurones are believed to provide the inhibitory control to the response by mediating 
incoming information from basal forebrain cholinergic neurons (Freedman et al., 
1993) (2) Improvement with nicotine in the above response can be blocked by a- 
bungarotoxin (a-Bgt; an a7 selective antagonist) (Luntz-Leybman et al., 1992). (3) 
Linkage between a dinucleotide polymorphism on chromosome 15q13-14 which 
contains the a7 nAChR gene CHRNA7 and deficient auditory gating (Freedman et 
al., 1997 & 2001). (4) Binding studies also show a marked decrease of 
[125l]bungarotoxin (a7 nAChR) labelling in the hippocampal formation of 
schizophrenic post mortem brain as well as in the cingulate cortex (Freedman eta!., 
1995; Marutle et al., 2001). However, an up-regulation of [3H]epibatidine (possibly 
a4p2* nAChR) binding in temporal cortex of schizophrenics has been described, 
suggesting involvement of two different nicotinic receptor mechanisms (Marutle et 
al., 2001).
As well as attentional improvements, Levin eta l. (1996) demonstrated improvement 
in a variety of cognitive tasks in schizophrenics subjected to nicotine administration, 
that corroborates other reports of impaired cognition in schizophrenics (Hyde et al., 
1994; Goldstein etal., 1998).
Schizophrenia is characterised symptomatically into positive and negative symptoms 
(Positive; psychosis, delusions and hallucinations. Negative; cognitive impairment, 
and impaired sensory processing). Some of these symptoms are exacerbated with 
respect to existing treatment strategies for schizophrenia such as haloperidol, but 
interestingly, haloperidol increases smoking behaviour (McEvoy et al., 1995). The 
majority of beneficial effects of nicotine specifically improve negative symptoms and
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it is believed that nAChR modulation of dopaminergic and glutamatergic 
neurotransmission, particularly in the frontal cortex provide the means to which 
nicotine exerts its affect on these negative symptoms (Dalack et al., 1998). Again, 
presynaptic nAChR could be pivotal in the modulation of these neurotransmitter 
systems, as well as others (ACh, GABA; for review see Wonnacott, 1997), and 
therefore the involvement of high and low affinity nAChR in schizophrenia may 
influence the hypofunctionality of dopaminergic and glutamatergic systems as well 
as improve the aberrant inhibitory modulation as described in schizophrenia 
(Freedman etal., 2000).
1.1.4.3 Parkinson’s disease and nAChRs
In addition to AD and schizophrenia, changes in CNS cholinergic systems have also 
been identified in PD, where a loss of cholinergic basal forebrain nuclei has been 
described in PD post mortem brain tissue (for review see Perry etal., 1995). Indeed 
the degree of dementia is believed to be directly proportional to the loss of cortical 
cholinergic markers in PD patients (Perry et al., 1995). Reduced fronto-temporal 
regional activity in PD patients (measured using cerebral blood flow markers) 
undertaking cognitive tasks again highlights the importance of basal forebrain 
cholinergic innervation to this area in aspects of attentional and memory processing 
(Reid et al., 1990). Similar to the improvement of cognitive tasks in AD and 
schizophrenia, nicotine treatment to PD patients also improves cognition (Kelton et 
al., 2000) and therefore although PD, schizophrenia and AD have different 
underlying cellular and macropathology, it is likely that the loss of cholinergic 
innervation and lack of nAChR function are a shared feature in mechanisms
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contributing to altered attentional and cognitive performance in these diseases 
(Newhouse & Kelton, 2000).
It is therefore apparent that cholinergic innervation through to hippocampal and 
cortical areas of the brain are crucial for memory formation as well as certain 
attentional aspects of cognitive tasks. Supported by lesion experiments and 
consequent decrements in nAChR binding as well as the use of nAChR antagonists, 
the nAChR appears heavily implicated in the flow of cholinergic information arriving 
in these areas of the brain (for review see Sarter etal., 2003). However, these gross 
anatomical studies convey little information of nAChR subtype specificity mediating 
these physiologies or of the intricate synaptic circuitry in which the nAChR may be 
located. In order to address these issues, a more detailed investigative approach is 
required at the cellular level of anatomy, to which this thesis in part, aims to 
elucidate.
1.2 nAChR subtypes and expression
1.2.1 nAChR heterogeneity in the vertebrate nervous system
From its historical experimental beginnings as a ‘receptive substance’ identified at 
the neuromuscular junction (Langley, 1905) the continued investigation of this 
substance in various regions of the vertebrate nervous system, eventually classified 
as a receptor (for review of nAChR history see Lukas et al., 1999), lead to the 
identification of multiple subtypes of nAChR, composed of a pentameric assembly of 
different subunits in a region specific manner. The earliest studies of nAChR subunit 
composition at the site of the neuromuscular junction were aided by the identification 
of an analogous nAChR found in the Torpedo Electroplax; this species provided an
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abundant and accessible source of nAChR for biochemical studies. These studies 
revealed a difference in composition between those nAChRs at the neuromuscular 
junction and those found within the central nervous system, the major difference 
being the inclusion of Sand s/y subunits in the neuromuscular junction nAChR 
compared to the nAChR found in the vertebrate brain that is composed solely of a 
and p subunits (heteromeric), or a subunits alone (homomeric). Also, the 
neuromuscular nAChR p subunit shares little homology to the vertebrate brain 
nAChR p subunit and is sometimes referred to as non-a subunit (See McGehee & 
Role, 1995).
1.2.2 Different neuronal populations of nAChR within the brain
Further heterogeneity of nAChR within the CNS was suggested from 
autoradiographical studies of neuronal nAChR distribution. A number of nAChR 
ligands, examined in the neuromuscular junction and shown to have an affect on 
neurotransmission, also showed binding properties to rodent brain membranes 
(Nordberg & Larsson, 1980; Schmidt & Freeman, 1980). However on comparison of 
radiolabelled nAChR ligands in rat brain sections by autoradiography, a distribution 
difference was noted between specific ligands; a-bungarotoxin (a-Bgt; a snake toxin 
from the species Bungarus Multicinctus), originally an important tool for the 
identification of the ligand-binding domain and structure of the neuromuscular 
nAChR (Changeux e ta l.,  1970; Raftery etal., 1980), displayed aberrant properties 
of binding to rat and mouse brain preparations in its iodinated form ([125l]a-Bgt) 
compared to that of tritiated nicotine or ACh ([3H]Nicotine, [3H]ACh) (Clarke et al., 
1985). Radiolabelled nicotine and ACh show very similar distribution patterns (as 
well as binding affinities to membrane preparations) in the rat brain when examined
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by autoradiography and are believed to label the same nAChR (Schwartz et al., 
1982; Clarke et al., 1985). However, at the time, controversy surrounded the 
significance of a-Bgt binding in the CNS: the large size of this toxin (and consequent 
concerns over it’s ability to access synaptic receptors) and its slow onset of binding 
and inhibition added to the debate. Further, this toxin displayed no antagonistic 
affects to the central actions of the cholinergic system or nicotine, nor displacing 
bound [3H]Nicotine (unless at very high concentrations) (Romano & Goldstein, 1980; 
Schmidt & Freeman, 1980; Clarke et al., 1985). In fact, it appears that if not for one 
experiment where a-Bgt inhibited the ACh activation of a pineal enzyme in the 
suprachiasmatic nucleus (mimicking the light induced effects on this enzyme) then 
CNS a-Bgt sensitive nAChRs may have been forever obscured (Zatz & Brownstein, 
1981; See McGehee & Role, 1995). Yet consistent reports of this toxin’s ability to 
bind to rodent brain sections, producing a labelling pattern different to radiolabelled 
nicotine or ACh (Marks & Collins, 1982; Schwartz et al., 1982; Costa & Murphy, 
1984) supported the notion of more than one nAChR subtype in the CNS. By the 
mid-1980’s it was generally agreed that [3H]Nicotine and [125l]a-Bgt bind to two 
different populations of nAChR, coining the term High and Low affinity nAChRs 
(Wonnacott, 1986), the latter representing receptors that bind a-Bgt with high affinity.
1.2.3 Further nAChR heterogeneity in the vertebrate CNS
With the advent of molecular cloning techniques, evidence of nAChR subunit 
heterogeneity amassed, where screening of various brain and PC12 cDNA libraries 
revealed a number of different subunits (for review see Deneris etal., 1991), that are 
categorised into two subfamilies, the a-type and p-type; the difference based on the 
presence of conserved cysteine residues (Cys 192 and 193) on a-type but not p-
13
type subunits (Karlin, 1993; Karlin and Akabas, 1995). To date, there are thought to 
be at least 9 subtypes of a-type subunits (a2-a10) and 3 p-type subunits (p2-p4) 
(Boulter etal., 1986; Goldman etal., 1987; Deneris etal., 1988 & 1989; Wada etal., 
1988; Boulter et al., 1990; Couturier et al., 1990; Elgohoyen etal., 1994 & 2001). 
With this development, came the next hurdle of identifying functional nAChRs from 
the assembly of these identified subunits - what could be thousands of possible 
permutations. However, co-expression of specific subunits into oocytes of Xenopus 
laevis, (a common vector for the expression and assessment of function of ligand 
gated ion channels) coupled with electrophysiological recordings, revealed that only 
a small number of nAChR subtypes were functional in terms of activation of ionic 
currents on application of nAChR agonists. It was these experiments that finally 
highlighted the differences between the a-Bgt binding nAChRs to that of mainstream 
nicotine-binding nAChRs; nAChRs that bind a-Bgt consist of a homologous 
pentameric assembly of a7 subunits only (however see Anand etal., 1993; Palma et 
al., 1999; Khiroug etal., 2002), are rapidly desensitising, display a high permeability 
to Ca2+ than other nAChRs and are highly sensitive to blockade by a-Bgt (Couturier 
etal., 1990; Bertrand etal., 1992; Seguela etal., 1993; Gopalokrishnan etal., 1995; 
Chen & Patrick, 1997). Similar to a7 nAChR, homomeric nAChRs have also been 
described for a8 and a9 subunit expression in Xenopus oocytes, however to date 
the homomeric/heteromeric a8 nAChR is confined to the chick brain (Keyser et al., 
1993) whereas the a9 nAChR has only been identified in the rat and human 
cochlear hair cells and rat dorsal root ganglion cells and also displays unusual 
pharmacology in the form of responses to both muscuranic and nicotinic agonists 
(Elgohoyen et al., 1994). a10 nAChR subunit shares a high homology with a9 
(Sgard et al., 2002) but does not form a functional nAChR when expressed alone in
14
Xenopus oocytes. Recent work has demonstrated a possible a9 and a10 heteromer 
in the rat dorsal root ganglion (Lips etal., 2002).
Receptor
Subtype Subunits Subunit combinations
Muscle-type a1, 01, 5, e, y a1 ,01, y, 6 (embryonic muscle) 
a1 ,01, e, 5 (Adult muscle)
Neuronal 
(a-Bgt insensitive)
a2-a6, 02-04 a2 02 (Xenopus oocyte) 
a2 04 (Xenopus oocyte) 
a3 02 (Xenopus oocyte) 
a3 04 (Xenopus oocyte) 
a4 02 (Xenopus oocyte) 
a4 04 (Xenopus oocyte) 
a6 02 (HEK cells)
a6 04 (Xenopus oocyte, Chick Retina)
a 2a5 02 (Chick optic lobe)
a3 a5 02 (Xenopus oocyte)
a3 a5 04 (Xenopus oocyte)
a3a 602 (Xenopus oocyte)
a6 03 04 (Xenopus oocyte)
a3a50204 (Xenopus oocyte)
a3a5 0204 (Chick ciliary ganglion
a3a60304 (Xenopus oocyte, Chick ciliary ganglion)




a7, a8 a7 (Xenopus oocyte)
a8 (Xenopus oocyte, Chick optic lobe)
a702 (Xenopus oocyte)
a703 (Xenopus oocyte))
a7a8 (Chick retina, Xenopus oocyte)
Other (sensory 
epethelia)
a9,a10 a9 (rat cochlear hair cells, Xenopus oocyte) 
a9a10 (rat cochlear hair cells, Xenopus oocyte)
Table 1.1. Summary of nAChR subunit combinations. To date nAChRs have been 
categorised into two main groups, muscle type and neuronal type nAChRs. Vertebrate 
nAChRs in the hair cells of sensory epithelia do not fall into this classification. Subunit 
composition of nAChRs have been identified from heterologous expression studies of 
defined subunit combination and assessed for function in electrophysiological studies or 
defined from immunoprecipitation studies of native nAChR. Adapted from Millar. (2003)
Functional nAChR have been described for the heterologous pairwise combinations 
of a2, 3 and 4 subunits with 02 or 04 subunits (for review see McGehee & Role, 
1995). In the brain, heterologous nAChRs are believed to arrange in the general
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stoichiometry (2a, 3p) (for review see Galzi & Changeux, 1995), with, in many 
cases, more than one a-type subunit per pentamer (Conroy et al., 1992; Vernaiis et 
al., 1993; Wang etal., 1996).
Most recently, a study investigating the most prevalent nAChR subtype in the 
mammalian brain, the a4p2 subtype, described that different stoichiometries of a4 
and p2 subunits co-expressed in Xenopus oocytes (a4(2)p2(3) or a4(3)p2(2) enabled by 
covalent linking of subunits) display marked differences in both ACh induced 
currents and sensitivity (Zhou et al., 2003). A summary of heterologous 
combinations of a and p nAChR subunits is given in Table 1.1 (for review see Millar, 
2003), where evidence is derived from heterologous expression studies of nAChR 
with defined subunit combinations or derived from studies of native nAChR to 
support nAChR subunit composition.
Developments made in revealing nAChR assembly and function in expression 
systems underlie our present understanding of native nAChR, however, many of the 
proposed combinations fail to match the physiological and pharmacological 
properties of native nAChR measured in neurons. For example, native a7 nAChRs 
have been described to desensitise more slowly and have a decreased channel 
conductance compared to recombinant homomeric a7 nAChRs, despite showing 
remarkably similar pharmacology (Shao & Yakel, 2000; Sudweeks & Yakel, 2000).
1.3 Distribution and localisation of nAChR with respect to cognition
The lack of subtype selective pharmacological tools for the nAChR has hampered 
the precise pharmacological definition of nAChR subtypes involved with cognition 
(Lloyd & Williams, 2000). However, the nAChR antagonist sensitivities of particular
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cognitive function tests as well as those of electrophysiological assessment of 
nAChRs in regions of the brain highly associated with cognitive function suggest that 
both the a7* and p2* containing nAChR are implicated in cognitive functions (For 
review of cognitive tests see Levin & Simon, 1998) (a7* represents native a7 
nAChRs that are possibly heteromeric in nAChR subunit composition).
The distribution of these specific subunits in the brain have been assessed using a 
variety of techniques that either detect the presence of individual subunits in their 
encoded form such as in-situ hybridisation or their native form such as 
immunohistochemistry. These two techniques show only distribution of subunits and 
inform little about the whole nAChR construct, in the former technique, only the 
encoded information for the nAChR subunits is detected and therefore does not 
reveal the amount of nAChR protein expressed.
Detection of whole nAChR subtypes in brain homogenates or tissue sections is 
characterised using autoradiographical analysis of tritiated nAChR ligands, however, 
only [3H]Nicotine and [125l]bungarotoxin reveal nAChR subtype specific information 
in the form of their relative selectivity for a4p2* and a7* containing nAChRs. 
Nonetheless, nAChR distribution from ligand binding studies has been demonstrated 
across a wide range of brain regions in chick, mouse, rat, primate and human brain 
(Clarke et al., 1985; Pauly et al., 1991 ;Court & Clementi, 1995; Han et al., 2003). 
With respect to a7 distribution in the rat brain (the animal model used in this thesis) 
investigations using the a7 selective ligands [125l]a-Bgt and [3H]methyllycaconitine 
([3H]MLA; however see Mogg etal., 2002 for its questioned specificity to a7 nAChR; 
Segal et al., 1978; Clarke et al., 1985; Fuchs, 1989; Davies et al., 1999; Whiteaker 
etal., 1999) and a7 transcript riboprobes (Seguela etal., 1993; Dominguez del Toro 
et al., 1994) have all described similar distribution of the a7 nAChR. Radioligand
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binding of these ligands is highest in the cerebral cortex, hypothalamus, inferior 
colliculus and in certain brain stem nuclei. In particular, layers I and VI of the 
cerebral cortex (extending to the frontal cortex) and the CA3 region of the 
hippocampus are particularly dense with labelling. Other regions displaying 
moderate labelling of tritiated a7 selective ligands include certain areas of the pons 
and medulla, medial septal nucleus and amygdala (basolateral and medial nuclei). 
The thalamus and striatum are relatively devoid of labelling, although weak in-situ 
hybridisation signals were demonstrated (Seguela et al., 1993) reflecting the 
differences in these two methods of nAChR transcription and ultimate protein 
expression. This corroborates the work of Fuchs (1989) who reported transitory 
expression of a-Bgt binding sites in primary sensory areas (i.e. frontal cortex) of 
thalamic input zones suggesting a particular role of these receptors in cortical 
connectivity.
With respect to p2 nAChR distribution, nAChRs containing this subunit are very 
widespread; perhaps a reflection of the number of different types of heterologous 
nAChR subtypes containing this subunit. The similar labelling patterns of tritiated 
ligands nicotine and acetylcholine, i.e. high-affinity nAChR agonist binding sites, are 
believed to encompass those nAChRs containing this subunit due to vast similarities 
observed with the immunocytochemistry and in-situ hybridisation studies using 
antibodies to this subunit (Whiting & Lindstrom, 1986; Wada et al., 1989; Hill et al., 
1993). These regions include the interpeduncular nucleus, all thalamic nuclei except 
posterior and intralaminar, superior colliculus and medial (but not lateral) habenula, 
substantia nigra pars compacta, ventral tegmental area, molecular dentate gyrus, 
presubiculum and cerebral cortex (in this instance, particularly layers III and IV,
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extending to the frontal cortex). Moderate labelling was demonstrated in the 
neostriatum, ventral striatum, dorsal tegmental nucleus and cerebellum.
There is little indication of vast differences between radioligand binding and in-situ or 
immunohistochemistry techniques, suggesting the predominantly somato-dendritic 
nature of p2 containing nAChR location, however, slight discrepancies in 
immunohistochemistry studies have revealed fine and diffuse staining in particular 
regions of the brain (e.g. hippocampal molecular layer and striatum; Hill et al., 1993, 
Jones et a/., 2001) that may represent terminal field staining. Indeed electron 
microscope analysis of p2 nAChR in rat nigrostriatal dopaminergic neurones reveal 
the presynaptic location of the p2 subunit, lending support to the dendritic and 
axonal transport of p2 containing nAChR (Swanson etal., 1987; Jones etal., 2001).
It is therefore apparent that common place to the distribution of a7* and p2* 
subunits, implicated in cognition, are those brain loci common to cognition, namely 
the hippocampal region and frontal cortex regions of the cerebral cortex, in the latter 
an apparent dissociation between the two sets of layers exists; I and VI for a7 and 
lll-V for p2 nAChR (Wada et al., 1989, Clarke et al., 1985; Hill et al., 1993; Seguela 
et al., 1993).
1.4 nAChRs and Acetycholine
1.4.1 A brief history
Acetylcholine (ACh) is arguably one of the founding substances of modern day 
pharmacology. In the earliest of case studies and unbeknown to the investigator, 
ACh served as one of the first ‘pharmacological tools’ used in the understanding of 
blood pressure control (Hunt, 1895), cardiac function (Loewi, 1926) and
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neuromuscular transmission. It was not until 1936 from work by Dale and colleagues 
that ACh was identified as a neurotransmitter at the skeletal neuromuscular junction. 
Dale himself dismissed the term ‘receptors’ as sophistry rather than science, yet the 
physiological effects of ACh implored the need for defining a ‘receptive substance’ 
that could turn a chemical signal into a physiological consequence. With definitive 
evidence of ACh acting on neuronal nAChRs (for review see Changeux & Edelstein., 
1998), the path was then set to then integrate native nAChR function with its 
endogenous neurotransmitter.
1.4.2 ACh synthesis and cholinergic pathways in the rat CNS
Acetylcholine is synthesised in cholinergic neurons from choline and acetyl- 
coenzyme A by choline acetylcholine transferase and is packaged into synaptic 
vesicles by vesicular acetylcholine transporters (VAChT) (Eiden, 1998; for review 
see Parsons et al., 1993). Therefore on exocytosis of these packed vesicles (ACh 
concentration approximately 100 mM), ACh synthesis is maintained by active 
transport of choline (from its subsequent breakdown in the synapse by 
acetylcholinesterase) by a high affinity choline transporter (CHT). Blockade of this 
transporter ultimately abolishes ACh production and release suggesting a 
presynaptic location of this transporter (Haga & Noda, 1973; Simon & Kuhar, 1976; 
Mai re & Wurtman, 1985; Ferguson etal., 2003).
The utilisation of antibodies and riboprobes to the transporter proteins and mRNA of 
CHT or VAChT have revealed the distribution of cholinergic neurons and their 
afferent pathways (Woolf, 1991; Descarries et al., 1997; Schafer et al., 1998). The 
broad distribution of these cholinergic pathways in the rat brain is summarised in Fig. 
1.2. Mesulam and colleagues (1983), devised nomenclature that grouped the major
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cholinergic cell groups providing long projection systems of the rat brain, termed ‘Ch’ 
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Figure 1.2. Sagital section through rat depicting the major cholinergic pathways. Of
particular importance are the forebrain projection pathways originating from the Nucleus 
basalis and the medial septal and diagonal band nuclei supplying the cortex, hippocampal 
areas, amygdala and olfactory bulb with cholinergic innervation. (Adapted from Feldman, 
Meyer & Quenzer. 1997. Principles of Neuropsychopharmacology. Chapter 7.)
The medial septum (Ch1 group), the nuclei of the vertical and horizontal limbs of the 
diagonal band (Ch2 and Ch3 groups) and the nucleus basalis of Meynert (Ch4 
group), make up the basal forebrain cholinergic groups, supplying afferent 
cholinergic connections to the olfactory regions, entire cerebral cortex (incorporating 
frontal, parietal, temporal and visual cortices), hippocampal and amygdala regions. 
One other cholinergic projection from the medial septum to the second major area of 
cholinergic cell bodies in the diencephalon, the medial habenula, makes up the Ch7 
group which together, project to the interpeduncular nucleus. A major cholinergic set 
of interconnections between the telencephalon and the diencephalon are the lateral 
dorsal tegmental nuclei and pedunculopontine cholinergic projections (Ch5 and Ch6
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groups). These pathways essentially divide into two, that terminate in the thalamus 
and basal forebrain areas and are believed to be associated with arousal, attention 
and memory, linking the responsiveness of cortical and thalamic neurons to the 
sensory stimuli collated from the periphery, collectively known as the ascending 
arousal system. Other projections from the Ch6 group link this area with the brain 
stem reticular formation (Mesulam et al., 1983; Woolf et al., 1991; Schafer et al., 
1998).
The main projection fields of cholinergic cell groups from the basal forebrain areas 
are very widespread and encompasses an extrinsic innervation to practically all 
layers of the cortex and hippocampus and amygdala (Woolf, 1991; Schafer et al., 
1998), however an intrinsic level of innervation also exists, revealed by riboprobe 
hybridisation in cell bodies of these regions, suggesting the possible existence of 
cholinergic interneurons. Cholinergic interneurons have been well characterised in 
the striatum (for review see Calabresi et al., 2000) and are predominantly innervated 
by glutamatergic projections from the cortex and thalamus. Frontal cortex areas also 
display the presence of these giant neurones (Kawaguchi & Kondo, 2002), although 
the functional integration of these neurons into synaptic circuitry presently lacks 
detail.
1.4.2.1 ACh and diffuse neurotransmission
Despite this large degree of cholinergic innervation in the CNS an extremely 
important observation made from an array of electron microscope studies in various 
regions of the rat brain revealed that at the very most, less than 10% of all ACh 
nerve terminals (encompassing axon terminals, boutons or variscosities) made 
junctional membrane specialisations i.e. hallmarks of synapses (Umbriaco et al., 
1994, 1995; For review see Descarries et al., 1997). In fact the majority of ACh
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terminals are ‘non-synaptic’ and thus support a prevailing view that the majority of 
ACh release might diffuse into the extracellular space over a large spatial and 
temporal domain to exert its influence.
It is therefore the current opinion that, at least in densely innervated areas of the 
CNS, an ambient level of ACh is maintained that contributes to the physiological and 
physiopathological aspects of cholinergic transmission, supported by the inference 
that AChesterase does not serve the same level of ACh breakdown in neuro­
neuronal synaptic transmission as it does at the neuromuscular junction (Constant et 
al., 1996; Descarries etal., 1997; Sarter & Bruno, 1999). For instance, microdialysis 
studies have revealed that ACh efflux is uniform across cortical areas rather than 
cortical area specific, modality specific or task specific (Sarter & Bruno, 1997). 
However at the cellular level, inferred from electrophysiological studies, the ACh 
mediated enhancement of selective synaptic effects appears to be with the 
integration of other converging afferent inputs from other neurotransmitter systems.
In summary, the presence of ACh and cholinergic cell groups appears crucial in the 
processing of incoming sensory information from the reticular formation, through to 
the basal forebrain areas, where its detection, selection and discrimination are 
processed into forms of higher cognitive functions such as memory and retrieval. In 
fact, aberrations of this cortical cholinergic neuron input contribute to some of the 
symptoms of cognitive and behavioural symptoms of neuropsychiatric and 
neuropathological disease as outlined above (section 1.1.4; for review see Perry et 
al., 1999; Sarter etal., 2003).
The diffuse nature of the cholinergic system and indeed the diffuse release of ACh 
itself create an inherent problem with respect to the receptors that mediate its
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actions, particularly fast actions exerted by ACh in the CNS. In fact one of the 
leading and unanswered questions in nAChR research is the effect of diffuse volume 
transmission of ACh on nAChR function, where to date, only the effects of direct 
synaptic contact and the application of exogenous nAChR agonists (including ACh) 
have been examined (See McGehee, 2002). What could be the role of such a 
diffuse transmission? One particularly interesting example is the induction of fast 
(so-called gamma) oscillations (mainly 30-40 Hz) in both the thalamus and the 
cortex that are characteristic of brain-activated states in particular attention-requiring 
tasks (the beginning aspects of information processing). This phenomenon was 
attributed to a generalised responsiveness of neuronal collectivities from various 
sources that depend on a diffuse rather than synaptic specific focused transmission 
(Steriade etal., 1991). Therefore a plausible physiological role for the nAChR is that 
in these heightened states of cholinergic activity, nAChR transduces this information 
into an increased excitability of the receiving neuronal populations, nAChR could 
serve to modulate the processing of the incoming information by way of increasing 
the synaptic strength of the connections that contribute to these gamma oscillations, 
at either a presynaptic or postsynaptic locus.
1.5 Structural determinants of the nAChR and nAChR ligand binding
To bind and transduce the chemical signal of ACh into a functional application, the 
nAChR relies on certain elements of its structure.
In gross anatomy, the nAChR is a large glycoprotein complex (approximately 290 
kDa) formed from five membrane spanning subunits. Each of the subunits exhibit
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significantly high amino acid sequence homology (Le Novere & Changeux, 1995), 















Figure 1.3. nAChR subunit structure. Membrane topology of the individual nAChR 
subunit, revealing the extracellular N and C-terminus, membrane spanning domains M1-4, 
the agonist binding domain and cysteine loop (characteristic of the ligand gated ion 
channel superfamily and the large variable sequence loop linking M3 and M4 that contains 
a number of phosphorylation sites.
Each subunit, shares the generalised features of: (1) A signal peptide removed from 
the polypeptide chain during translocation, (2) a large, conserved hydrophilic N- 
terminal domain containing one or more glycoslylation sites, a 15 residue cysteine 
loop and a portion of the ACh binding site, (3) A compact hydrophobic domain split 
into three segments of 19-27 amino acids termed M1, M3 and M4, (4) An ampipathic 
a-helical M2 domain that lines the channel of the receptor, (5) A large and variable 
hydrophilic intracellular loop (between 100-200 amino acids in length), found 
between M3 and M4 containing consensus serine/threonine and tyrosine 
phosphorylation sites and lastly (6) a small hydrophilic C-terminal segment of around
10-20 amino acids (see Fig. 1.3; Galzi & Changeux, 1995; For review see Corringer 
etal., 2000).
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The secondary and tertiary elements of nAChR structure (defined from the Torpedo 
electrolax nAChR) are still disputed (Hucho et al., 1996; Corringer et al., 2000); 
structural analysis using Fourier Transform infrared (FTIR) and circular dichroism 
(CD) suggest different percentages of a-helices and (3-sheet conformations of the 
nAChR, although these methods agree that the majority of the receptor is composed 




Figure 1.4. Tertiary and quaternary structures of the nAChR from the Torpedo 
electrolax. (A) and (B), cross sections of the nAChR in the middle of the membrane 
revealing the closed and open states of the nAChR gate, lined by the M2 membrane 
spanning segments of each subunit around a fivefold axis of pseudosymmetry (Unwin, 
2003). (C) Three dimensional reconstruction of the nAChR based on the electron 
micrograph analysis of the Torpedo electrolax nAChR at 9 A resolution; Approximately 170 
A long, of which 65 A protrudes into the extracellular domain and 20 A into the cytoplasmic 
domain (Unwin, 1993)
Photoaffinity labelling experiments have helped elucidate the disposition of the 
membrane spanning segments in relation to the lipid bilayer for each of the subunits; 
M4 displays an a-helical like structure based on its label binding properties, which 
reveals that in all subunits, M4 faces the lipid bilayer (Blanton & Cohen, 1994). M2
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faces the ion channel lumen of the nAChR (Hucho eta l, 1986) and M1 and M3 also 
bind labels that approach the receptor through the lipid phase (Hucho etal., 1996). 
The first electron microscope studies of the nAChR revealed more elements to the 
tertiary and quaternary structure, at first suggesting a 5 or 6 subunit structure, 
shaped like a ‘donut’ all arranged around a central pore (Nickel & Potter, 1973; 
Cartaud etal., 1973). Since this first observation, much the same has been inferred; 
the present consensus is that the nAChR is a pentameric structure, made of five 
subunits arranged in a fivefold axis of pseudosymmetry (Brisson & Unwin, 1985), 
also confirmed in the neuronal nAChR using quantified radiochemistry (Anand etal., 
1991). Resolution has been increased to 4.6 A for the Torpedo electrolax nAChR 
(Unwin, 1993 & 2003; Miyazawa et al., 1999; see Fig. 1.4).
1.5.1 nAChR ligand binding
The ligand binding site for the nAChR has been the subject of renewed attention in 
light of a recent set of publications revealing the cloning and atomic structural 
determination of a soluble acetylcholine binding protein (AChBP), derived from and 
released by the glial cells of the snail Lymnaea stagnalis (Smit et al., 2001; Brejc et 
al., 2001). This protein shares remarkable homologies to the extracellular domains 
of both the neuromuscular and neuronal nAChR (it lacks the intracellular ion channel 
pore domain); a pentameric structure, the presence of binding loops A-F (see below 
Fig. 5), a disulphide loop between Cys 128 and Cys 142, key conserved aromatic 
residues, vicinal cysteine residues and the MIR at the top of a-subunits. Smit et al, 
(2001) describe how AChBP is associated with the modulation of cholinergic 
transmission in response to presynaptically released ACh, essentially suppressing
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the postsynaptic action of ACh, as well as demonstrating that this protein can bind 




Figure 1.5. Representation of nAChR ligand binding site determined from Torpedo 
electroplax nAChR (I) and the pentameric structure of AChBP (II). Left diagram. Specific 
residues involved with nAChR agonist binding are found on loops A-F. Loops A, B and C 
reside on the primary component (a1 subunit of Torpedo nAChR) and loops D, E and F 
reside on the complementary component of the ligand binding site (6/ysubunit of Torpedo 
nAChR) Residues were identified by affinity labelling and site directed mutagenesis 
experiments (for review see Corringer et al., 2000). Right picture. Conservation of these 
loops is preserved in AChBP, where ligand binding (represented as ball-and-stick) exists 
between the interfaces of each subunit (represented in different colours; adapted from Brejc 
etal., 2001)
The work by Brejc et al. (2001) demonstrated that ACh binding occurs between the 
interfaces of two subunits, similar to that previously demonstrated using Torpedo 
electroplax or expression of pairwise combinations of nAChR subunits in cell lines 
(for review see Corringer et al., 2000). Further to this, Brejc et al. (2001) revealed 
identical binding ‘loops’, principal (loops A-C; found on the a subunit of the Torpedo 
electroplax) and complementary (loops D-F found on the 6/y subunits of the Torpedo 
electroplax) components of the binding pocket for ACh (See Fig. 1.5). Because the 
AChBP is a homopentamer, at least 5 ligand binding sites exist for ACh, a predicted
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value of binding sites for the neuronal homomeric nAChRs e.g. a7 nAChR (Palma et 
al., 1996), compared to the two ACh binding sites of the neuromuscular nAChR. One 
disparity that was presented by Brejc et al. (2001) in contrast to the findings of 
Miyazawa et al. (1999), was that ACh appeared to gain access to the binding site 
from the periphery of the pentamer rather than through the central vestibule.
Figure 1.6 3D Structural model of the al receptor-aCbtx (cobratoxin) complex. The
five subunits of the receptor are depicted with their (3-sheets colored blue and the apical 
helices colored red and yellow. One toxin molecule is shown at an arbitrary subunit interface 
with its p-sheet in yellow and its backbone in red. (4) Top view of the model (£) The receptor 
is seen perpendicularly to the 5-fold axis with the toxin in an equatorial position. Adapted 
from Fruchart-Gaillard etal. (2002)
In a complex assessment of complementary loop F of the wild type and mutated a7 
nAChR subunit, expressed in HEK 293 cells, both binding assays and 3D-modelling 
predictions (based on the AChBP) identified specific residues involved with the 
binding of snake-neurotoxins and proposed a model for the spatial orientation to 
which the nAChR-toxin complex binds to the extracellular region of the nAChR 
(Fruchart-Gaillard etal., 2002; see Fig. 1.6).
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1.5.2 nAChR ion gate
The nAChR is an allosteric protein and therefore another main objective in the 
research of the nAChR ligand binding domain, is its second function; coupling of 
ligand binding into structural changes of the ion channel pore.
The nAChR channel has three main functions; it moderates the energy barrier for 
ionic conductance, selects among ions and it opens and closes (Karlin, 2003). Data 
collected from photoaffinity labelling experiments and mutational analysis have 
identified that certain amino acids that line the pore of the nAChR contribute to these 
functions, and that that these amino acids are conserved to each a-helical 
membrane spanning segment, likely to be the M2 segment of each subunit (Unwin, 
1995; Le Novere etal., 1999).
Figure 1.7. Representation 
of specific amino acid 
determinants of nAChR ion 
channel gate defined from 
mouse muscle type nAChR. 
SCAM analysis of specific 
residues within the M2 
domain of the nAChR ion 
channel gate revealed 
specific hydrophobic
interactions of these residues 
in the closed state. On 
binding ACh, these 
hydrophobic interactions are 
broken and allow for the 
passage of ions
Use of non-competitive blockers, of which their site of action is believed to be the ion 
channel pore, helped postulate that these aligned amino acids formed rings of 
mostly negatively charged residues; an outer, extracellular ring, a cytoplasmic ring 
and an intermediate ring (inner ring). SCAM (substituted-cysteine accessibility





method) was utilised to assess the mutational effects of M1 and M2 domain amino 
acids to cysteine, ultimately revealing those amino acids that are exposed to water 
(Akabas et al., 1994 & 1996; Zhang & Karlin, 1997 & 1998). This data supported 
evidence from electron microscope studies, in that mutated residues of M2 were 
exposed to water over its entire length, however in the M1 only one third of the 
amino-terminal domain was exposed, suggesting that M2 domains form a funnel like 
structure into the cytoplasm, creating gaps at the pore entrance that exposes 
residues of the M1 a-helix to water (see also the electron microscopy findings of 
Unwin, 1993).
Further structural assessment of this ‘funnel like structure’ using cryo-electron 
microscopy revealed that a ‘kink’ existed in the M2 pore lining segments, and that 
these kinks were inferred to block the channel of the nAChR in the absence of ACh, 
but then move out of the way on binding ACh (Unwin, 1995). This supported 
previous mutational data and electrophysiological data (Dani, 1989; Imoto et al., 
1991; Konno etal., 1991; Cohen etal., 1992), that a ‘gate’ existed for the passage of 
ions depending on the ‘open’ or ‘closed’ state of the receptor However, it required 
SCAM analysis again to define the currently accepted residues forming this gate, 
where initial experiments described mutated residues (that would react with water) of 
the nAChR in the closed state only up until (and including) T244, which lines the 
beginning of the gate at the intracellular region of the pore. Specific mutations of 
residues within the proposed gate (M243, K242, E241 and G240) were not exposed 
to water in the closed state (ACh bound receptor) but on application of ACh, the 
hydrophobic interactions of these residues between subunits were broken and 
allowed for the passage of ions (see Fig. 1.7; Pascual & Karlin, 1998; Wilson & 
Karlin 1998)
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1.5.3 Ionic selectivity of the nAChR
Except for the anion selective invertebrate nAChR (Takahama & Klee, 1990), all 
known nAChRs are cation selective, for both monovalent and divalent ions where in 
neuronal nAChRs, compared to neuromuscular nAChRs, a particular high 
permeability to Ca2+ is displayed, particularly that of a7 nAChR where its pca/PNa 
ratio (the ratio of Ca2+ permeability relative to Na+) is 20 (For comparison of pca/pNa 
ratios of neuronal nAChR see McGehee & Role, 1995). The selectivity to ions seems 
again to be from inherent residues located on the M2 domain of the nAChR, where 
mutations particularly in the intermediate rings of negative charge or polar residues 
in this region reduce or abolish cation conductance and even in some cases cation 
selectivity (Imoto etal., 1988; Leonard etal, 1988; Cohen etal., 1992). Mutations of 
two adjacent rings of leucines (Leu-254 and Leu-255) at the synaptic end of the M2 
domain selectively reduces calcium permeability without affecting other properties of 
the nAChR (such as inactivation or desensitisation) suggesting that these particular 
amino acids are pertinent to calcium conductance through the nAChR (Bertrand et 
al., 1993). One notable example for their meticulous efforts and surprising findings is 
the work of Corringer et al, (1999), where by, implicating three changes to the M1- 
M2 loop and M2 of the a7 nAChR (removal of the negative residues of the 
intermediate ring, lengthening the M1-M2 loop and substitution of Val13 in the wider 
part of the channel to threonine) had the effect of changing the receptor cation 
selectivity to anion selectivity.
All together, these data highlight the contribution of the M2 domain to ion selectivity 
and transport, however as highlighted above, the conformational changes that 
convert ligand binding into ion conductance are still today of much attention in 
nAChR research. A recent publication by Unwin. (2003), explicitly details the
32
conformational changes induced by p-sheets on binding ACh (structures that 
compose the majority of the ligand binding domain of the nAChR) that are 
communicated through to the a-helices of the M2 that break apart the hydrophobic 
interactions of the gate, allowing for ion passage.
1.6 nAChR and desensitisation
Mutational analysis of the nAChR in a variety of residues within and outside of the 
M2 domain and their consequent effects on ionic conductance support the notion 
that the nAChR is subject to a series of structural changes on binding ACh or other 
nAChR ligands, thus supporting the notion first suggested by Monod and colleagues 
(1965) that the nAChR isomerises between a number of structural conformations in 
the absence, presence and persistence of binding ligand.
Figure 1.8. Diagram 
representing the minimal four 
state model of allosteric 
transitions of the nAChR 
(adapted from Galzi & 
Changeux, 1995). From rapid 
mixing experiments performed on 
Torpedo membranes rich in 
nAChR, a model with a minimum 
of four transition states was 
proposed. R is the low affinity 
resting state that occurs in the 
absence of agonist, A represents 
the active receptor state and D 
and I are the desensitised states.
These different theoretical conformations were generalised into a minimum of four 
allosteric interconvertible transitions of the receptor (see Fig. 1.8), termed the
M M
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‘concerted model’; an active state A, where the channel opens and possesses a low 
affinity for ACh (60-100 fxM), two desensitised states I and D, which are refractory to 
activation, exhibit a high affinity for agonists (I; 10 |iM. D; 10 nM), that represent the 
quickly and more slowly desensitised states of the receptor respectively and lastly, 
the R state, the resting state of the receptor of low affinity to agonists occurring in 
the absence of agonist and where competitive antagonists are supposed to 
selectively bind (Galzi & Changeux, 1995).
Because these transformations are dependant on the local concentration of ligand 
this model therefore implies that in certain physiological conditions, release of ACh 
at the synaptic cleft will first stabilise the A state (due to high concentrations of ACh) 
prior to slowly stabilising the I and D desensitised states. These latter two states 
would then ultimately regulate the amount of nAChR in the R state depending on the 
level of ACh in the synaptic environment.
In terms of channel opening times, the rate of desensitisation onset is therefore a 
crucial property in the regulation of ion flow through the receptor, necessary for the 
prevention of repetitive stimulation of the receptor and ionic exocytotoxicity of the 
neuron.
The rate of desensitisation can vary dependent upon the subunit composition of the 
nAChR (for review see Quick & Lester, 2002). Homomeric a7 nAChR undergo rapid 
desensitisation upon high concentrations of agonist. In fact, of all the nAChRs, this 
receptor displays the fastest desensitisation time constant, where single cells from 
hippocampal neurons (Alkondon & Albuquerque, 1991), ciliary ganglion cells (Zhang 
et al., 1994) and cortical neurons (Kawai & Berg, 2001) report a single exponential 
component in a-Bgt sensitive currents of around 20 ms. Interesting observations by
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Papke et at, (2000), from recordings of a-Bgt sensitive currents of hypothalamic 
neurons, propose that this nAChR receptor desensitisation properties depends on 
fractional agonist occupation (of the five sites available; Palma et al., 1996), where 
complete receptor binding site occupation, enabled in high agonist concentrations, 
permit rapid and complete desensitisation whereas in low agonist concentrations 
(low receptor binding site occupancy) a prolonged channel opening state exists (100 
ms). However, heteromeric assemblies of a7 incorporating the p2 subunit, such as 
the a7p2 nAChR expression study in Xenopus oocytes, report almost a two-fold 
slower desensitisation time constant than homomeric a7 nAChR assembly in these 
cells (Khiroug eta!., 2002).
Of the heteromeric assemblies of nAChR, much of the data revealing desensitisation 
properties has been obtained from a combination of binding assays and 
electrophysiology studies, where these two approaches, particularly with respect to 
the desensitised affinity states of the nAChR, should produce equivalent results. 
Indeed, nicotine displacement by the high affinity broad spectrum nAChR agonist 
[3H]epibatidine in rat CNS tissue is biphasic, revealing two sites of high affinity (Kd 
approx 3-5 nM) and moderate affinity (Kd approx 90-250nM) (Perry & Kellar, 1995; 
Whiteaker et al., 2000). The high affinity component likely reflects a4p2* nAChR 
binding whereas the more moderate affinity nAChRs putatively contain a3* subunits. 
Moreover, IC50 values for desensitisation of functional channels of a4 and a3* 
nAChRs are in the same range as their binding Kd’s (0.1-10 nM for a4* and 150-400 
nM for a3*; Hsu et al., 1996; Fenster et al., 1997; for review see Quick & Lester, 
2002).
In heteromeric assemblies of non-a7 nAChR, a-subunits and p-subunits display 
slower desensitisation time constants than the homomeric a7 nAChR. Summarised
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by Fenster et al. (1999) desensitisation kinetics of the heteromeric nAChRs was 
ordered (from fastest to slowest) a302 > a4 p2 > a3 p4 > a4 04, thus reflecting the 
structural importance of both heteromeric assembly and the inherent properties of 
the a and p subunits themselves. Presently, p-subunits (p2/ p 4) have been shown to 
dramatically influence the rate of onset of desensitisation, where p2* containing 
nAChR desensitise faster than p4* containing nAChR (Fenster etal., 1997; Wang et 
al., 1998; Boulter et al., 2001).
1.6.1 Physiological significance of desensitisation
At this point, attention needs to be drawn to two aspects presented above in the 
introduction: (A) receptors heavily implicated in working memory and the frontal 
cortex, (the a7*nAChR and the high affinity nAChR a4p2* nAChRs) and (B) the 
concept of diffuse transmission of ACh (see section 1.4.2.1) with respect to the 
desensitising properties of these receptors. Because these receptors are either 
rapidly desensitising (a7 nAChR) or have a high affinity for ACh (a4p2* nAChR) then 
in an environment of diffuse ACh, these receptors are likely to be, in the majority, 
desensitised. Desensitised nAChRs have been reported to potentiate certain forms 
of synaptic plasticity, exampled in the rat hippocampus where MI_A (an a7 nAChR 
antagonist) mimicked the nicotine-induced potentiation of LTP, inferring that 
desensitised nAChRs are implicated in this process (Fuji et al., 2000). As well as 
this, desensitisation of nAChRs, in the presence of chronic nicotine, is purported to 
lead to the up-regulation of nAChR (Fenster etal., 1999).
The physiological significance of persistent desensitised states of nAChR in the 
frontal cortex remains unanswered. In this configuration, nAChRs are unlikely to 
augment an increase in either neurotransmitter release from the presynaptic terminal
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or an increase in cell excitability via activation at the postsynaptic membrane, 
therefore their normal physiological role may be to prevent over-excitation in 
response to increased cholinergic activity from the basal forebrain areas, selectively 
filtering certain aspects of information processing to specific higher modalities of the 
CNS. Alternatively, with little information of the exact concentration of ACh within the 
synaptic environment of nAChR, these nAChRs could change their conformation 
from a desensitised state to an active configuration from only slight increases in ACh 
concentration in response to increased cholinergic activity, thereby desensitised 
nAChR acts as ‘coincidence detectors’ to increased cholinergic activity. In support of 
this possibility, Rogers & Sargent (2003) demonstrate that ACh released from nerve 
terminals of the chick ciliary ganglion can induce increases in calyceal nerve 
terminal calcium concentration, mediated by presynaptic a7 nAChR.
1.7 nAChR and neurotransmitter release
The majority of nAChR characterisation, from subunit expression to structural 
quantification is determined from nAChRs located on somatodendritic membranes. 
Because of this location, ionic currents and other intracellular events can be easily 
recorded in an electrophysiological or spectroscopic paradigm. Yet as highlighted in 
Section 1.3, above, nAChRs are also located on the presynaptic terminal, made 
directly evident from electron microscopy studies in the guinea pig frontal cortex, rat 
hippocampus, auditory cortex and basal ganglia (Hill etal., 1993; Lubin etal., 1998; 
Jones etal., 2001; Fabien-Fine eta l, 2001; Levy & Aokie, 2002). Functional studies, 
preceding the recent electron microscopy data, from intact synapses in-vivo, newly 
formed synapses in vitro and from biochemical isolates of presynaptic terminals 
(Wonnacott, 1997; MacDermott et al., 1999), also define a presynaptic locus by
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modulating neurotransmitter release in a Ca2+-dependent and tetrodotoxin 
insensitive manner. Notably, the very first study that presented the case for 
presynaptic receptor modulation of neurotransmitter release was the discovery that 
ACh could modulate its own release from preganglionic sympathetic neurons 
(Koelle, 1961), nowadays termed ‘autoreceptor’ regulation.
Since then, presynaptic nAChRs have been described to modulate the release of 
other neurotransmitters other than ACh, including dopamine (DA) noradrenaline 
(NA), 5-hydroxy-tryptamine (5-HT), y-aminobutyric acid (GABA) and glutamate. The 
release of these neurotransmitters can be detected either directly by analysis of 
perfusate from the tissue source (superfusion, amperometry, microdialysis) or 
indirectly by measurement of postsynaptic effects of neurotransmitter release 
(generally whole cell recordings in an electrophysiology paradigm or spectroscopic 
detection of increases in intracellular Ca2+). In general, direct analysis of nAChR- 
evoked neurotransmitter release has been demonstrated for monaminergic 
neurotransmitters DA and 5-HT, whereas indirect analysis of neurotransmitter 
release has been, in the majority demonstrated for excitatory amino acid release 
(glutamate). The release of inhibitory neurotransmitter GABA evoked by nAChR 
agonist has been detected by both methods.
1.7.1 Direct detection of nAChR-evoked neurotransmitter release: Measuring 
glutamate release
Superfusion has served as one of the most utilised methodologies for the direct 
detection of nAChR-evoked neurotransmitter release (for review see Raiteri & 
Raiteri, 2000). Brain preparations, either synaptosomes or slices, are commonly 
loaded with exogenous radiolabelled neurotransmitter and then placed within a
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chamber on top of a filter bed (see Chapter 2, Methods section 2.7). Physiological 
buffer medium is then perfused over the tissue and the perfusate is collected in 
timed aliquots. After establishing a basal release of radiolabel, the buffer medium is 
switched to agonist containing medium (in this thesis either depolarising agents or 
nAChR agonists or both) and then back to the physiological buffer medium after a 
timed period for the remainder of the experiment. Incorporation of antagonists into 
the physiological buffer can also be used to assess the pharmacological identity of 
nAChR-evoked release in conjunction with agonist sensitivities of evoked 
neurotransmitter release. After the experiment has ended, each aliquot containing 
radiolabelled perfusate is counted on a scintillation counter and results determined 
appropriately. Within one experiment, up to 6 different conditions can be assessed 
on the standard superfusion apparatus (see Chapter 2, Methods section 2.7.1) 
although a recent adaptation to a 96 well plate has enabled a high throughput assay 
for the detection of nAChR-evoked release of dopamine and noradrenaline 
(Anderson etal., 2000; Puttfarcken etal., 2000).
Despite this relatively straightforward approach for the examination of 
neurotransmitter release, direct detection of glutamate release (or EAA release) via 
nAChR activation has eluded demonstration (discussed below), whereas 
superfusion analysis of nAChR-evoked release of other neurotransmitters has 
provided a good deal of information with respect to nAChR subtype association and 
mechanism of release. In particular, the nAChR-evoked release of dopamine from 
the rat striatum has been extensively studied using this method from our own 
laboratory, and has provided pharmacological evidence for nAChR heterogeneity at 
the presynaptic terminals, inferring the presence of a3(a6)p2* containing nAChR on 
dopaminergic striatal terminals as well as a Conotoxin Mil insensitive,
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mecamylamine sensitive component, presumably a4|32* containing. (Kaiser et al., 
1998; Sharpies et al., 2000; Mogg et al., 2002). Superfusion techniques have also 
revealed that nAChR evoked dopamine release is both Ca2+ and Na+ dependent (by 
incorporation of Ca2+ and Na+ channel blockers into the perfusion medium), 
specifically revealing an association with P/Q and N-type Ca2+ channels (Soliakov et 
al., 1995; Soliakov & Wonnacott, 1996). More recently, nAChRs (a3|32* containing) 
have been shown to possibly couple to these channels (Kulak etal., 2001).
Diffuse ACh transmission
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Figure 1.9. Model of the indirect nAChR-evoked release of DA from dopaminergic 
terminals of the striatum. Diffuse transmission of ACh within the rat striatum activates a7 
nAChR on glutamatergic terminals making synaptic contact with spiny neurons. In turn, a.7 
nAChR activation elicits glutamate release, which activates glutamate receptors located on 
dopaminergic terminals, evoking dopamine release. Dopamine release can be evoked 
directly by non-a7 (a6p2*) containing nAChR on these terminals. Adapted from Kaiser & 
Wonnacott, 2000
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However, one interesting feature to the pharmacological analysis of nAChR-evoked 
dopamine release, and of relevance to this thesis, was the revelation of a a7 nAChR 
component, demonstrated in rat striatal slices but not in synaptosomes (see Fig. 1.9; 
Kaiser & Wonnacott, 2000). In consideration of the complexity of examining slices 
over synaptosomes, these authors inferred that this component of nAChR-evoked 
dopamine release was the result of activating a l  nAChRs iocated on glutamatergic 
terminals in the striatum (the facilitation of dopamine release could be blocked by a7 
nAChR antagonists and iGluR antagonists). In turn, this would release glutamate 
that acted upon ionotropic glutamate receptors of dopamine terminals to elicit 
dopamine release.
This study provided the first indirect evidence for nAChR evoked release of 
glutamate using a superfusion paradigm, which, until now has eluded direct 
demonstration using superfusion on the notion that this method lacks the fast 
application and high temporal resolution required for the detection of EAA release.
In spite of this, Marchi et al, (2002) reported the direct detection of nAChR evoked 
glutamate release using superfusion (modelled by using [3H]D-aspartate as a 
surrogate for glutamate) in the rat striatum. These authors report a a7 nAChR- 
mediated, Ca2+-dependent release of [3H]D-aspartate when nAChR agonists were 
combined with a depolarising agent (KC112 mM), however, nAChR agonists applied 
alone did not facilitate release (See Chapter 3 Section 2). Perfusion rates in this 
study were increased to almost twice the rate used to detect nAChR evoked 
dopamine release in attempt to override the efficient uptake systems utilised for 
glutamate as well as prevent nAChR desensitisation by increasing the time 
resolution of agonist application. However the success of this investigation was 
based on the assumption that nAChR activation enhanced the release evoked by
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KCI by increasing the preterminal Ca2+ concentration, thereby increasing the 
probability of vesicular exocytosis, analogous to the inferences made from nicotine 
enhancement of glutamate release in the hippocampus (Gray etal., 1996; Sharma & 
Vijaraghavan, 2003).
Microdialysis provides another means of direct detection of neurotransmitter release 
revealing a more in-depth analysis of the possible inter-circuitry connections that 
might influence endogenous nAChR-evoked neurotransmitter release. However, in 
contrast to superfusion techniques, expediency is hampered by low throughput and 
lengthy procedures of neurotransmitter analysis (such as HPLC analysis of 
dialysate), has poor temporal resolution and is impractical for detailed dose- 
response relationships. Nonetheless, this technique has revealed nAChR-mediated 
release of ACh, NA, DA, 5-HT and glutamate in a number of brain regions and 
implicating a variety of nAChR subtypes. The majority of microdialysis studies have 
examined the nAChR modulation of DA release in the basal ganglia and associated 
structures (Marshall et al., 1997), corroborating superfusion data inferences, and 
with the use of nAChR gene knockout animals, have recently provided new 
information on the contribution of p2 and a4 subunits to the nAChR subtype(s) 
contributing to DA release (Picciotto, 1998; Marubio etal., 2003).
Microdialysis analysis of nAChR evoked glutamate release has implicated a7* 
nAChR subtype in the ventral tegmental area (VTA), nucleus accumbens and 
striatum (Toth et al., 1992; Reid et al., 1997; Reid et al., 2000; Schilstrom et al., 
1998 & 2000). These latter studies report increased glutamate levels evoked by 
nicotine, which is blocked by nAChR antagonists mecamylamine, a-Bgt and MLA 
and is Ca2+-dependent. However, in contrast to this, in the nucleus accumbens, 
which receives prominent glutamatergic innervation from limbic structures, it was
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reported by Reid et al. (2000), that the nicotine-evoked release of glutamate 
appeared to be Ca2+-independant, where the glutamate transport inhibitors (L-trans- 
pyrrolidine-2,4-dicarboxylic acid; PDC) inhibited the nicotine-induced release, 
indicating a novel mechanism of nAChR modulation of release. Microdialysis studies 
of nAChR-mediated glutamate release in the frontal cortex are few in number, 
however, Gioanni eta l. (1999) demonstrated nicotine-evoked release of glutamate in 
the prelimbic (Prl) area rat of the frontal cortex, which was Ca2+-dependent and 
sensitive to the p2* preferring antagonist dihydro-p-erythroidine (DHpE). Although no 
a7 nAChR specific antagonists were applied in the microdialysis paradigm, MLA at 
high concentrations (100 nM) applied to slices of the Prl prevented the facilitation of 
glutamate release examined by electrophysiology.
Other direct evidence for the implication of a7 nAChR in the modulation of glutamate 
release comes from cell culture studies. Cortical cultures and cerebellar cultures 
released glutamate (and aspartate; assessed by either HPLC or scintillation counting 
of exogenously loaded [3H]D-aspartate) when exposed to nicotine or ACh, in a Ca2+ 
-dependant manner (Beani etal., 2000; Lim etal, 2000: Lopez et al., 2000). Beani et 
al. (2000) reported a poor facilitation of [3H]D-aspartate release by nicotine or ACh 
when these drugs were applied alone to cortical cultures, but when concomitantly 
applied with electrical stimulation a more robust and pharmacologically definable 
response was produced, implicating both a7 and p2* nAChR in the facilitation of 
EAA release. These reports examining cell cultures fail to define the mechanism of 
nAChR-evoked release, but again implicate the possibility that nAChRs are in 
someway associated with glutamate transporter function: glutamate transport activity 
of glial cells was reduced, NMDA responses of cerebellar granule cells were 
increased after exposure to nicotine and cortical cells display a large calcium
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independent component of nicotine-evoked glutamate release (Lim et al., 2000; 
Lopez et al., 2000).
Direct methods of detecting glutamate release reveal a presently unclear picture of 
the nAChR subtype-association and mechanism of release, however, the fast 
kinetics of a7 nAChR activation/desensitisation and glutamate release/uptake per se 
are more suited for detection in a system that pertains the ability to detect these 
types of changes, i.e. electrophysiology.
1.7.3 Indirect detection of nAChR-evoked neurotransmitter release
The majority of studies that have provided evidence for the nAChR facilitation of 
glutamate release have utilised an electrophysiological paradigm. These studies 
have demonstrated the presynaptic release of glutamate by examining the post- 
synaptic responses of glutamate acting upon ionotropic receptors, such as miniature 
excitatory postsynaptic potentials (mEPSPs) or evoked excitatory postsynaptic 
currents (eEPSCs). These events are mediated by the activation of ionotropic 
glutamate receptors and can be pharmacologically defined by blockade of these 
responses in the presence of glutamate receptor antagonists such as DL-2-amino-5- 
phosphonopentanoic acid (DL-AP5) and 6-cyano-7-nitoquinoxaline-2,3-dione 
(CNQX).
mEPSPs are small depolarisations in the post synaptic neuron that are the result of 
quanta of transmitter release by spontaneous fusion of vesicles at nerve terminals, 
independent of action potentials arriving at the presynaptic terminal (Katz & Miledi, 
1967). The physiological significance of mEPSPs, originally thought of as ‘synaptic 
noise’ has gained renewed attention in a series of experiments by Sharma & 
Vijaraghavan (2003), where presynaptic nAChR activation can increase both the
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frequency and amplitude of nicotine-evoked mEPSPs. These events are shown to 
drive the postsynaptic neuron above its firing threshold, ultimately resulting in 
efficient impulse propagation. mEPSPs have frequently been observed in both 
rodent CA1 and CA3 regions of hippocampal slices and from hippocampal neurons 
in culture (Gray et al., 1996; Radcliffe & Dani, 1998; Ji et al., 2001; Alkondon & 
Alburquerque, 2002; Maggi et al., 2002) as well as at the synapse of the medial 
habenula and interpeduncular neurons and the synapse of olfactory bulb and 
amygdala neurons (McGehee etal., 1995; Alkondon etal., 1996; Girod etal., 2000; 
Girod & Role, 2001; Covernton & Lester, 2002).
All of these experiments report the nAChR facilitation of glutamate release to be 
Ca2+ dependant, TTX insensitive and sensitive to a7 nAChR specific antagonists (a- 
Bgt and MLA), inferring predominantly that a7 nAChR governs the presynaptic 
release of glutamate. However, in the frontal cortex, virtually no pharmacological 
evidence exists for a7 nAChR and their involvement with glutamate release (Vidal & 
Changeux, 1989; Vidal & Changeux 1993; Vidal, 1996; Gioanni etal., 1999; Lambe 
et al., 2003) Gioanni et al. (1999) are the only group to report MLA inhibition of 
nAChR mediated facilitation of glutamate release on to prelimbic frontal cortex 
neurons, although the concentration used (100 nM) is unlikely to be selective for a7 
nAChR. One of the first investigations postulating the involvement of presynaptic 
nicotinic receptors in the rodent brain was carried out in the rat prefrontal cortex 
(Vidal & Changeux, 1993). These authors reported an increase in amplitude of 
eEPSC in pyramidal cells located in layers II and III of the rat PFC when nicotine or 
ACh was applied iontophoretically, which could only be inhibited by the non-a7
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nAChR antagonists DHpE and neuronal bungarotoxin, thereby implying that 02* 
containing nAChRs modulate this type of presynaptic release of glutamate. 
eEPSCs are the result of ‘stepping’ the postsynaptic membrane potential via 
depolarising voltage increments or by stimulation of afferents serving the 
postsynaptic neuron (e.g. Schaffer collateral afferents serving a postsynaptic 
pyramidal cell in CA1 of the hippocampus). Essentially this serves to increase the 
membrane potential above firing threshold where increases in amplitude or duration 
of postsynaptic responses are easily recorded and defined into NMDA or non-NMDA 
components. Both the amplitude and duration can be modified dependant upon the 
level of presynaptic input to that neuron. Similar to the study of Vidal & Changeux, 
(1993), the enhancement, in terms of amplitude, of eEPSCs was demonstrated in 
cultured hippocampal neurones making autaptic connections (Fisher & Dani, 2000). 
However, these authors went on to further demonstrate that this increase in 
amplitude, evoked by presynaptic release of glutamate, was only in the non-NMDA 
component of the eEPSC. By inhibiting the action of calmodulin postsynaptic nAChR 
activation reduced the responsiveness of the NMDA component of the eEPSC via a 
calmodulin-dependent mechanism. This gave rise to the possibility that nAChRs, 
particularly a7 nAChRs, could modulate glutamate transmission in the hippocampus 
at both the pre and postsynaptic membrane respectively. Indeed, postsynaptic 
nAChRs on hippocampal neurons and interneurons have been identified for some 
time and have been categorised into four groups based on their current kinetics and 
pharmacology (See Chapter 3 section 3). Of these groups type IA serves as the 
most frequently identified nAChR current in both sets of neurones and is likely to 
include a7 subunits (Alkondon & Alburquerque, 1993; Alburquerque et al., 1996; 
Alkondon etal., 1998; Frazier et al., 1998).
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It is therefore a common theme from these studies that the nAChR exerts an 
influence on glutamatergic transmission, so much so that LTP, the cellular model of 
memory, can be induced by ACh or nicotine, dependent on the timing and location of 
nicotinic activity (Mansvelder & McGehee, 2000; Ji et al., 2001; For review see 
McGehee, 2002). Indeed the most noteworthy observation from the studies of 
presynaptic a7 nAChR mediated release of glutamate, is that the effect of nicotine or 
ACh is long-lasting (up to 40 minutes in the absence of nicotine or ACh), particularly 
that of eEPSCs recorded in pyramidal cells of the hippocampus (Radcliffe & Dani, 
1998; Dani & Fischer, 2000; Fuji et al., 2000; Ji et al., 2001) and in the VTA 
(Mansvelder & McGehee, 2000), suggesting that activation of presynaptic nAChR 
can substitute for presynaptic stimulation usually required for LTP induction. As well 
as the evidence for glutamate release in mature developed hippocampal circuits and 
in cultures, brief application of nicotine or ACh to immature glutamatergic synapses 
of hippocampus from newborn rats can convert ‘silent’ synapses, that exhibit no 
mEPSPs, into functional ones (Maggi et al., 2002). This study went on to infer that 
activation of presynaptic a7 nAChRs that release glutamate contribute to the 
maturation of the functional synaptic contacts of the developing hippocampus.
In summary, electrophysiology has provided substantial evidence for the nAChR- 
evoked release of glutamate from presynaptic terminals, mainly via the activation of 
a7 subunit containing nAChR, although in the frontal cortex evidence is only 
provided for non-a7, possibly p2*-containing nAChR. Therefore it is plausible that 
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Figure 1.10. Representative circuit diagram of nAChR modulation of hippocampal 
activity, o7 nAChRs modulate the release of glutamate from presynaptic terminals and the 
excitation of postsynaptic membranes. a7 and a4p2 nAChRs also modulate the excitability 
of pyramidal cells, but also regulate inhibitory neuron activity. Evidence also exists for a non- 
a7 modulation of glutamate release onto inhibitory neurons (Adapted from Alkondon & 
Albuquerque, 2002)
In support of the latter, it has been recently made evident that certain hippocampal 
interneurons (in the CA1 region) receive non-a7 mediated glutamatergic input 
(Alkondon & Alburqeurque, 2001) and therefore the different properties of subtypes 
of nAChR (a7 or non-a7) as well as their location (on inhibitory terminals or 
excitatory terminals) may exert an influence on the overall activity (excitation or 
inhibition) of the output neurons (see Fig. 1.10). It is therefore the goal of current 
nAChR research to determine the precise definition of nAChR subtype and location 
within synaptic circuitry in different regions of the brain in order to understand how 
the cholinergic system and/or nicotine may exert its influence in learning, memory 
and addiction.
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1.8 Thesis aims and objectives
A substantial body of evidence supports the a7 nAChR-mediated release of 
glutamate from presynaptic terminals from various regions of the brain. However this 
has not been reported in the frontal cortex, despite one small and overlooked 
observation of MLA inhibition of glutamate release in this area (Gioanni etal., 1999). 
Electron microscopy analysis has only confirmed the presence of a7* nAChR on 
presynaptic terminals of the guinea pig frontal cortex but not p2* nAChR, although 
the presence of p2* nAChR on presynaptic terminals has been confirmed elsewhere. 
nAChR subtype distribution studies support the presence of both a7* and p2* 
nAChR in the frontal cortex, and interestingly, their distribution appears separated 
across the layers of the frontal cortex. It is therefore likely that the failure to observe 
‘cx7 nAChR-like’ modulation of glutamate release, an arduous task in the very least, 
may be the result of the position in which recording probes and/or stimulating probes 
are placed, indeed electrophysiological recordings have only positioned these 
probes in layers ll-V where 02* nAChR has been identified in autoradiographical 
analysis.
To address this disparity this study aimed to investigate a7 nAChR function and 
location in the rat frontal cortex, as well as to corroborate the existing evidence for 
non-a7 nAChR function and location in this region, using direct methods of analysis: 
superfusion and immunocytochemistry.
In the first part of this thesis, superfusion experiments were undertaken to validate 
the use of [3H]D-aspartate as a suitable marker for glutamate release from 
presynaptic terminals (see Chapter 3 section 1). Secondly, recently reported 
attempts that reveal nAChR modulation of EAA release found this to only occur
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when nAChR agonists are combined with depolarising stimuli. We aimed to emulate 
this data using a variety of depolarising agents and nAChR agonists combined (see 
Chapter 3 section 2). In the third part we investigated direct nAChR-evoked release 
of EAA, without the need of concomitant depolarising stimulation. Having 
established that this could be reproducibly demonstrated we subsequently 
characterised the nAChR response with the presently available nicotinic 
pharmacopia (see Chapter 3 section 3).
Lastly, we endeavoured to provide support for the nAChR functional data described 
in Chapter 3 (section 2 and 3) with immunocytochemical data, using probes specific 
for a l  nAChR and p2* nAChR (either fluorescent labelled ligands or antibodies) that 
can be detected using confocal microscopy (Chapter 4).
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Chapter Two
2.1 Materials And Methods
2.2. Materials & Equipment
[3H]D-aspartate (14-21 Ci/mmol) was purchased from Amersham International, 
Amersham, Bucks, UK. Percoll™ was obtained from Amersham Pharmacia Biotech, 
Uppsala, Sweden. Conotoxin Iml was obtained from Calbiochem. 5-lodo-A-85380 
dihydrochloride (5-I-A-85380), L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC), DL-threo-fi- 
benzyloxyaspartic acid (TBOA), (±)anatoxin-a fumarate, and MLA were obtained from 
Tocris Cookson, Bristol, UK. a-Bgt and a-Bgt Alexa Fluor® 488 and 546 conjugate were 
obtained from Molecular Probes Europe BV, PoortGebaow, The Netherlands. Anti-p2- 
nAChR subunit rat polyclonal (mAb 270) was generously provided by Professor Jon 
Lindstrom, University of Pennsylvania. Anti-synaptophysin mouse monoclonal, VGIuTI 
and VGIuT2 rabbit and guinea pig polyclonal antibodies were obtained from Synaptic 
Systems GmbH, Gottingen, Germany. Vectorshield™ mountant was obtained from Vector 
laboratories Inc Burlingame, Canada. All other chemicals were of analytical grade and 
obtained from Sigma Aldrich Company Ltd, Poole, Dorset, UK.
Equipment
Homogenisor: Cilenco® rotor with attached Teflon™ homogenisor.
Superfusion systems: 12 parallel open chamber modified Brandel® superfusion apparatus 
(Model SF-12; Brandel, Gaithersburg, MD; (Soliakov et al., 1995), containing Whatman 
GF/B filter discs. 20 parallel closed chamber automated Brandel® superfusion apparatus 
with combined Electrical Stimulation Unit.
Scintillation Counter: Packard Tri Carb 1600®TR Liquid scintillation analyser.
Vibratome: Model Vibratome™ 1000 (General Scientific, Redhill, Surrey).
Confocal imaging system: Zeiss Axiovert 100 M microscope combined with LSM 510 
confocal system.
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Floor standing centrifuge: Beckman Coulter Avanti™ J-25.
2.3 Buffers
Krebs-Bicarbonate (KB): in mM; NaCI 118, KCI 2.4, CaCI2.H20  2.4, MgS04 1.2, KH2P04
1.2, Na2HC03 25, glucose 10; oxygenated with 95% 0 2/5% C 02 for 1 hour (and adjusted 
to pH7.4).
Sucrose-Hepes (SH): 0.32 M sucrose, 5 mM Hepes pH 7.4 (and adjusted to pH7.4). 
Phosphate Buffer Saline (PBS): 10 mM phosphate buffer containing NaCI 150 mM and 
KCI 2 mM, (pH 7.4).
2.4 Rat brain dissection
Male Sprague-Dawley rats of approximate weight (250-300 g) were killed by cervical 
dislocation and the brains rapidly removed. Frontal cortex tissue (approximately 350 mg) 
was dissected by cutting anterior to the corpus callosum, after removing the olfactory lobes 
and striatum. Tissue was immediately placed in ice cold SH buffer and then subject to 
synaptosome preparation, section preparation (for electrical stimulation) or vibratome 
sectioning (for immunocytochemistry experiments).
2.5 Frontal cortex tissue preparation
2.5.1 P2 synaptosome preparation
Synaptosomes were isolated by differential centrifugation using a method previously 
employed by Soliakov et al. (1995). For each superfusion experiment frontal cortex from 
two male Sprague-Dawley rats was homogenised 10% (w/v) in ice-cold SH buffer at pH 
7.4 by 12 strokes of the glass/Teflon homegenisor attached to the Cilenco® rotor, set at a 
rotation speed of 2000 rpm.
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This homogenate was then transferred to a polycarbonate centrifuge tube (16 ml) and 
made up to 10-11 ml with the SH buffer. This sample was centrifuged for 10 min at 1000g 
(using the Sorvall® SM-24 rotor and Beckman Coulter Avanti™ J-25 centrifuge). The 
resulting supernatant (Si) was then transferred to a clean polycarbonate centrifuge tube 
and made up to 10-11 ml with SH Buffer. This sample was then centrifuged using the 
same rotor for 20 min at 12000g. The supernatant from this spin (S2) was discarded and 
the resulting pellet (P^ was then initially resuspended in 4 ml of ice-cold KB buffer and 
triturated gently using a 1 ml pipette for 20 s. The sample was further resuspended to a 
total volume of 10 ml in KB buffer and centrifuged for a final 10 min at 1000g. The 
supernatant from this final spin was removed and the remaining pellet (P2) was re­
suspended in 2.5 ml of KB buffer (to a final concentration of 4-5 mg/ml), triturated for 30 s 
and then left on ice to await further experimentation.
2.5.2 Percoll™ purified synaptosomes
Subjecting the initial Si supernatant to centrifugation on discontinuous Percoll™ gradients, 
allows for a suspension that is enriched with synaptosomes and has a reduced content of 
other intracellular debris (e.g. mitochondria, myelin and plasma membranes) from the 
homogenised frontal cortex tissue (Dunkley et al., 1988; Thorne et al., 1991; Thomas et 
al., 1993) (See Fig. 2.1 for summary of the procedure). The enrichment of synaptosomes 
is particularly advantageous for immunocytochemical examination, as this preparation 
minimises intracellular debris and other membrane components that might otherwise be 
labelled for receptors and transporters that are not associated with an intact nerve 
terminal.
54
1.10% (w/v) of rat 
frontal cortex 
homogenate in SH 
buffer
10OOg for 
10 min 2. Si supernatant layered 
onto Percoll discontinuous 
density gradient
Figure 2.1. Schematic of synaptosome 
purification by use of Percoll™ 
discontinuous density gradients.
Synaptosomes were homogenised as described 
in section 2.3.1. The resultant Si supernatant 
was layered onto the prepared Percoll™ 
gradients. Fractions F1-F5 contain the following; 
F1: membranes, myelin, small synaptosomes. 
F2: myelin, small synaptosomes. F3: Large 
synaptosomes, plasma membranes. F4: 
Synaptosomes. F5: Mitochondria and
synaptosomes (Robinson & Lovenburg, 1986; 
Dunkley etal., 1988; Harrison etal., 1988). The 














Percoll™ was filtered using 5pM Millipore SM filters to remove coagulates. Four solutions 
of SH buffer were made up consisting of 23,15,10 and 3% (v/v) Percoll™ respectively. 
Starting with the highest percentage Percoll™/SH solution, 2 ml of each of the solutions 
were layered upon one another using a peristaltic pump (via tubing fitted with 12g needle 
ends) set at a rate of 0.5 ml per min in polycarbonate centrifuge tubes. Four centrifuge 
tubes were prepared in this manner and then left in the fridge at <4°C until required.
Frontal cortex supernatant (Si fraction; described above) was layered onto the gradients 
(using 20g needles attached to the tubing). The gradients were then centrifuged for 5 min 
(not including acceleration/deceleration times) at 33,000g (using a Sorvall SM-24 rotor and 
Beckman Coulter Avanti™ J-25 centrifuge)
This produced five visible fractions above, below and between the gradients, numbered 
sequentially from the top with fraction 1 being the first visible fraction from the top of the 
centrifuge tube. (See Fig. 2.1.). Fraction 4 was carefully removed using a Pasteur pipette
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and pooled equally into two clean centrifuge tubes. The pooled F4 fractions were then re­
suspended to 10 ml of cold sucrose-Hepes buffer and centrifuged at 20,000g for 15 
minutes. The resulting pellet was extracted, re-suspending with cold KB buffer 
centrifugation at 20,000g was repeated leaving a small pellet of synaptosomes that could 
then be transferred for immunocytochemical investigation.
2.5.4. Frontal cortex mince preparation
Frontal cortex minces were prepared using a Mcllwain tissue chopper; 250uM slices cut at 
3x 60Q angles (minces). Minces were then placed in 5 ml of ice cold KB and subject to 
washing (three times in 6 ml KB buffer, spinning down between washes using a bench 
centrifuge; 2000 rpm for 5 seconds). The final pellet was gently resuspended in 4 ml of KB 
buffer and left to incubate for 10 min in a 10 ml universal sterile tube placed in a 
thermostatically controlled water bath set at 37°C, prior to subsequent steps detailed 
below (section 2.7.2).
2.6 [3H]D-aspartate uptake.
2.6.1 Standard [3H]D-aspartate uptake for release experiments
The final P2 suspension in KB buffer (described at end of section 2.5.1) was incubated for 
15 min at 37°C containing a final concentration of 0.2 nM [3H]D-aspartate (14-21 Ci/mmol) 
in a closed polycarbonate centrifuge tube. These ‘loaded’ synaptosomes were then subject 
to [3H]D-aspartate release experiments (see below; section 2.7.1).
2.6.2 Temperature dependency of [3H]D-aspartate uptake
The uptake of [3H]D-aspartate was assessed at two different temperatures, <4°C and 
37°C. For the <4°C experiments, an 800 pil aliquot taken from the final 2.5 ml P2 
suspension in KB buffer was placed in a 1.5 ml Eppendorf and left on ice for 15 min. [3H]D-
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aspartate was then added to the Eppendorf to give a final concentration of 0.2 pM and left 
to incubate on ice for a further 15 min. For the 37°C experiments, the investigation was 
carried out in parallel to the <4°C experiment. All subsequent steps were exactly as 
described for the <4°C experiment except that of the incubation temperature, maintained 
at 37°C using a thermostatically controlled water bath. All subsequent steps for both 
conditions are described below in section 2.6.5 (see below).
2.6.3 Concentration dependence of [3H]D-aspartate uptake
[3H]D-aspartate was added to 800 pi aliquots of the final P2 suspension described above 
(section 2.5.1) to give final concentrations of 0.03, 0.1, 0.2 and 0.3 pM. Each suspension 
was then incubated for 15 minutes at 37°C in a temperature controlled water bath. All 
subsequent steps are described in section 2.6.5 (see below).
2.6.4 Substrate specificity of [3H]D-aspartate uptake: Glutamate transporter 
blockers and endogenous glutamate transporter ligands
To determine if the uptake of [3H]D-aspartate was via a transporter mediated process, 
natural ligands and transporter blockers were added to the synaptosome suspension 
medium, prior to and during the incubation with [3H]D-aspartate (Final concentration 0.2 
M-M).
Similar to the temperature and concentration dependence experiments, 800 jllI aliquots of 
the final P2 synaptosome suspension were initially placed in a 1.5 ml Eppendorf and 
incubated at 37°C for 15 min. The aliquots of synaptosomes were then subject to the 
following: For glutamate transporter blocker experiments, the compound DL-TBOA (10- 
10OpiM) or L-trans-2,4-PDC (1-100 pM) was added to an 800 pi aliquot suspension of 
synaptosomes and incubated for a further 15 minutes prior to the addition of [3H]D-
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aspartate (Final concentration 0.2 pM). For natural transporter ligand experiments L- 
glutamate and D-aspartate were added as a 1000 fold excess concentration (200 pM) to 
the synaptosome suspension at the same time as the addition of [3H]D-aspartate (Final 
concentration 0.2 pM). Aliquots were incubated for 15 min at 37°C in a temperature 
controlled water bath. All subsequent steps are described in section 2.6.5 (see below).
2.6.5 Filtration and scintillation counting
At the end of these procedures (sections 2 .6 .2 -2 .6.4), 3 x 150 jliI of each suspension was 
extracted from the Eppendorf tubes and dispensed onto a GF/C Millipore filter within a 
chamber of the Millipore® Manifold filtration system. Each filter was then washed twice with 
KB buffer and the filters carefully removed and placed into scintillation vials. Optisafe liquid 
scintillant (4 ml) was added to each of the vials and then counted for radioactivity using a 
Packard Scintillation counter (Packard Tri Carb 1600 TR Liquid scintillation analyser). 2 x 
150 pi of each unfiltered suspension from the Eppendorf tubes was added directly to the 
scintillation vials containing 4 ml of Optisafe liquid scintillant and also counted for 
radioactivity (Counting efficiency = 46 %).
2.7 [3H]D-aspartate release: Superfusion
2.7.1 Superfusion of frontal cortex synaptosomes loaded with [3H]D-aspartate
From the 2.5 ml final suspension of synaptosomes in KB buffer, (pre-loaded with a final 
concentration of 0.2 pM [3H]D-aspartate; Section 2.5.1) 120 pi aliquots were added 
(approximately 0.2 mg of protein per aliquot) to each of the 12 parallel open chambers of a 
modified Brandel® superfusion apparatus (Model SF-12; Brandel, Gaithersburg, MD; 
Soliakov et a l, 1995. See Fig. 2.2.), containing Whatman GF/B filter discs. Synaptosomes 
were superfused at a rate of 0.75 ml/min with KB buffer. After a 24 min washout period,
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two-min fractions of perfusate were collected. After a further 6 min, nAChR agonist and/or 
depolarising agent in KB buffer or buffer as a control, were delivered to the chambers as a 
90 s pulse, separated from the bulk buffer flow by 2 s air gaps. Synaptosomes were 
superfused for a further 22 min with Krebs-bicarbonate buffer. The radioactivity of each 
fraction was measured in a Packard Tri Carb 1600 TR Liquid scintillation analyser. When 
present, nAChR antagonists or glutamate transporter inhibitors were included in the 
perfusing buffer for 10 min prior to agonist stimulation (except for a-Bgt which was applied 
for 20 min and PDC or TBOA applied throughout). Antagonist was present during the 
stimulation and remained throughout the rest of the experiment. To determine the Ca2+- 
dependency of KCI and nAChR evoked release, synaptosomes were perfused with Ca2+- 









Figure 2.2. Diagram of the 12 channel manual Brandel® superfusion system. P2
synaptosomes (120 pil) loaded with [3H]D-aspartate were placed directly on each of the twelve 
chambers containing 2x Whatman GFB filters (D). Collecting probes (B), are placed in test tubes 
containing KB perfusing buffer, agonists or antagonists, kept at 37°C in the attached water bath 
reservoir (A). Attached peristaltic pump; (C), pumps buffer over the filter bed containing the 
synaptosomes and perfusate is collected via tubing (E, blue) attached to a second peristaltic pump 
(F), that pumps perfusate through to scintillation vials set in an automated fraction collection tray;
SSL__________________________________________________________________________________
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Each set of conditions described above (depolarising agent, agonist, antagonist and 
glutamate transport blocker) was carried out in a triplicate set of chambers within each 
experiment. Radioactivity remaining in the synaptosomes at the end of the experiment was 
determined by counting the filters from the superfusion chambers. Total radioactivity 
present in synaptosomes at the time of agonist stimulation was calculated as the sum of 
subsequently released [3H]D-aspartate plus radioactivity remaining on the filters.
2.7.2 Superfusion of frontal cortex sections loaded with [3H]D-aspartate
Frontal cortex slices (‘minces’, prepared from section 2.5.4) were spun down using a 
bench centrifuge (2000 rpm for 5 seconds) to form a loose pellet and re-suspended again 
in 4 ml of KB (pre-warmed to 37°C). [3H]D-aspartate (13 Ci/mmol -final concentration 
0.2pM) was added to the suspension of minces and left to incubate for 30 min at 37°C. 
After priming the superfusion system with KB buffer, aliquots of the mince suspension (100 
jiil; 30 mg tissue) were loaded onto each of the 20 chambers of the superfusion apparatus. 
A Nylon mesh and GF/B filter were placed at each end of the chamber to prevent slices 
from flowing out of the apparatus (See Fig. 2.3). Minces were then superfused at a rate of 
0.75 ml/min with KB buffer. After a 30 min washout period, 90 s fractions of perfusate were 
collected. After a further 6 min, nAChR agonist in KB buffer or buffer as a control, were 
delivered to the chambers as a 90 s pulse. Minces were superfused for a further 22 min 
with KB. The radioactivity of each fraction was measured in a Packard Tri Carb 1600 TR 
Liquid scintillation analyser. When present, nAChR antagonists or glutamate transporter 
inhibitors were included in the perfusing buffer for 10 min prior to agonist stimulation 
(except for a-Bgt which was applied for 20 min and TBOA which was applied throughout). 
Antagonist was present during the stimulation and remained throughout the rest of the 
experiment.
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Closed chamber where 
minces are ‘freely’ 
suspended in buffer 
medium, flowing from 
bottom to top of chamber
Figure 2.3. Diagram of the automated 20 channel Brandel9 superfusion system combined 
with electrical stimulation generator. Frontal cortex mince suspension (100 |il) loaded with 
[3H]D-aspartate were placed directly on each of the twenty chambers. Chambers were sealed at 
each end with a nylon mesh and GF/B filter to contain the minces. Electrical stimulation pegs were 
attached to either end of the chambers (See insert D). Collecting probes attached to robotic arm for 
automated changing (B), are placed in test tubes containing KB perfusing buffer, agonists or 
antagonists, kept at 37°C in the attached water bath reservoir (A). Attached peristaltic pump (C), 
pumps buffer into the closed chambers containing the minces from bottom to top of the chamber. 
Electrical stimulating pegs (red) attached to electrical stimulation generator (E). Perfusate collected 
in scintillation vials set in an automated fraction collection tray (F).
Electrical stimulation was applied as a 90 s 5Hz, 50mA bi-directional pulse, 12 min after 
the start of perfusate collection, this allows for an approximate 90 s washout of nAChR 
agonist from the closed chamber prior to electrical stimulation. Each set of conditions 
described above (electrical stimulation, agonist, antagonist) was carried out in a triplicate 
set of chambers within each experiment. Control conditions within the experiment 
consisted of disconnecting three individual chambers from the electrical stimulation 
generator.
Radioactivity remaining in the minces at the end of the experiment was determined by 
solubilising the filters containing the minces from the chambers in Solvable™ and then
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adding scintillant to count the filters from the superfusion chambers. Total radioactivity 
present in minces at the time of agonist stimulation was calculated as the sum of 
subsequently released [3H]D-aspartate plus radioactivity remaining on the filters.
2.8. Immunocytochemistry
2.8.1 Immunoiabeiling of synaptosomes
Percoll™ purified synaptosomes (Fraction 4 and some of 3, resuspended in 1.5 ml Krebs- 
bicarbonate buffer) were layered onto poly-L-lysine coated slides (0.75 ml of synaptosome 
suspension per slide) in a humidified chamber, and incubated for 45 min at room 
temperature to allow the synaptosomes to adhere. Slides were rinsed in Krebs bicarbonate 
buffer to remove non-adherent synaptosomes and incubated with 100 nM Alexa-Fluor® 
488 a-Bgt for 20 min. The specificity of labelling with Alexa-Fluor® 488 a-Bgt was 
assessed by pre-incubating the slides with a 100 fold excess of MLA or a-Bgt for 20 min, 
prior to the addition of the fluorochrome. Further controls were incubated with Krebs buffer 
alone. Slides were rinsed in Krebs and fixed in PBS (10 mM phosphate buffer containing 
NaCI 150 mM and KCI 2 mM), containing 4% paraformaldehyde (PFA) for 10 min. Slides 
were washed in PBS to remove fixative and incubated in PBS containing 10% normal goat 
serum, 0.5% BSA and 0.1% saponin for 30 min at room temperature. Primary antibodies 
(mouse anti-synaptophysin (1/500 dilution), rabbit anti-VGluT 1(1/1000 dilution) and anti- 
VGIuT2 (1/500 dilution) were added in PBS containing 1% normal goat serum, 0.5% BSA 
and 0.1% saponin. For those experiments where 02 nAChR identification was necessary, 
the primary rat antibody specific for the 02 nAChR subunit (mAb 270; generously donated 
by Professor J Lindstrom, University of Pennsylvania) was also incubated, with the 
omission of the mouse anti-synaptophysin antibody from the incubation. Slides were 
incubated overnight at 4°C in a humidified chamber. After three 5 min washes with PBS
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containing 0.1% saponin, slides were incubated with secondary antibody solution (anti­
rabbit IgG 633 and anti-mouse IgG 546, (and/or anti-rat IgG 546 for P2 subunit labelling 
experiments) both 1:750 in 1% normal goat serum, 0.5% BSA and 0.1% saponin in PBS) 
for 1 h at room temperature in the dark. Slides were washed in PBS containing 0.1% 
saponin for 5 min followed by PBS alone, to remove excess secondary antibodies before 
mounting with Vectorshiela™ and viewing under the Zeiss Axiovert 100 M microscope 
combined with an LSM 510 confocal system.
2.8.2 Immunolabelling of rat frontal cortex sections
For rat frontal cortex sections, male Sprague Dawley rats (250 g) were anaesthetised with 
sodium pentobarbitone (Sagatal™, 60mg/kg, i.p) and trans-cardially perfused with 150 ml 
4% PFA in PBS. Coronal and sagital sections of the frontal cortex (50 pM thick) were cut 
using a Vibratome™ 1000 (General Scientific, Redhill, Surrey) and incubated in PBS 
containing 1% sodium borohydride for 10 min to block free aldehyde groups. After washing 
in PBS, sections were blocked in PBS containing 10% normal goat serum, 0.5% BSA and 
0.5% Triton-X100 for 30 min at room temperature. Primary antibodies (mouse anti-NeuN 
(1/500 dilution), rabbit anti-VGIuT1 (1/1000 dilution), anti-VGIuT2 (1/500 dilution) and 100 
nM Alexa-Fluor® 488 a-Bgt were added in PBS containing 1% normal goat serum, 0.5% 
BSA and 0.5% Triton-X100 and the sections incubated overnight at 4°C on a shaker. For 
those experiments where P2 nAChR identification was necessary, the primary rat antibody 
specific for the P2 nAChR subunit (mAb 270; generously supplied by Professor Jon 
Lindstrom) was also incubated, with the omission of the mouse anti-NeuN antibody from 
the incubation. All subsequent steps followed the same procedures as for synaptosomes, 
with the replacement of 0.1% saponin with 0.5% Triton-X100 in all washing and antibody 
solutions. After the final washing step, sections were mounted on slides with
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Vectorshield™ and viewed under the Zeiss Axiovert 100 M microscope combined with 
LSM 510 confocal system. Controls were performed in the same manner as for the 
synaptosomes experiments, by preincubating with a 100-fold excess of MLA or a-Bgt and 
by the omission of the primary antibodies.
2.8.3 Confocai microscopy
Immunolabelled synaptosomes and tissue sections were analysed using the Zeiss multi­
tracking protocol, which eliminates the possibility of fluorochrome ‘cross-talk’ through the 
use of sequential fluorochrome excitation. Fluorochromes were excited using an argon 
laser at 488nm (505-530nm emission filter), a helium-neon laser at 543nm (560-615nm 
filter) and a helium-neon laser at 633nm (650nm emission filter). To ensure that the 
respective fluorescence emissions were recorded at the same level, the emission pinhole 
for each track was set at 1 airy unit.
a-Bgt labelling was recorded from ten random fields in each test group at the same 
magnification (x63 objective lens). The density of the a-Bgt binding in control and 
antagonist competition groups was compared using the Student’s paired t-test. To assist 
the interpretation of the spatial localisation of a-Bgt labelled sites with respect to other 
neurochemical markers, such as VGluT, the Zeiss profiling software was utilised. This tool 
enables the quantification of individual fluorescence emission intensities along a user- 
defined axis through the sample. Colocalisation of a-Bgt with VGluT fluorescent labelling 
was quantitated in fifteen random fields by inspection of intensity profiles
2.9 Protein Estimation
To ensure consistent protein concentration of synaptosome preparations between 
experiments, protein concentration was measured using the Bradford method (Bradford,
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1976). Now adapted commercially, the Biorad™ protein assay kit enables a fast 
determination of protein in tissue samples.
Essentially the assay reagent was diluted 1:4 using distilled water and filtered through 
Whatman filter paper. A standard protein curve was constructed using triplicate samples of 
Bovine Serum Albumin (BSA), dissolved in assay buffer (the same buffer used for 
incubation of synaptosomes) over a concentration range of 0.1-1 mg/ml. Rat synaptosome 
samples were diluted 1:2, 1:4 and 1:8 in KB buffer, in triplicate. Using LP4 tubes, the 
reaction mixture consisted of 1 ml diluted assay reagent plus 10 pi of either BSA standards 
or diluted synaptosome samples. Tubes were vortexed and left to react for 1 h. Samples 
were then transferred to 1 ml optical cuvettes and measured for optical density at 595 nm 
using a Helios Gamma spectrometer.
2.10 Data analysis
For release experiments, superfusion data were analysed by fitting a double exponential 
decay equation to the baseline data (Soliakov et at, 1995) using the Sigma plot (v.2.0) for 
programme for Windows 3.1 (Jandel Scientific):
y =  ae~bx + ce dx
where a and c are initial (at x=0) release in each phase, b and d are the decay constants 
in each phase, and x is the fraction number. Evoked [3H]D-aspartate release was 
calculated as the area under the peak after subtraction of baseline and expressed as a 
percentage of the total radioactivity present in the synaptosomes at the point of stimulation 
(fractional release). This was taken to be the sum of subsequently released [3H]D- 
aspartate plus that on the filters (synaptosomes or minces).
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Data are presented as either fractional release, which has been subtracted for buffer 
response, or expressed as a percentage of buffer control, i.e. the release evoked by buffer 
(containing no drug conditions), was taken as 100%. Values in histograms and 
concentration response curves represent the mean ± S.E.M of the number of independent 
experiments carried out, with each experiment consisting of 2 or 3 replicate chambers for 
each condition. Statistical analysis of data was carried out using Student’s unpaired t-test 
or ANOVA with post hoc tukeys analysis, as stated in the figure legends. Values of P<0.01 
or p<0.05 were taken to be statistically significant.
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Chapter 3 Section 1
3.1 Characterisation of [3H]D-aspartate uptake and 
release in the rat frontal cortex
67
3.1.1 Introduction
3.1.2 A critical analysis of the use of D-aspartate
[3H]D-aspartate is one of the most widely employed radiolabelled EAA used to 
examine the release of EAA from vertebrate CNS tissue. Added exogenously, in vivo 
or in vitro, to brain slices, synaptosomes or neuronal cell cultures, [3H]D-aspartate 
(and D-aspartate) has elucidated the identification of glutamatergic terminals and 
pathways (Taxt & Storm-Mathisen, 1984; Jay et al., 1992; Saint-Mairie 1996; 
Gundersen et al., 1996) as well as reveal the ionic dependency for uptake and 
release of EAA (Erecinska etal., 1983. Arqueros et al., 1985; Simonato etal., 1993; 
Palmer & Reiter, 1994; Muzzolini etal., 1996; Savage et al., 2001). As well as these 
studies, [3H]D-aspartate has proved a useful marker for EAA uptake experiments 
with respect to the identification of novel ligands for the EAA transporters and indeed 
for the characterisation, localisation and sub-cellular localisation of EAAT subtypes 
in brain tissue (Ferkany & Coyle, 1986; Bridges et al., 1991; Kuwahara et al., 1992; 
Dunlop et al., 1993; Waagepetersen et al., 2001; For review see Takahashi et al., 
1997 and Danbolt, 2001).
Several advantages of D-aspartate support its use as a surrogate for the 
examination of uptake and release of endogenous EAA. Firstly, D-aspartate is a 
ligand for the EAAT (the family of presently cloned glutamate transporters) and is 
actively taken up into brain preparations in vivo and in vitro (Davies & Johnston, 
1976; Storm-Mathisen & Wold, 1981; Fischer et al., 1986; Dunlop et al., 1993; 
Dunlop, 2001; Waagepetersen et al., 2001; Suchak et al., 2003). EAA transporters 
affinity for D-aspartate is typically in the low micromolar range (30-80 piM) and a 
factor of two less than L-glutamate (Drejer etal., 1983; Gegelashvilli etal., 1998: for 
review see Danbolt, 2001). Secondly, D-aspartate has a limited role in cellular
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metabolic activities, compared to that of endogenous EAA’s such as L-glutamate, 
thereby increasing the ‘releasable’ pool of neurotransmitter available for detection of 
its release. However, this does not rule out that D-aspartate does not exist 
endogenously within the vertebrate CNS, where possible roles of this amino acid in 
neuroendocrine function have been demonstrated (Schell et al., 1997). Possible 
roles in neurotransmission have yet to be demonstrated, at present this ligand fails 
to evoke responses in reconstituted ionotropic or metabotropic glutamate receptors 
(NMDA/AMPA/mGluR receptors; for review Dingledine et al., 1999), yet an 
interesting observation by D’Aniello & colleagues (2000) demonstrate that intra- 
peritoneal administration of D-aspartic acid in rats increases the concentration of 
NMDA in the adenophysis, suggesting that D-aspartate acts as a precursor 
substrate to in vivo formation of NMDA catalysed by the enzyme methyltransferase. 
Thirdly D-aspartate displays no affinity for EAA receptors (either metabotropic or 
ionotropic) that can mediate excitatory neurotransmission, thereby avoiding any 
receptor interaction that might influence auto-regulation of release (however the 
release of endogenous EAA may influence this possibility) (Zhou et al., 1995; Patel 
& Croucher, 1997; Thomas etal., 2000; for review see Cartmell & Schoepp, 2000). 
However the use of this analogue has not been without criticism (see Nicholls, 1989; 
Nicholls & Attwell, 1990) mainly based on the lack of evidence supporting the 
containment of D-aspartate in synaptic vesicles of glutamatergic terminals and the 
apparent lack of evidence for Ca2+-dependant release of [3H]D-aspartate.
More recently, the concern of whether [3H]D-aspartate is taken up into vesicles has 
been addressed in an extensive study by Fleck et al. (2001). Using rat synaptic 
vesicles purified by immunoprecipitation with monoclonal anti-synaptophysin
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antibodies, these authors reported that D-aspartate does accumulate into a common 
vesicular pool shared with L-glutamate.
With respect to release of [3H]D-aspartate, a number of superfusion studies 
demonstrate Ca2+-dependancy; [3H]D-aspartate release is reduced in the absence of 
Ca2+ in the perfusing buffer and sensitive to the synaptic vesicle toxin bafilomycin, 
consistent with an exocytotic mechanism of vesicular release as described for 
endogenous glutamate release (Simonato et al., 1993; Palmer & Reiter, 1994; 
Muzzolini et al., 1997; Savage et al., 2001). As well as this, the propensity for the 
EAAT to reverse in depolarising conditions is also observed using [3H]D-aspartate 
(Waagepetersen et al., 2001) in agreement with the calcium-independent 
component of depolarisation-evoked [3H]D-aspartate and glutamate release being 
attributed to EAA transporter reversal (Nicholls & Attwell, 1990; Szatkowski et al., 
1990; Phillis etal., 1994).
The purpose of this section is to provide supporting evidence for the use of D- 
aspartate as a suitable surrogate to EAA in both uptake and release experiments 
using rat frontal cortex synaptosomes.
[3H]D-aspartate uptake experiments demonstrate the effect of temperature and 
substrate specificity of the transporter mechanisms that exist in rat frontal cortex 
synaptosome preparations. General depolarising agents (KCI, 4-AP and veratradine) 
were examined for their effect on release of [3H]D-aspartate from rat frontal cortex 
synaptosomes. Release evoked by KCI displayed both Ca2+-dependant and Ca2+- 
independent components of release in agreement with reports described for 
glutamate release from rat synaptosomes (Reviewed by Nicholls, 1998).
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3.1.3 Results
3.1.4 Characterisation of [3H]D-aspartate uptake
The accumulation of [3H]D-aspartate into synaptosomes was first assessed using rat 
frontal cortex Percoll™ purified synaptosomes (See methods; Thorne et al., 1991). 
Aliquots of Percoll™ purified synaptosomes were incubated for 15 min at 37°C prior 
to the addition of [3H]D-aspartate (See methods). Percoll™ purified synaptosomes 
incubated with [3H]D-aspartate over a concentration range of 0.03-0.3 liM, displayed 
a relatively uniform percentage uptake of radiolabel (49.9-56.9%; see Fig. 3.1.1).
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Figure 3.1.1 Uptake of [3H]D-aspartate into rat frontal cortex Percoll™ purified 
synaptosomes. Percoll™ purified synaptosomes were incubated for 15 minutes and 
divided into aliquots prior to the addition of [3H]D-aspartate. Each aliquot was then incubated 
for a further 15 min with a specific concentration of [3H]D-aspartate. After this period, 
synaptosomes were placed on filters, washed twice with KB buffer and then counted for 
radioactivity (see Methods 2.6.5). (A) Radioactivity taken up by synaptosomes retained on 
the filters is expressed as a % of the total radioactivity added to the respective aliquot. (B) 
Uptake of [3H]D-aspartate is expressed as pmoles per mg of synaptosome protein. Results 
are expressed as the mean ± S.E.M of at least three independent experiments.__________
Protein concentration of each aliquot was also examined using the Bradford method 
(see Methods section 2.9) and showed that each aliquot had a relatively constant 
synaptosome concentration in each condition examined (1.09 ± 0.03 mg/ml). 
Combining both the raw C.P.M of the uptake data and the synaptosome protein
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concentration, uptake can be expressed as pmoles/mg of protein (See Fig. 3.1.1 B). 
Uptake showed a linear increase with concentration reflecting that uptake is not 
saturated in this concentration range.
Both the temperature dependency of uptake and ligand specificity were examined to 
confirm that the uptake of [3H]D-aspartate is via a transporter-mediated process in 
rat frontal cortex synaptosomes.
Control <4°C XS- XS- DL-
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Figure 3.1.2 Temperature dependency and substrate specificity of [3H]D-aspartate
uptake into rat frontal cortex Percoll™ purified synaptosomes. Percoll™ purified 
synaptosomes (1.1 ± 0.2 mg/ml) were incubated for 15 minutes and then divided into 
aliquots. Each aliquot was then incubated for a further 15 min with [3H]D-aspartate + specific 
condition (see Methods 2.6.1-2.6.4). After this period, synaptosomes were filtered, washed 
twice with KB buffer and counted for radioactivity (see Methods section 2.6.5). Results are 
expressed as the % of uptake in control conditions. Results are expressed as the mean ± 
S.E.M of at least three independent experiments.
To assess the effect of temperature dependency, synaptosomes were pre-incubated 
for 15 min in ice cold KB (<4°C) prior to the addition of [3H]D-aspartate (0.2 pM) (see 
Methods section 2.6.2). As shown in Fig 3.1.2, incubation of synaptosomes at <4°C 
reduces uptake by 63.3 ± 11.9% compared to control. However, the addition of 
synaptosomes to buffer containing [3H]D-aspartate (0.2 pM) and an excess of D- 
aspartate or L-glutamate (20 pM), reduced uptake by only 14.2 ± 4.3% and 17.6 ±
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14.0% respectively. Transporter specificity was also assessed using the transporter 
blocker DL-TBOA, a non-transportable blocker of EAAT1-3 (Shimamoto etal., 1998; 
Jabaudon etal., 1999; Waagpetersen etal., 2000). Synaptosomes pre-incubated for 
15 min at 37°C with 10 [xM DL-TBOA and then further incubated with KB containing 
DL-TBOA and [3H]D-aspartate (0.2 jxM) demonstrated no blockade of [3H]D- 
aspartate uptake (see Fig. 3.1.2).
The lack of effect of these conditions raised grave concerns over the specificity of 
uptake and so a repeat of these conditions was assessed in P2 synaptosomes on 
the grounds that the preparatory conditions required for Percoll™ purified 
synaptosomes made them unviable for assessment of uptake (see discussion). In 
support of this, it was observed from release experiments that basal release of 
[3H]D-aspartate from Percoll™ purified synaptosomes was approximately 4 fold 
higher than that shown for P2 synaptosomes (See Fig. 3.1.11 below), raising the 
argument that the membranes of Percoll™ purified synaptosomes are ‘leaky’ and 
simply allow for the passive movement of [3H]D-aspartate across the membrane 
independent of EAAT.
P2 synaptosomes displayed a similar level of uptake for 0.2 [3H]D-aspartate
compared to Percoll™ purified synaptosomes (47.1 ± 3.4% of total radioactivity 
added to synaptosome aliquot). P2 synaptosomes were slightly higher in protein 
concentration compared to Percoll™ purified synaptosomes (1.75 ± 0.18 mg/ml) 
where the final amount of [3H]D-aspartate taken up into synaptosomes was 58.01 ± 
3.4 pmoles/mg. When P2 synaptosomes were subjected to different incubation 
temperatures and substrate conditions, a clear case for transporter specificity of 
uptake was demonstrated. At low temperatures (<4°C), uptake of a standard 
concentration of [3H]D-aspartate (0.2 jxM) is reduced by 39.9 ±13.1% compared to
73
control (control conditions 37°C; 100 ± 3.4%). With respect to the presence of 
excess D-aspartate and L-glutamate (20 nM), uptake is reduced to a similar extent:
35.0 ± 6.2% and 44.2 ± 5.8% respectively. In addition, the presence of TBOA in the 
incubating medium reduced uptake by P2 synaptosomes by 40.0 ± 3.1 % (See Fig. 
3.1.3).
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Figure 3.1.3 Temperature dependency and substrate specificity of [3H]D-aspartate 
uptake into rat frontal cortex P2 purified synaptosomes. P2 synaptosomes (1.8 ± 0.3
mg/ml) were incubated for 15 minutes prior and then divided into separate aliquots. Each 
aliquot was then incubated for a further 15 min with a [3H]D-aspartate + specific condition 
(see Methods 2.6.1-2.6.4). After this period, synaptosomes were filtered, washed twice with 
KB buffer and counted for radioactivity (see Methods 2.6.5). Results are expressed as the % 
of uptake compared to control conditions. Results are expressed as the mean ± S.E.M of at 
least three independent experiments. * Significantly different from control P<0.05, one way 
ANOVA with post hoc Tukeys analysis.
All these values were significantly different from control (P<0.05) using a one-way 
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Figure 3.1.4 Concentration dependant effect of L-Trans-2,4-PDC (PDC) on [3H]D- 
aspartate uptake into rat frontal cortex P2 purified synaptosomes. P2 synaptosomes 
(1.8 ± 0.3 mg/ml) were incubated for 15 minutes prior and then split into separate aliquots. 
Each aliquot was then incubated for a further 15 min with [3H]D-aspartate (0.2 pM) + PDC 
(see Methods section 2.6.4). After this period, synaptosomes were filtered, washed twice 
with KB buffer and counted for radioactivity. Results are expressed as the % of compared to 
control conditions. Results are expressed as the mean ± S.E.M of at least three independent 
experiments. * Significantly different from control P<0.05, one way ANOVA with post hoc 
Tukeys analysis.
Another glutamate transporter inhibitor, L-trans-Pyrrolidine-2,4-dicarboxylic acid 
(PDC) was assessed for inhibition of [3H]D-aspartate over a range of concentrations. 
Concentration dependant inhibition of uptake was observed at 10 and 100 pM PDC, 
reducing uptake by 28.3 ± 4.1% and 36.1 ± 3.4% respectively (control conditions = 
100 ±5.5%: See Fig. 3.1.4).
Another set of uptake experiments aimed to look at the effect of diluting the P2 
synaptosome sample. Endogenous release of synaptosome metabolites or 
neurotransmitters may effect the local pH environment as well as other receptors on 
the synaptosome membrane, which may, in turn, effect the functioning of the EAA 
transporter. In diluted conditions these changes may be buffered more efficiently,
75
thereby decreasing any possible effects on the transporter, in terms of transporter 
reversal or non-specific entry of [3H]D-aspartate into synaptosomes.
In control conditions total radioactivity taken up in the 1 in 5 diluted synaptosomes 
(48.4 ± 3.9 %) was not statistically different from undiluted synaptosomes. However 
the amount of [3H]D-aspartate per mg of synaptosome protein was approximately 5 
fold higher than undiiuted synaptosomes (245 ± 12.4 pmoies/mg of synaptosome 
protein) reflecting efficient uptake when synaptosome protein concentration is lower. 
Uptake into synaptosomes diluted 1 in 5 in KB demonstrated a different profile of 
inhibition compared to the undiluted P2 synaptosomes when subjected to the 
conditions described above.
Figure 3.1.5 Temperature dependency and substrate specificity of [3H]D-aspartate 
uptake into rat frontal cortex P2 purified synaptosomes diluted 1 in 5 in KB. P2
synaptosomes diluted 1 in 5 from their original suspension (0.41 ± 0.08 mg/ml) were 
incubated for 15 min at 37°C and then split into separate aliquots. Each aliquot was then 
incubated for a further 15 min with [3H]D-aspartate (0.2 p,M) + specific condition (see 
Methods 2.6.2-2.6.4). After this period, synaptosomes were filtered, washed twice with KB 
buffer and counted for radioactivity. Results are expressed as the % uptake compared to 
control conditions. Results are expressed as the mean ± S.E.M of at least three independent 
experiments. * Significantly different from control P<0.05, one way ANOVA with post hoc 
Tukeys analysis.
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Both low temperature and excess D-aspartate resulted in relatively similar levels of 
uptake inhibition as described for undiluted synaptosomes (33.7 ±9.8% and 61.5 ± 
21.3% inhibition respectively, compared to control; 100 ± 12.7%). However, the 
presence of excess glutamate in the incubation medium produced an 80.2 ± 4.0% 
inhibition of [3H]D-aspartate uptake (see Fig. 3.1.5; compare 44.2 ± 5.8% inhibition in 
undiluted P2 synaptosomes in Fig. 3.1.3). TBOA (10 \iW\) also inhibited uptake at 10 
pM, reducing uptake by 27.5 ± 10.8%, which is lower, although not statistically 
different, than that observed in undiluted P2 synaptosomes. Increasing the 
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Figure 3.1.6 Substrate specificity of [3H]D-aspartate uptake into rat frontal cortex P2 
purified synaptosomes diluted 1 in 10 in KB. P2 synaptosomes diluted 1 in 10 from their 
original suspension (0.2 ± 0.04 mg/ml) were incubated for 15 min at 37°C and then split into 
separate aliquots. Each aliquot was then incubated for a further 15 min with [3H]D-aspartate 
(0.2 nM) + specific condition (see Methods 2.6.2-2.6.4). After this period, synaptosomes 
were washed twice with KB buffer and counted for radioactivity. Results are expressed as 
the % uptake compared to control conditions. Results are the mean ± S.E.M of at least three 
independent experiments. * Significantly different from control P<0.05, one way ANOVA with 
post hoc Tukeys analysis.
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A similar set of experiments looked at further diluting the original P2 synaptosome 
suspension to 1 in 10 in KB. In this case the total amount of radioactivity taken up in 
control conditions represented 20.9 ± 2.7% of the total radioactivity added however 
the amount of [3H]D-aspartate per mg of protein was approximately similar to the 1 in 
5 dilution of synaptosomes (244 ± 15.4 pmoles/mg of synaptosome protein). Only 
the effect of different substrates and TBOA was examined in these experiments (Fig.
3.1.6 above). In these diluted synaptosomes the presence of excess D-aspartate 
had a dramatic effect on the inhibition of [3H]D-aspartate, reducing uptake by 82.4 ± 
0.3%, whereas the inhibition incurred in the presence of excess L-glutamate was 
similar to that obtained in the synaptosomes diluted 1 in 5 (82.9 ± 1.3%). TBOA (10 
^M) inhibited [3H]D-aspartate uptake by a 58.9 ± 1.4% again similar to that obtained 
in synaptosomes diluted 1 in 5.
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3.1.5 Characterisation of [3H]D-aspartate release
The release of [3H]D-aspartate from frontal cortex synaptosomes was studied by 
superfusion, and was first assessed using classical depolarising agents, applied as a 
90 s pulse to the superfused synaptosomes. 4-Aminopyridine (4-AP), KCI and 
veratradine each provoked the release of [3H]D-aspartate (Fig. 3.1.7).
10 nM
Figure 3.1.7 [3H]D-aspartate release as evoked by depolarising agents applied to 
frontal cortex synaptosomes. Rat frontal cortex P2 synaptosomes were superfused with 
KB buffer and stimulated for 90 s with a range of depolarising agents using a 12 channel 
Brandel™ superfusion apparatus. Release evoked by veratridine was also examined in the 
presence of TTX, applied 10 min prior to and throughout veratradine stimulation. Release is 
expressed as a fraction of the total radioactivity remaining in the preparation at the point of 
stimulation. Results represent the mean ± S.E.M of at least three independent experiments 
for each depolarising agent concentration.
4-AP (1 mM) released 2.4 ± 0.1% of the total radioactivity (‘fractional release’). 
Veratradine (10 pM) produced a bigger response, of 11.6 ± 0.9%, and this was 
inhibited by 87% in the presence of tetrodotoxin (TTX; 10 nM), to 1.5 ± 0.2%. The
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response to KCI was concentration-dependent, with 12 mM and 30 mM KCI 
stimulating the release of 1.9 ± 0.1% and 4.8 ± 0.1% of [3H]D-aspartate respectively. 
Over a concentration range of 3-100 mM, KCI-evoked release displayed an 
exponential increase in release whereas the concentration-dependant release of 4- 
AP was relatively linear, with an EC5oOf 0.14 mM (Fig 3.1.8 A & B).
Log KCI concentration (mM) Log 4-AP concentration (mM)
Figure 3.1.8 Concentration-dependant effect of KCI and 4-AP-evoked release of [3H]D- 
aspartate from rat frontal cortex synaptosomes. Rat frontal cortex P2 synaptosomes 
were superfused with KB buffer and stimulated for 90 s with either KCI or 4-AP over a range 
concentrations (KCI, 3-100 mM and 4-AP, 0.01-1 mM). Release for both depolarising agents 
has been adjusted for buffer-evoked release and is expressed as a fraction of the total 
radioactivity remaining in the preparation at the point of stimulation. (A) Concentration 
dependant release of [3H]D-aspartate evoked by KCI. (B) Concentration dependant release 
of [3H]D-aspartate evoked by 4-AP. Results represent the mean ± S.E.M of at least three 
independent experiments for each depolarising agent concentration. Curves fitted using 
Regression Wizard from Sigma plot v8.0 for Windows XP.
In view of the propensity of the glutamate transporter to reverse, thereby releasing 
the amino acid in a Ca2+-independent manner (Nicholls & Atwell, 1990), [3H]D- 
aspartate release in response to the lower concentration of KCI was further 
evaluated. This concentration of KCI was chosen because the magnitude of the 
response is more akin to the responses evoked by nAChR stimulation, in studies of 
dopamine release (Soliakov et al., 1995) and was also used in on-line fluorescence 
assays to determine the effect of glutamate transporter reversal of endogenous
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glutamate release (McMahon & Nicholls, 1989). Synaptosomes were perfused in the 
absence of Ca2+ (Fig. 3.1.9 A and 3.1.10), and/or the presence of an inhibitor of the 
glutamate transporter (Fig. 3.1.9 B and 3.1.10).
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Figure 3.1.9 Representative [3H]D-aspartate release profiles from rat frontal cortex 
synaptosomes: (A)The effect of absence of Ca2+ and the addition of EGTA and (B) The 
effect of glutamate transport inhibitors PDC and TBOA (A) Rat frontal cortex P2 
synaptosomes were superfused with KB buffer (± Ca 2+ and or EGTA 5 mM) and stimulated 
for 90 s with KCI 12 mM in normal KB (open circles), KB (- Ca2+; closed triangles) and KB (-
Ca + EGTA 5 mM; closed circles). (B) Rat frontal cortex P2 synaptosomes were 
superfused with KB buffer (± PDC or TBOA) and stimulated for 90 s with KCI 12 mM in 
Normal KB (closed circles), KB (+ PDC 10 |xM; open circles) and KB (+ TBOA 10 îM; closed 
triangles). Release is expressed as C.P.M of [H] D-aspartate collected in 12-14 fractions 
using the 12 channel Brandel superfusion system. Results represent the mean ± S.E.M of at 
least three chambers from a representative experiment
The decision to use KB buffer devoid of any Ca2+ rather than standard KB devoid of 
Ca2+ and supplemented with EGTA (5 mM), was because EGTA significantly raised 
the baseline release of [3H]D-aspartate from the frontal cortex synaptosomes and 
interfered with the extent of KCI-evoked release compared to control conditions (see 
Discussion for reasoning). The absence of Ca2+ (replaced with an equimolar 
concentration of Mg2+) in the KB did not affect baseline release of [3H]D-aspartate 
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Figure 3.1.10 Release of [3H]D-aspartate from rat frontal cortex synaptosomes in 
response to KCI 12 mM. Rat frontal cortex P2 synaptosomes were superfused with KB 
buffer (± Ca2+ and or transport blockers) and stimulated for 90 s with KCI 12 mM. The 
glutamate transporter was blocked by perfusing with Krebs buffer containing L-trans-2,4- 
PDC (PDC; 10 pM) or DL-TBOA (TBOA; 10 pM). To see if Ca2+-dependence was additive 
with transporter blockade, PDC was also applied in Ca2+-free buffer. Release of [3H]D- 
aspartate is expressed as a % of the KCI control, determined in parallel in Krebs buffer 
without inhibitors. Values are the mean ± S.E.M of three independent experiments with each 
condition examined in triplicate. * Significantly different from KCI control conditions, P<0.05 
students unpaired t-test, n=4
The carrier itself transports PDC, whereas TBOA is a non-transportable inhibitor 
(Bridges etal., 1991; Dunlop etal., 1993; Shimamoto etal., 1998; Waagepetersen et 
al., 2001); both compounds were compared. In the absence of Ca2+ there was no 
change in basal release, but KCI-evoked release was significantly diminished by
47.0 ± 11.0%, (Fig. 3.1.9 A and 3.1.10). PDC (10 pM) and TBOA (10 pM) reduced 
KCI-evoked release by 52.1 ± 0.4% and 50.3 ± 2.7% respectively (Fig. 3.1.9 B and 
3.1.10). PDC (10 pM) in the absence of Ca2+ produced a partially additive inhibition, 
with KCI-evoked release reduced by 81.8 ± 1.9% (Fig. 3.1.10), suggesting that under
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the conditions of our assay, exocytosis and reversal of the transporter contribute 
approximately equally to [3H]D-aspartate release elicited by 12 mM KCI. Similar 
findings have been reported with respect to the release of endogenous glutamate 
from synaptosomes (Nicholls et al., 1987).
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Figure 3.1.11 Representative [3H]D-aspartate release profiles from rat frontal cortex 
Percoll™ purified and P2 purified synaptosomes: Rat frontal cortex Percoll 
synaptosomes (closed squares) and P2 synaptosomes (open squares) were superfused 
with KB buffer and stimulated for 90 s with 4-AP (30 pM). Release is expressed as raw 
C.P.M values of [3H]D-aspartate collected in 14 fractions using the 12 channel Brandel 
superfusion system. Results represent the mean ± S.E.M of at least three chambers from a 
representative experiment.
These findings were from experiments with P2 frontal cortex synaptosomes. Initial 
studies used Percoll purified synaptosomes to assess the effect of depolarising 
agents, however it was soon observed that the baseline release of [3H]D-aspartate 
was approximately 4 fold higher than that observed for P2 synaptosomes and also 
displayed a high degree of variability (See Fig. 3.1.11). This raised the possibility 
that the lengthy procedure required to form these synaptosomes may have led to 
adverse effects on the synaptosome membrane integrity. The high baseline release 
of [3H]D-aspartate also raised doubt that with a ‘high background release’ we would
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be unable to detect, in future experiments, the nAChR modulation of [3H]D-aspartate 




To verify the use of [3H]D-aspartate as a surrogate for glutamate, we assessed its 
suitability in both uptake and release studies using rat frontal cortex synaptosomes 
(sections 3.1.1 and 3.1.5).
3.1.7 Uptake of [3H]D-aspartate
Initial experiments into uptake of [3H]D-aspartate utilised the preparation of Percoll™ 
purified synaptosomes. Although this preparation displayed accumulation of [3H]D- 
aspartate after filtration and counting (Fig. 3.1.1 A and B), there appeared little 
evidence of a transporter-mediated process of uptake (Fig. 3.1.2). Lowering the 
temperature of the incubation medium inhibited uptake: although this could reflect 
the indirect energy dependence of the EAAT’s, (Danbolt, 2001), it is more likely to 
reflect a reduction in passive movement of [3H]D-aspartate across the lipid bilayer of 
the synaptosomes or compromised functioning of EAAT. In terms of membrane 
viability, Percoll™ purification of an Si fraction of synaptosomes is a relatively 
extensive procedure (approximately 1 hour longer than a P2 preparation), where the 
tissue is subjected to a more severe mechanical procedure in the final resuspension 
and separation of the synaptosome pellet compared to P2 synaptosomes. Although 
synaptosomes are maintained in isotonic conditions, the harsh resuspension steps, 
due to the dense nature of the final pellet, could result in lower membrane integrity 
for Percoll™ purified synaptosomes compared to that of P2 synaptosomes. This 
possibility is supported further in our own experiments where it is noted that the 
baseline release of [3H]D-aspartate in superfused synaptosomes is considerably 
higher (approximately 4 fold) in Percoll™ synaptosomes than in P2 synaptosomes 
(see Fig. 3.1.11). However, according to the reports by Dunkley et al. (1988), and
85
Harrison etal. (1988), fractions 3 and 4 of the Percoll™ separation of Si have a high 
content of viable synaptosomes with slight differences detailed in the size of 
synaptosomes between the two fractions. These authors report that synaptosomes 
are functional in terms of protein phosphorylation, and NAdr uptake and release. 
Further to this, results presented in Chapter 4 demonstrate that Percoll™ purified 
synaptosomes can be labelled with anti-synaptophysin and anti-VGluT 1 & 2, 
indicative of a glutamatergic presynaptic terminal; confocal images of these 
synaptosomes appear as clear rounded terminals with little evidence that membrane 
integrity is compromised. It therefore remains to be determined that this viability 
extends to the efficient functioning of EAAT; interestingly, many studies looking at 
[3H]D-aspartate uptake or [3H]L-glutamate uptake in synaptosomes do not utilise 
Percoll™ purified synaptosomes (Bridges et a!., 1991; Mitrovic & Johnston 1995; 
Fleck etal., 2001).
One important consideration that may account for the differences of uptake 
described for Percoll™ versus P2 synaptosomes is the possible contamination of the 
synaptosome preparations with gliosomes (closed vesicle elements of glial cells). 
Percoll™ gradients are believed to contain gliosomes in fractions 2 and 3, whereas 
P2 synaptosomes should contain a higher content of these vesicles. It is believed 
that the major contribution to EAA transport is via glial cells, which contain the 
EAAT, EAAT1 and EAAT2 (Danbolt, 2001; Anderson & Swanson, 2000). These 
transporters, on gliosomes, could be responsible for retaining [3H]D-aspartate 
described from the Percoll™ and P2 synaptosomes, however according to the 
literature, they should be sensitive to TBOA as well as excess D-aspartate or 
glutamate which was displayed for P2 but not for Percoll synaptosomes (see Fig. 
3.1.2; Anderson & Swanson, 2000). This could support the low content of gliosomes
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in the suspension of Percoll™ purified synaptosomes compared to P2 synaptosome 
suspension. Therefore the [3H]D-aspartate uptake demonstrated in Percoll™ purified 
synaptosomes remains unaccounted for and is likely to represent compromised 
membrane integrity or transporter function.
The use of P2 synaptosomes has been extensively used in our laboratory for the 
examination of nAChR modulation of [3H]Dopamine release (Soiiakov et al., 1995; 
Wilkie et al., 1996; Kaiser & Wonnacott 2000; Mogg et al., 2002). Although this 
preparation is essentially contaminated by non-synaptosomal elements (Nakamura 
et al., 1993; Suchak et al., 2003), the intention of use was to minimise the possible 
mechanical damage and time of preparation of the synaptosomes compared to 
Percoll™ purified synaptosomes. P2 synaptosomes showed a similar proportion of 
total radioactivity taken up in control conditions compared to Percoll™ purified 
synaptosomes, however, the amount of [3H]D-aspartate contained in the 
synaptosomes was significantly less (approximately 50%); this is likely to be the 
result of P2 synaptosomes having a higher protein concentration from other 
membrane components.
P2 synaptosomes displayed a reduced uptake of [3H]D-aspartate at <4QC and in the 
presence of excess substrates, D-aspartate and L-glutamate (see Fig. 3.1.3). A 
complete inhibition of uptake was not described, particularly in the presence of a 
thousand fold excess of D-aspartate or L-glutamate. This suggests a proportion of 
[3H]D-aspartate uptake may still be via a passive mechanism in this synaptosome 
preparation. Interestingly DL-TBOA inhibited uptake to the same extent as excess 
substrates. This non-transportable inhibitor is selective for EAAT1 and EAAT2, as 
well as EAAT3, and therefore should block all known EAAT’s present in this 
preparation, although additional unidentified EAATs could exist (for review see
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Danbolt, 2001). The IC50for DL-TBOA varies between 1-100 |liM, depending on the 
CNS tissue being used and the transporter being assessed (Jaubudon et al., 1999; 
Shimamoto et al., 1998; Waagpetersen et al., 2001;). Therefore it is not possible to 
ascertain if the concentration used (10 jliM) in these experiments would completely 
inhibit all known EAAT’s and subsequently block all uptake of [3H]D-aspartate. 
Uptake, in most conditions, could only be inhibited by approximately 50%, a 
consistent observation seen especially with low temperature experiments. However 
it is this latter observation that lends support for a passive mechanism of [3H]D- 
aspartate uptake when either transporter or membrane viability is compromised. 
Essentially, low temperatures will cease energy production that maintains the ionic 
gradients across the plasma membrane. In turn, the directional import of EAA into 
the cytoplasm, which relies on these ionic gradients, will be prevented. In these 
conditions no uptake of EAA should occur, more likely, the EAA transporter should 
reverse (Nicholls & Attwell, 1990), yet approximately 50% uptake is still observed. If 
disruption of ionic gradients or transport/cell membrane viability is the factor 
contributing to the inability to see complete inhibition of uptake by assessment of the 
transporter specificity, then, by improving the local environment of the synaptosomes 
and hence decreasing the likelihood of non-specific uptake, it was hoped that we 
could then detect, to a better extent, the transporter specific uptake of [3H]D- 
aspartate. By increasing the volume to which the original synaptosomes suspension 
is diluted in, the hypothesised increase in buffer capacity and decreased effect of 
synaptosome metabolites and endogenous neurotransmitters on synaptosome 
viability, membrane viability and EAAT function enabled almost a complete inhibition 
of uptake in the presence of excess substrates. In diluted volumes, excess substrate 
inhibited [3H]D-aspartate by as much as 80% (Both excess D-aspartate and L-
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glutamate; Fig. 3.1.6). Notably, the effect of low temperature was consistent in either 
of the dilutions (approximate 50 % uptake inhibition), supporting the possibility that 
the ionic disruption leads to non-specific, passive uptake of [3H]D-aspartate into the 
synaptosome, as seen in the original P2 preparation. The approximate 50% 
blockade by incubating synaptosomes with TBOA suggests that the concentration 
applied was sub-maximal. However, ihe inhibition described is in good agreement 
with IC5o values described for the compound in cerebellar granule neurons 
(Waagepetersen etal., 2001).
It is possible that other co-transport mechanisms for glutamate/aspartate that 
compensate for the loss of action of the EAAT 1 and 2 through DL-TBOA inhibition, 
may be at play at the level of the synaptosome membrane. Of the five EAATs cloned 
to date (EAAT1-5), the subtype specificity of EAATs at the presynaptic terminal 
membrane is poorly characterised, where only EAAT2 (Suchak et al., 2003) and a 
subtype variant form of EAAT2 (GLT 1b; Chen etal., 2002) have been described so 
far, despite a large body of evidence that EAATs responsible for [3H]D-aspartate 
uptake are present on nerve terminal endings (Robinson et al., 1993; Palmer et al., 
2003; Suchak etal., 2003). However, this considered, the effects of TBOA and PDC 
reported here are consistent with the EAAT2 subtype at the presynaptic terminal. 
Other than these transporters, it is possible that other high-affinity transporters such 
as the glutamate-cytisine heteroexchanger or glutamate-ascorbate heteroexchanger 
could contribute to the uptake of D-aspartate, that cannot be blocked by TBOA or 
PDC, or are unaffected by low temperatures. These plausible transport mechanisms 
are poorly characterised and therefore the contribution of these means of transport 
uptake is purely speculative.
89
3.1.8 Release of [3H]D-aspartate
The utility of [3H]D-aspartate as a marker for EAA release was demonstrated using 
general depolarising agents. All the data presented was obtained from the use of P2 
frontal cortex synaptosomes. This was on the basis that the use of the Percoll™ 
purified synaptosomes displayed high baseline release of [3H]D-aspartate and 
displayed no transporter specificity for [3H]D-aspartate uptake. For reasons outlined 
in results section 3.1.5, the decision was made to discontinue with the use of 
Percoll™ purified synaptosomes for the study of EAA release.
4-AP, KCI and veratridine all successfully evoked release of [3H]D-aspartate from 
synaptosomes (Fig. 3.1.7). 4-AP blocks the rapidly inactivating voltage sensitive K+A 
channels (Tibbs et al., 1989), thus raising the threshold point of the membrane 
potential to increase the likelihood of depolarisation. Interestingly, increasing 4-AP 
concentration did not evoke the release of [3H]D-aspartate to the same extent as 
increasing concentrations of KCI (see Fig. 3.1.8 A & B), which is likely to be a 
consequence of its mechanism of action; 4-AP induces brief depolarising spikes 
(mediated by Na+ channels) that avoids the propensity of the glutamate transporter 
to reverse and adds to the largely Ca2+-independent release of [3H]D-aspartate as 
exampled by KCI-evoked release (Nicholls et al., 1989; Tibbs et al., 1989; McMahon 
& Nicholls, 1991; reviewed by Nicholls, 1989 and 1993). Veratridine-evoked release 
was TTX sensitive, indicating a reliance on the activation of Na+ channels for 
membrane depolarisation, which is in agreement with previously published reports 
(Arqueros etal., 1984; Nicholls, 1989; Heron etal., 1994).
To investigate the propensity of the EAAT to reverse, the release evoked by KCI was 
examined further. Initial investigations utilised the incorporation of the Ca 2+-chelator 
EGTA to ensure that no Ca2+ was in the perfusing buffer. This has previously been
90
employed in superfusion investigations of our laboratory to demonstrate the Ca2+- 
dependency of nAChR modulation of [3H] dopamine release (Soliakov et al., 1995). 
However, as demonstrated in Fig. 3.1.9 A, baseline release of [3H]D-aspartate from 
synaptosomes perfused with KB (+ EGTA) was almost two fold greater than normal 
KB buffer. Serendipitously, the use of EGTA actually reveals EAAT reversal; EGTA 
increases Na+ influx -  the rise in intracellular Na+ removes the gradient necessary 
for EAA uptake and accordingly reverses the EAAT (Szatkowski et al., 1990; 
Bernarth et al., 1992; Simonato et al., 1993). In the absence of Ca2+-chelators 
(substituting Ca2+ with equimolar Mg2+ in the KB), baseline release of [3H]D- 
aspartate was comparable to control conditions. However, 12 mM KCI-evoked 
release was reduced by approximately 50 %. This Ca2+-dependent release is 
consistent with vesicular storage of [3H]D-aspartate and exocytotic release.
Reversal of the glutamate transporter could be directly demonstrated by using EAAT 
inhibitors. Of the two assessed, PDC significantly raised baseline release of [3H]D- 
aspartate, compared to TBOA which did not affect baseline release. This is 
consistent with the two modes of action of these transport inhibitors. PDC is a 
transportable, competitive inhibitor of EAAT; upon binding to the transporter it is 
transported across the membrane into the cytosol of the synaptosome. However, 
when it is transported across the membrane, it exchanges with intrasynaptosomal 
[3H]D-aspartate, contributing to a higher basal release of [3H]D-aspartate 
(Waagepetersen et al., 2001). Therefore when depolarising the synaptosomes with 
KCI, and instigating a reversal of the EAAT, the transporter mediated release of 
[3H]D-aspartate will be reduced due to the intrasynaptosomal competition of PDC 
with [3H]D-aspartate for the transporter. TBOA is a competitive, non-transportable 
inhibitor of EAAT (specifically EAAT1-3). The non-transportable nature of blockade
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prevents the heteroexchange of this compound with pre-loaded [3H]D-aspartate, 
consequently this would have no effect on baseline release of [3H]D-aspartate 
compared to control conditions (as seen in Fig. 3.1.9. B). It could be hypothesised 
that in control conditions (normal KB perfused P2 synaptosomes), transporter 
reversal could be contributing to the baseline release of [3H]D-aspartate from a 
proportion of synaptosomes where membrane functionality is compromised. If this is 
true, then TBOA would be expected to decrease the baseline release of [3H]D- 
aspartate compared to control by preventing [3H]D-aspartate flux through transporter 
reversal. However this was not observed in our results and supports the notion that 
P2 synaptosomes are metabolically and functionally viable. TBOA reduces KCI- 
evoked [3H]D-aspartate release to the same extent as that described for PDC, 
consistent with KCI-evoked release being partly mediated via transport reversal and 
consistent with previous reports of K+-evoked release of [3H]D-aspartate from rat 
tissue (Simonato et al., 1993; Palmer & Reiter, 1994; Zhou et al., 1995; Savage et 
al., 2000; Sehmisch et al., 2001; Waagepetersen et al., 2001). Residual [3H]D- 
aspartate release was displayed in those experiments where both occlusion of Ca2+ 
and addition of PDC in the KB perfusing medium was utilised. This release could be 
attributed to the contribution of other co-transport mechanisms acting in reverse in 
depolarising conditions (Takahashi et al., 1997) and trace amounts of Ca2+ that 
remained in the synaptosome preparation and before being perfused with Ca2+ free 
buffer.
In summary, this section supports the use of [3H]D-aspartate for examining the 
uptake and release of EAA in presynaptic nerve terminals. Until a decade ago, the 
prevailing view was against the use of D-aspartate as a suitable analogue for
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glutamate (see Introduction section 3.1.2). The use of this analogue is now gaining a 
good deal of favour. Our results demonstrate that [3H]D-aspartate displays similar 
mechanisms of uptake and release as cited for endogenous glutamate.
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Chepter 3 Section 2
3.2 nAChR enhancement of membrane depolarisation- 
evoked release of [3H]D-aspartate
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3.2.1. Introduction
Depolarising agents and electrical stimulation of CNS tissue in vitro have previously been 
employed to reveal the effects of presynaptic adenosine A-i, AMPA, D2, mGlu, and 
prostaglandin E2 receptors on facilitating the release of EAA, on the basis that application 
of agonists alone, specific for these receptors, demonstrated no detectable effect, but either 
enhanced or depressed the depolarising stimulus-evoked release (Yamamoto & Davy, 
1992; Barrie & Nicholls, 1993; Nishihara et al., 1995; Zhou et ai., 1995; Pate! & Croucher, 
1997; Nicholls, 1998; Cartmell & Schoepp, 2000).
The inability of detecting changes in EAA release directly using presynaptic receptor 
agonists or antagonists alone may be a combination of the temporal characteristics of the 
measuring system itself and the inability to outweigh the EAA uptake transporter system; 
any released EAA evoked by presynaptic receptor activation could be immediately taken up 
by the tissue preparation and thus avoid detection. Attempts to outweigh these problems 
for the direct detection of presynaptic modulation of EAA release have included fast 
superfusion rates (Palmer & Reiter, 1994; Collard, 1996) or inclusion of EAAT blockers 
(Muzzolini et al., 1996; Savage et al., 2001; Sehmisch et al., 2001), yet it should be noted 
that the incorporation of transport blockers is not always necessary for some studies (e.g. 
See Patel & Croucher, 1997).
As demonstrated in Section 3.1 of this chapter, EAA are found in two pools, vesicular and 
cytoplasmic. Vesicular release of EAA relies on the calcium dynamics within the nerve 
terminal whereas the reversal of the EAAT is partly responsible for the release of EAA from 
the cytoplasm (Nicholls, 1998). With respect to the enhancement of EAA release, 
presynaptic receptors could modulate the release by increasing the probability of vesicular 
release in response to a depolarising stimulus or indeed by increasing the likelihood of the 
EAAT to reverse. The purported presynaptic mechanisms behind this enhancement were
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summarised by Sanchez-Prieto et al. (1996), and include; (1) changing the kinetics of K+ 
and Na+ channels involved with the depolarisation-evoked release of EAA. (2) Altering the 
activation or inactivation state of calcium channels coupled to release mechanisms or 
access of Ca2+ to the exocytotic trigger or (3) acting via secondary messenger cascades at 
specific intracellular loci to change the exocytotic mechanism of release. Such possibilities 
have been examined, where, for example, in mGluR presynaptic modulation of glutamate 
release, PKC activation from activation of a G-protein-coupled facilitatory mGluR, results in 
inhibition of a ‘delayed rectifier’ type K+ channel. Therefore on application of 4-AP and 
mGluR agonist, the frequency and duration of action potentials are increased, subsequently 
increasing glutamate release, compared to the effect of 4-AP alone (Sanchez-Prieto et al., 
1996; Cartmell & Schoepp, 2000).
With respect to the nAChR, evidence from electrophysiological investigations indicates that 
the high Ca2+ permeability of the a7 nAChR (Vernino et al., 1999; Seguela et al., 1993, 
Delbono et al., 1996) is the likely candidate responsible for increasing the probability of 
glutamate release (Gray et al., 1996; Ji et al., 2001; Sharma & Vijaraghavan, 2003; For 
review see McGehee, 2002). These authors proposed that if presynaptic nAChRs open just 
before the arrival of an action potential, the presynaptic concentration of Ca2+ is elevated so 
that on arrival of an action potential, the probability of neurotransmitter release is increased, 
in a similar manner as described for paired-pulse facilitation. The most recent report to this 
facilitation describes that calcium flux through presynaptic nAChR leads to mobilisation of 
store calcium by calcium induced calcium release (CICR) (Sharma & Vijaraghavan, 2003).
It is this hypothesis that supports the theory of nAChR enhancement of depolarisation- 
evoked release when combining a depolarising stimulus with nAChR agonists, reported by 
Marchi et al. (2002). In this study, application of nAChR agonists alone to human 
neocortical or rat striatal synaptosomes in a superfusion paradigm had no effect on [3H]D-
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aspartate release. When nAChR agonists were combined with a KCI (12 mM) depolarising 
stimulus a facilitation of [3H]D-aspartate release was detected. The release evoked in these 
conditions was Ca2+-dependent and sensitive to the a7 nAChR antagonists a-Bgt and MLA 
also inferred from electrophysiological studies (Couturier etal., 1990; Seguela etal., 1993). 
This study prompted our own investigation into the nAChR enhancement of KCI-evoked 
release of [3H]D-aspartate.
Prior to the Marchi et al. (2002) report, electrical-evoked release of [3H]D-aspartate (and 
KCI-evoked release) from rat primary cortical cultures was shown to be enhanced on 
concomitant application of nicotine (Beani et al., 2000). This release was Ca2+ dependent 
and sensitive to a-Bgt and mecamylamine where the authors went on to propose that 
nAChR facilitation of [3H]D-aspartate release may be mediated by a7 and non-a7 nAChR. 
By manipulation of the experimental protocol described by Beani et al. (2000) a Brandel™ 
automated 20-channel superfusion machine with combined electrical generator was utilised 
to assess the effect of electrical stimulation to rat frontal cortex sections pre-exposed to 
nicotine. These experiments are also based on previous ‘electrical stimulation’ superfusion 
experiments (Muzzolini et al., 1996; Savage et al., 2001; Sehmisch et al., 2001). Each of 
these studies have demonstrated the Adenosine A1 receptor modulation of electrical- 
evoked release of either [3H]D-aspartate or [3H]L-glutamate; by inhibiting A1 receptors, 
evoked release was increased suggesting that endogenous adenosine acts to inhibit EAA 
release. Only Sehmisch et al. (2001) investigated the effect of nicotinic modulation of 
electrical-evoked release of [3H]L-glutamate but reported no effect. However, only nAChR 
antagonists were employed (mecamylamine) to discern the involvement of nAChR. In the 
study presented here, frontal cortex minces loaded with [3H]D-aspartate and placed in a 
closed chamber superfusion system will be subjected to nicotinic agonist stimulation prior 
to the application of an electrical stimulus. It is hypothesised that those chambers exposed
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to a nAChR agonist would give a higher electrical evoked release of [3H]D-aspartate 
compared to control conditions, on the same basis of nAChR activation increasing the 
‘probability’ of release (Gray etal., 1996; Ji etal., 2001 Sharma & Vijaraghavan, 2003).
Here we describe the effect of nAChR agonists on different means of depolarisation- 
evoked release of [3H]D-aspartate from rat frontal cortex synaptosomes or minces.
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3.2.2 Results
3.2.3 nAChR agonists and depolarising agents
The initial investigation of nAChR-evoked release of [3H]D-aspartate from rat 
synaptosomes was carried out using a 6 channel Brandel™ superfusion system. Rat 
striatal synaptosomes were loaded with [3H]D-aspartate and superfused in the same 
manner as described by Marchi et al. (2002). Nicotine, over the concentration range 1-100 
fxM, applied for a 90 s stimulation concomitantly with KCI (12 mM), failed to evoke any 
significant additional release of [3H]D-aspartate compared with KCI alone (see Fig. 3.2.1.), 
which is in contrast to the observation made by Marchi et al. (2002). Similarly, nicotine 
failed to enhance 12 mM KCI-evoked release of [3H]D-aspartate from frontal cortex 
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Figure 3.2.1 KCI-evoked release of [3H]D-aspartate from rat frontal cortex synaptosomes: 
The effect of a combined nicotine stimulus. Rat synaptosomes were superfused with KB buffer 
and stimulated for 90 s with KCI (12 mM) with or without nicotine (over a concentration range of 1- 
100 (xM). (A) [3H]D-aspartate evoked release from rat striatal synaptosomes using a 6 channel 
Brandel™ superfusion apparatus. (B) [3H]D-aspartate evoked release from rat frontal cortex 
synaptosomes using a 12 channel Brandel™ superfusion apparatus. Release is expressed as a 
percentage of KCI (12 mM) alone control taken as 100% of the response. Results represent the 
mean ± S.E.M of at least three independent experiments.
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The percentage fractional release of [3H]D-aspartate by KCI (12 mM) alone showed no 
significant difference between the two superfusion systems (2.1 ± 0.1% and 1.8 ± 0.2% for 
rat striatal synaptosomes and rat frontal cortex synaptosomes respectively). This confirmed 
that similar perfusion and collection rates of the two systems were maintained. Uniformity 
was also maintained in terms of similar protein concentrations of tissue between the two 
systems; rat striatal synaptosomes at 0.25 ±0.02 mg per chamber and rat frontal cortex 
synaptosomes at 0.22 ± 0.01 mg per chamber, also reflected in similar total [3H]D-aspartate 
counts recorded on the filters at the end of each experiment.
Failure of nicotine to enhance KCI-evoked release of [3H]D-aspartate lead to the use of 
another depolarising agent, 4-AP, concomitantly applied with nicotine. An initial experiment 
indicated an enhancement of 1 mM 4-AP-evoked release of [3H]D-aspartate from rat frontal 
cortex synaptosomes by co-application of nicotine (150 \M). This concentration of nicotine 
was chosen for further repetition of the experiment on the 6-channel superfusion system. 
Over a set of experiments, the release evoked by co-application of 4-AP (1 mM) with 
nicotine (150 \iM) showed considerable variability and hence no significant enhancement to 
control was observed (see Fig. 3.2.2).
In attempt to reduce the variability, the application of nicotine was combined with a lower 
concentration of 4-AP, but again, no significant enhancement of the 4-AP evoked release 
was observed (see Fig. 3.2.2). Fractional release of 0.1 mM 4-AP (1.7 ± 0.1%) was 
approximately 45% lower than that evoked by 1 mM 4-AP (3.0 ± 0.5%), however, the 
variability at lower concentrations of 4-AP (0.1 mM) evoked release of [3H]D-aspartate was 
reduced, reflecting only 5% variability of the release between experiments, compared to 4- 
AP (1 mM) where the variability was 17% between experiments.
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Figure 3.2.2 The effect of 4-AP co­
application with nicotine (150 11M) on 
[3H]D-aspartate release . Rat frontal cortex 
synaptosomes were superfused with KB 
buffer and stimulated for 90 s with 4-AP (at 1 
and 0.1 mM) with or without nicotine (150 
^M) using a 6-channel Brandel™ 
superfusion apparatus. Release is 
expressed as a percentage of 4-AP alone 
control taken as 100% of the response. 
Results represent the mean ± S.E.M of three 
independent experiments.
Different nAChR agonists were applied concomitantly with KCI (12 mM) as another 
approach to detect a nAChR enhancement of depolarisation-evoked release. Epibatidine, 
tested at a concentration range of 0.1-1000 nM concomitantly applied with KCI (12 mM) 
resulted in a biphasic profile suggesting two phases of increased release (see Fig. 3.2.3).
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Figure 3.2.3 Epibatidine 
concentration dependence of 
enhanced KCI-evoked [3H]D- 
aspartate release. Rat frontal cortex 
synaptosomes were superfused with 
KB buffer and stimulated for 90 s with 
KCI (12 mM) and epibatidine (over a 
concentration range of 0.1-100nM) 
using a 12 channel Brandel™ 
superfusion apparatus. Release is 
expressed as a percentage of KCI 
(12mM) control taken as 100% of the 
response. Results represent the mean 
± S.E.M of at least six independent 
experiments. * Statistical significance 
observed P<0.05, n=8, one-way
ANOVA with post-hoc tukeys analysis.
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However, epibatidine only significantly enhanced the KCI-evoked release of [3H]D- 
aspartate at one concentration: 1 nM (32.0 ± 5.7% above control; KCI 12 mM control = 100 
± 6.4%). Epibatidine at 3 and 100 nM also raised evoked release to 36.2 ± 10.0% and 26.0 
± 8.9% above the effect control, but these values are just outside statistical significance 
using a one-way ANOVA with post-hoc tukeys analysis. All other concentrations tested 
failed to evoke a significant enhancement of KCI-evoked [3H]D-aspartate release (Fig.
3.2.3).
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Figure 3.2.4 Calcium dependency of epibatidine (1 nM) enhancement of KCI-evoked release 
of [3H]D-aspartate. Rat frontal cortex synaptosomes were superfused with KB buffer and 
stimulated for 90 s with KCI (12 mM) and KCI (12 mM) + epibatidine (1 nM) in the presence and 
absence of Ca2+ (Ca2+ was replaced with an equimolar concentration of Mg2+). Release is 
expressed as a percentage of control (KCI 12mM in the presence of Ca2+), taken as 100% of the 
response. Results represent the mean ± S.E.M of at three independent experiments. * Statistical 
significance observed to control, P<0.05, n=3, one-way ANOVA with post-hoc tukeys analysis.
Epibatidine (1 nM) enhancement of KCI-evoked [3H]D-aspartate release displayed 
complete Ca2+-dependency (See Fig. 3.2.4). By removing Ca2+ from the perfusing buffer, 
KCI-evoked release was reduced to 44.97 ± 4.7% of the control response (KCI 12 mM in
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the presence of Ca2+ = 100 ± 6.4%). This is in agreement with the approximate 50% 
inhibition of KCI-evoked release of [3H]D-aspartate reported in Chapter 3 Section 3.1.5 (Fig 
3.1.10). Concomitant application of epibatidine in the absence of Ca2+ produced no 
enhancement of [3H]D-aspartate release compared to the release evoked by KCI alone. In 
normal Ca2+ containing KB buffer, epibatidine enhanced KCI-evoked release [3H]D- 
aspartate by 29.5 ± 6.4% above control; the magnitude of this effect is consistent with Fig. 
3.2.3.
Anatoxin-a was also examined in the same manner as described for epibatidine, over a 
concentration range of 10-1000 nM. Similar to the KCI enhancement of [3H]D-aspartate by 
co-application of epibatidine, only one concentration of anatoxin-a (300 nM) showed a 
significant enhancement of KCI-evoked release (25.2 ± 10.0% above control; KCI 12mM 
control = 100 ± 7.3%). At concentrations of anatoxin-a above 600 nM, the variability of the 
data prevented statistical significance (Fig. 3.2.5).
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Figure 3.2.5. Anatoxin-a 
concentration dependence of 
enhanced KCI-evoked [3H]D- 
aspartate release. Rat frontal cortex 
synaptosomes were superfused with 
KB buffer and stimulated for 90 s with 
KCI (12 mM) with or without anatoxin- 
a (over a concentration range of 10- 
1000 nM) using a 12 channel 
Brandel™ superfusion apparatus. 
Release is expressed as a 
percentage of KCI (12 mM) control 
taken as 100% of the response. 
Results represent the mean ± S.E.M 
of at least five independent 
experiments. * Statistical significance 
observed P<0.05, n=6, One way 
ANOVA with post-hoc tukeys 
analysis.
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3.2.4 nAChR specificity of enhanced KCI-evoked [3H]D-aspartate release
In order to confirm nAChR specificity of both epibatidine (1 nM) and anatoxin-a (300 nM) 
enhancement of KCI-evoked release of [3H]D-aspartate, the nAChR antagonist 
mecamylamine (20 |nM) was perfused for 10 min in the KB buffer, prior to stimulation with 
agonist and KCI (12 mM) or KCI alone.
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Figure 3.2.6 Mecamylamine antagonism of epibatidine and anatoxin-a enhancement of KCI- 
evoked [3H]D-aspartate release. Rat frontal cortex synaptosomes were superfused with KB buffer 
and perfused for 10 min with Mec (20 \iM) prior to a 90 s concomitant stimulation with KCI (12 mM) 
and epibatidine (1 nM) or anatoxin-a (300 nM). Release is expressed as a percentage of KCI (12 
mM) control taken as 100% of the response. Results represent the mean ± S.E.M of at least five 
independent experiments. * Statistical significance observed between KCI + epibatidine/anatoxin-a 
compared to control P<0.05, n=8, One way ANOVA with post-hoc tukeys analysis. ** Statistical 
significance observed between KCI + epibatidine/anatoxin-a + Mec compared to KCI + 
epibatidine/anatoxin-a, P<0.05, n=8, one way ANOVA with post-hoc tukeys analysis.
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Mecamylamine significantly inhibited the epibatidine (1nM) enhancement of KCI-evoked 
[3H]D-aspartate release by 100 ± 7.9% (Fig. 3.2.6). Release evoked by KCI + epibatidine 
was 26.7 ± 5.6% above the release evoked by KCI alone (100 ± 8.8%) which is comparable 
to that obtained from the concentration dependence experiments in Fig. 3.2.3, and reached 
statistical significance.
For anatoxin-a (300 nM) enhancement of KCI-evoked [3H]D-aspartate release, 
mecamylamine again significantly inhibited this response by 102.4 ± 4.9% (see Fig 3.2.6). 
Release evoked by KCI + anatoxin-a was 27.7 ± 4.1% above the release evoked by KCI 
alone (100 ± 13.9%). Here the KCI (12 mM) evoked release displayed a higher variability 
than observed in Fig. 3.2.5, however, the enhancement by anatoxin-a is comparable to that 
obtained from the concentration dependence experiments, and reached statistical 
significance when compared using one-way ANOVA with post hoc tukeys analysis. 
Mecamylamine showed no antagonism against the release evoked by KCI alone (See Fig
3.2.6).
To determine the nAChR subtype specificity of the nAChR enhancement of KCI-evoked 
release of [3H]D-aspartate, nAChR antagonists selective for the a7* nAChR subtype were 
perfused in the KB buffer for 10 or 20 min prior to the stimulation with the appropriate 
concentrations of epibatidine or anatoxin-a + KCI (12 mM).
Stimulation with KCI alone and KCI + epibatidine or anatoxin-a (minus antagonist) was 
carried out as control measures, with each condition examined in triplicate within the same 
experiment. The effect of MLA (50 nM) was first assessed against epibatidine (1 nM) 
enhancement of KCI-evoked release of [3H]D-aspartate. However, over a set of four 
experiments, only one experiment showed enhancement of KCI-evoked release of [3H]D- 
aspartate by epibatidine necessary for the comparison of effect of MLA (21.5 ± 12.5%
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blockade of the enhancement, mean ± S.E.M of 3 replicates). This variability in the 
response prevented a credible analysis of the effect of MLA. A similar problem was 
encountered in the assessment of MLA against the enhancement of KCI-evoked release of 
[3H]D-aspartate by anatoxin-a over three experiments.
The a7 nAChR specific antagonist a-conotoxin Iml (1 [xM; Cartier et a/., 1996) was 
assessed against anatoxin-a enhancement of KCI-evoked release of [3H]D-aspartate, in a 
final attempt to ascertain if the a7 nAChR subtype is associated with this enhancement. Of 
these experiments, three out of four experiments showed anatoxin-a (300 nM) 
enhancement of KCI-evoked release of [3H]D-aspartate (27.4 ± 13.3% above control, n=4; 
KCI 12 mM = 100 ± 9.6%). a-Conotoxin Iml (1 piM) inhibited the anatoxin-a enhancement of 
KCI-evoked release of [3H]D-aspartate by 54.7 ± 48.9%, hence the variability of the 
response prevented any conclusion being drawn (see Fig. 3.2.7).
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Figure 3.2.7. a-Conotoxin Iml antagonism 
of anatoxin-a enhancement of KCI-evoked 
[3H] D-aspartate release. Rat frontal cortex 
synaptosomes were superfused with KB 
buffer and stimulated for 90 s with KCI (12 
mM) and anatoxin (300 nM) using a 12 
channel Brandel™ superfusion apparatus. 
The a7 antagonist a-Conotoxin Iml (1 |xM) 
was present in the perfusing buffer for 10 
min before the application of KCI + anatoxin- 
a and remained throughout the remainder of 
the experiment. Release is expressed as a 
percentage of control (KCI 12 mM alone 
taken as 100% of the response). Results 
represent the mean ± S.E.M of four 
independent experiments.
The increasing variability of KCI-evoked responses and the inability to detect a clear a7 
nAChR involvement of the nAChR agonist enhancement of depolarising agent-evoked
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release of [3H]D-aspartate halted any further experiments aimed to characterise the nAChR 
subtype involved in this response. As described in the next section of this chapter (section
3.3), re-assessment of the effects of nAChR agonists applied alone began to reveal a 
significant effect above basal release. Further experiments then focused on this aspect of 
nAChR involvement of [3H]D-aspartate release.
3.2.5 Characterisation of electrical-evoked release of [®H]D-aspartate
The release of [3H]D-aspartate from frontal cortex minces was studied using an automated 
Brandel™ Superfusion system combined with an electrical stimulation generator. To 
examine the effect of an electrical stimulus, both current intensity and current frequency 
were tested for their effects on release from frontal cortex minces (see Fig. 3.2.8 A & B). 
The aim of these particular experiments was to ascertain a suitable level of release that 
could allow detection of an enhancement of release in the presence of (or pre-treatment 
with) nAChR agonists. The parameters of these conditions were based on previously 
established conditions by Savage et al. (2001) where electrical-evoked release of [3H]D- 
aspartate from hippocampal slices was demonstrated.
Maximal [3H]D-aspartate release was observed at a current intensity of 70mA (1.6% of total 
[3H]D-aspartate released). Increasing the current intensity to 90mA reduced [3H]D- 
aspartate release. No further experiments were carried on these high current intensities on 
the basis that the high [3H]D-aspartate evoked release would mask any possibility of being 
able to detect an enhancement from slices pre-treated with nicotine. At lower current 
intensities of 30 and 50mA, a more consistent response of [3H]D-aspartate release was 
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Figure 3.2.8 The effect of current intensity and current frequency effect on [3H]D-aspartate 
release from rat frontal cortex sections. (A) Rat frontal cortex minces were superfused as 
described in the methods with KB buffer only. After a 12 min collection of basal perfusates, minces 
were subjected to a 90 sec, 5Hz electrical stimulus (biphasic square wave pulse at 5Hz for 90 s) 
with current intensity varying between sets of four chambers across the Brandel superfusion 
system. (B) As in (A), but subjected to an electrical stimulus (50mA, biphasic square wave pulse for 
90 s) with current frequency varying between sets of four chambers across the Brandel superfusion 
system. [3H]D-aspartate release is expressed as percentage of total radioactivity present in the 
tissue at the point of electrical stimulation for both conditions. # note that fractional release is half 
that of the same conditions in (A), reflecting the inherent variability of the assay. Results represent 
the mean ± S.E.M of at least two independent experiments unless stated otherwise.
At 10mA, the release was considered too small (0.05 ± 0.05%) to provide reliable data for 
further experiments (see Fig. 3.2.8 A). Two current frequencies were tested for their effect 
on [3H]D-aspartate (see Fig. 3.2.8 B) (within the ranges used in the literature, see Savage 
eta l ,  2001, and Muzzolini et al., 1996), with the current intensity of the electrical pulse set 
at 50mA. A 10 Hz frequency gave a three fold increase in release (0.77 ± 0.13%) of total 
[3H]D-aspartate release compared to that evoked by a 5 Hz current intensity (0.25 ± 
0.02%). From these experiments, the standard control test stimulus consisted of a 50 mA, 
biphasic square wave pulses at 5 Hz for 90 s.
3.2.5.1 TTX sensitivity
Application of TTX (1pM), a general Na+ channel blocker, should prevent the 
depolarisation effect of the electric stimulus and ultimately the release of [3H]D-aspartate
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from the frontal cortex minces. To assess if the release of [3H]D-aspartate evoked by the 
test electrical stimulus depends on the propagation of an action potential through to the 
presynaptic terminal, TTX was applied to the superfusion medium prior to and during the 
electric stimulus (see Fig. 3.2.9). Fig. 3.2.9 shows that in the presence of TTX, electrical 
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Figure 3.2.9. TTX sensitivity of 
electrically-evoked release of [3H]D- 
aspartate from rat frontal cortex 
minces. Frontal cortex minces were 
superfused as described in methods 
and subjected to an electrical stimulus 
(50mA 2ms biphasic square wave 
pulse at 5HZ for 90 s) in the absence 
(control) and presence of TTX 1|xM. 
Results are expressed as a percentage 
of the control evoked release. Results 
represent the mean ± S.E.M of two 
independent experiments.
3.2.5.2 Nicotine enhancement
Having established a suitable level of electrical stimulation to give a relatively consistent 
response, we then determined the effect of a nicotine stimulus prior to the application of our 
standard electrical stimulus. In contrast to our previous investigation, where a nAChR 
agonist stimulus was applied concomitantly with a K+ depolarising stimulus, the application 
of both an electrical stimulus and a chemical stimulus at the same time is limited. This is 
because although flow rates of each chamber are the same, the tubing that provides buffer 
and drug medium differs slightly in length, enough to warrant that if the drug and electrical 
stimulus were applied at the same time, some chambers would be with or without drug 
therefore increasing the possibility of a varied response. Instead we opted to apply the 
electrical stimulus after an approximate 90 s washout of the agonist. Although some 
chambers might receive a washout period that may have been longer or shorter than others
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it is hypothesised that the downstream effects of ‘priming’ the presynaptic terminal, via 
nAChR activation, are sustained long enough to enhance the effects of a subsequent 
electrical depolarisation. Fig. 3.2.10 A demonstrates the effect of a pre-nicotine stimulus on 
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Figure 3.2.10. Enhancement of [3H]D-aspartate release as evoked by a standard electrical 
stimulus from pre-nicotine treated frontal cortex minces. (A) Raw trace example of [3H]D- 
aspartate release from rat frontal cortex minces. Frontal cortex minces were superfused as 
described in methods and subjected to an electrical stimulus. Nicotine (10 piM) was applied to 
superfusion chambers in parallel 3 min before an electrical stimulus (50mA, 2ms biphasic square 
wave pulse at 5HZ for 90 s) was applied. This nicotine pulse would reach the chamber at fraction 6, 
where no increase in release is observed. After a full 90 washout an electrical stimulus (50mA, 2ms 
biphasic square wave pulse at 5HZ for 90 s) was applied. Baseline (red line) fitted using a double 
exponential decay equation to the baseline data (see methods) (B) Nicotine (1-600 ^M) was applied 
to superfusion chambers in parallel 3 min before an electrical stimulus (50mA, 2ms biphasic square 
wave pulse at 5HZ for 90 s) was applied. Release is expressed as a percentage increase compared 
to control (electrical stimulus with buffer pre-treatment only taken as 100%). Results represent the 
mean ± S.E.M of three or more experiments. * Statistical significance observed between Nicotine + 
electrical stimulus compared to control electrical stimulus P<0.05, n=3, one way ANOVA with post- 
hoc tukeys analysis.
A standard 50mA, 2ms biphasic square wave pulse at 5Flz for 90 s was used as a control 
stimulus and varying nicotine concentrations were applied 3 min before the electrical 
stimulus (for a 90 s period thus allowing for a 90 s washout period). Concentrations of
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nicotine ranged from 1pM through to 600pM, with significant effects (Students unpaired t- 
test, n=3 P<0.05) seen at 10 pM and a general trend in increase seen at concentrations of 
1, 100, 300 and 600pM (see Fig. 3.2.10 B). Release of [3H]D-aspartate from the frontal 
cortex minces when nicotine was applied alone was not observed.
3.2.5.3 nAChR specificity of electrically evoked release of [3H]D-aspartate
nAChR specificity of the enhanced electrical-evoked release of [3H]D-aspartate was 
assessed using the nAChR antagonists mecamylamine (20 pM) and a-Bgt (40nM). These 
antagonists were applied to the minces prior, during and after the nicotine application, and 
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Figure 3.2.11 nAChR specificity of electrically evoked release of [3H]D-aspartate. Frontal 
cortex slices were superfused (± nAChR antagonists mec 20p,M and a-bgt 40nM) prior (20 min), 
during and after a 90 s nicotine perfusion. After washout, minces were subjected to a control 
electrical pulse (2ms biphasic square wave pulse at 5HZ for 90 s). [3H]D-aspartate release is 
expressed as percentage of total radioactivity present in the tissue at the point of electrical 
stimulation. Results represent the mean ± S.E.M of at least three experiments. * Statistically 
different to control conditions, P<0.05 students paired t test n=3. ** Statistically different to nicotine 
enhancement of electrical-evoked release, P<0.05, Students paired t-test, n=3)
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The enhancement shown by the pre-treatment of nicotine (1 OuM) was substantially blocked 
by mecamylamine (68.96 ± 28.32% block of nicotine induced enhancement) and 
completely prevented by a-Bgt (106.3 ± 28.2%) whereas release by electrical stimulation 
alone was not affected by the presence of nAChR antagonists (See Fig. 3.2.11).
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3.2.6 Discussion
In an attempt to emulate two previous studies measuring the direct release of nAChR- 
evoked EAA release from presynaptic terminals, we examined the effect of nAChR 
agonists in combination with depolarising stimuli. The first of these two studies (Marchi et 
al., 2002), showed a nicotinic facilitation of [3H]D-aspartate release from rat and human 
striatai synaptosomes only when a nicotinic agonist was co-applied with a 12 mM KCi 
stimulus. We replicated this observation in rat frontal cortex synaptosomes but demonstrate 
that only certain nAChR agonists enhance KCI-evoked release, which although is Ca2+ 
dependent and mecamylamine sensitive, does not display sensitivity to a7 nAChR 
antagonists. In the second of these two studies (Beani et al., 2000), the release of [3H]D- 
aspartate from rat primary cortical cultures is enhanced on concomitant application of 
nicotine with an electrical stimulus. This release was Ca2+ dependent and sensitive to a-Bgt 
and Mecamylamine. We demonstrate that nicotine enhances the release of [3H]D-aspartate 
from frontal cortex minces subjected to electrical stimulation, and similar to primary cortical 
cultures, nicotine enhanced release is sensitive to the nAChR antagonists a-Bgt and 
mecamylamine (See Fig. 3.2.11), inferring an a7 and non- a7 nAChR mediated 
enhancement of release, as suggested by Beani et al. (2000). However, these assays 
showed considerable variability and prevented further pharmacological analysis of nAChR 
subtype specificity of the response.
The exact mechanism by which nAChR enhancement of KCI-evoked release of [3H]D- 
aspartate occurs has not been investigated. However, the enhancement displayed by 
epibatidine is Ca2+-dependent (see Fig. 3.2.4.), suggesting that presynaptic nAChR 
activation causes exocytosis, consistent with a rise in intra-terminal concentration of Ca2+ 
that, in turn, increases the probability, or strength, of depolarisation-induced evoked release 
as proposed by Dani & colleagues (Gray et al., 1996; Dani et al., 2001; Ji et al., 2001;
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Sharma & Vijaraghavan, 2003). The synaptosome population within a superfusion chamber 
is heterogeneous in size and membrane integrity (Dunkley et al., 1988). A proportion of 
synaptosomes are likely to display a membrane potential more hyperpolarized than others, 
making the extent of the KCI depolarisation across the synaptosome population also 
heterogeneous. By increasing the intra-terminal calcium concentration and/or the 
membrane potential to a more positive value, caused by nAChR activation, it is then 
hypothesised that the combined KCI-depolarisation and Ca2+ dependent exocytotic release 
of [3H]D-aspartate may be more uniform across the synaptosome population. A second 
possibility for the enhancement is that all synaptosomes are depolarised on application of 
KCI, but concomitant activation of nAChR increases the number of synaptic vesicles 
‘primed’ for exocytotic release of [3H]D-aspartate, thereby increasing the quanta of [3H]D- 
aspartate release. Observations by McMahon & Nicholls (1991) support this hypothesis, 
where they revealed a biphasic release of glutamate from cerebrocortical synaptosomes of 
the guinea pig. These were attributed to a component of synaptic vesicles in close 
proximity with the plasma membrane that contributed to the fast phase of exocytotic 
glutamate release, and a second, more slower phase, that was attributed to the Ca2+- 
dependent ‘priming’ and dissociation of glutamate containing vesicles from the cytoskeleton 
and other associated proteins that are away from the active zone of release from the 
synaptosome plasma membrane.
3.2.6.1 nAChR agonist enhancement of depolarising agent-evoked release
No nAChR enhancement of KCI-evoked release of [3H]D-aspartate was observed using 
nicotine as the nAChR agonist. Marchi et al. (2002) reported that maximal nicotine 
enhancement of KCI-evoked release of [3H]D-aspartate from rat striatal and human cortical 
synaptosomes was on concomitant application of 100 p,M nicotine. In the present
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investigation, this concentration, as well as 1 and 10 pM nicotine, failed to evoke any 
significant release of [3H]D-aspartate when combined with KCI (12 mM) and compared to a 
KCI (12 mM) control. This observation was demonstrated in both rat striatal synaptosomes 
and rat frontal cortex synaptosomes. Initial reasons for this disparity could be due to 
methodological differences. However, the only methodological differences between the 
assay used and the assay described by Marchi et al. (2002) were the rate of superfusion 
(0.8 ml/min used in our assay compared to 0.6 ml/min) and a difference in calculation of 
release. For the former methodological difference, by increasing the superfusion rate, we 
would expect an enhancement of the detection of [3H]D-aspartate release by overcoming 
any possible EAA transporter effects of [3H]D-aspartate re-uptake. For the latter 
methodological difference, release of [3H]D-aspartate was calculated in the same manner 
as Marchi et al. 2002, and compared to our usual method. As described by Marchi et al. 
(2002), KCI + nAChR-evoked release (S1+ S2, counted as C.P.M), was calculated as the 
overflow after deduction of the basal release (B1 + B2), where B1 is the release in C.P.M. 
recorded before the stimulus and B2 is the release in C.P.M recorded after the stimulus). 
This value, and that obtained for KCI alone, is then expressed as a ratio to each other. 
Using the C.P.M values recorded from our own experiments, the comparison of the two 
methods of calculation showed no differences on the effect of nicotine-enhancement of 
KCI-evoked [3H]D-aspartate release. (See Fig. 3.2.13).
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Fraction KCI 12 KCI 12 mM
number mM + Nicotine
4 (B1) 1882 1822
5 (S1) 5455 5172
6 (S2) 1920 1874
7 (B2) 1851 1731
Marchi etal., 2002 calculation of release
Evoked release = (S1 +S2) -(B1 + B2) 
Enhancement of release = KCI + Nicotine evoke
6000
Therefore
KCI 12 mM alone (Control) 
KCI 12 mM + nicotine 10 jxM
S 3000




2 3 4 5 8 7
Fraction number
Enhancement of release ratio = 1 (i.e. no enhancement)
B2
 KCI + Nicotine
  KCI
Our method of calculation of release (see methods; Soliakov et al, 1995)
Evoked release = Area under peak /Total radioactivity at point of stimulation
Enhancement of release = ((KCI + Nicotine evoked release /KCI evoked release) x 100) -  100%
Therefore Area under Peak (see methods for calculation 
and baseline fih
Total radioactivity (total 
release in subsequent fractions 
+ Total left on filters at end of 
experiment
KCI 12 mM + nicotine 10 |xM 
KCI 12 mM alone (Control)
= 3378/ (17623 + 170720) = 1.79%
= 3582/ (18158 + 168897) = 1.914
Enhancement of release % = ((1.8/1.9) x 100) -  Control (100%)
= -5%
Fig.3.2.13. Comparison of two calculative methods to examine the nicotine (10 ^M) 
enhancement of KCI-evoked release. Inserted table represents raw C.P.M data of [3H]D- 
aspartate release expressed as the mean values from each condition examined in triplicate for 4 
fractions, taken from an example experiment; B1 and B2 (blue) represent basal release and S1 and 
S2 (red) represent drug-evoked release. Marchi et al. (2002) method expresses enhancement of 
release as a ratio between control conditions and drug effect. Our method (see methods chapter) 
expresses enhancement of release as the percentage increase above the effect of control 
conditions.
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In an another attempt to examine nicotine enhancement of depolarisation-evoked release 
of [3H]D-aspartate, a set of experiments looked at combining nicotine with another 
depolarising agent, 4-AP. By blocking the KA channel, the probability of depolarisation is 
increased, from induction by small changes in membrane potential. This results in 
spontaneous action potentials rather than ‘one cycle’ of depolarisation achieved by KCI 
depolarisation where the membrane potential is ‘clamped’. On this basis, 4-AP has been 
described as a more physiological depolarising agent (Tibbs et al., 1989; Nicholls, 1998) 
and has been used to reveal PKC modulation of glutamate release (Barrie et al., 1991; 
Coffrey eta!., 1993; Sanchez-Prieto etal., 1996). The release of [3H]D-aspartate evoked by 
1 mM 4-AP was similar in magnitude (in terms of fractional release) to KCI-evoked release 
(12 mM) of [3H]D-aspartate. However, when combined with nicotine, neither 0.1 mM or 1 
mM 4-AP-evoked release of [3H]D-aspartate was enhanced. Therefore it appears that 
nicotine cannot enhance the release of [3H]D-aspartate even when synaptosomes are 
depolarised in a different manner.
Further differences from the work published by Marchi et al. (2002) are revealed from the 
effect of the nAChR agonists epibatidine and anatoxin-a. Although they significantly 
enhanced 12 mM KCI-evoked release of [3H]D-aspartate above the effect of 12 mM KCI 
alone, they only did so at very limited agonist concentrations, although it should be noted 
that this could simply be a reflection of the variability of the data. As well as this, 
antagonists could not reliably block the enhancement seen with these agonist 
concentrations. Specifically, there is a 20-fold higher evoked release of [3H]D-aspartate 
release when 1nM epibatidine was concomitantly applied with KCI (12 mM) in our 
experiments compared to the same conditions described by Marchi et al. (2002). Lower or 
higher concentrations of epibatidine had no significant (but high variance) effect on the 
enhancement of KCI-evoked release, whereas Marchi et al. (2002) described an increase
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in [3H]D-aspartate release on increasing epibatidine concentration from 1nM to 10 pM. In 
our experiment, 100 nM epibatidine enhancement of KCI-evoked release only just failed to 
reach significance and it is plausible that increasing the n number of the experiment at this 
concentration would have resulted in statistical significance. Interestingly, there seems to 
be a biphasic nature to the concentration dependence effect of epibatidine combined with 
KCI, and although the values do not reach significance (bar one) could indicate that there is 
more than one type of nAChR that governs the enhancement of release; one that is 
activated by low concentrations of epibatidine and one by high concentrations of 
epibatidine.
Similar disparities are seen in the results for anatoxin-a. An increase in enhancement of 
KCI-evoked [3H]D-aspartate release was observed by Marchi et al. (2002) on increasing 
anatoxin-a concentrations from 1 nM to 100 nM. Maximal release of [3H]D-aspartate 
occurred at 100 nM anatoxin-a + KCI (12mM). Our results displayed no significant 
enhancement within this concentration range of anatoxin-a, but at 300 nM a significant 
enhancement was observed. Again, further repetition of each anatoxin-a concentration 
used may increase the likelihood of obtaining significant results. Unlike the epibatidine 
enhancement of KCI-evoked release, anatoxin showed no real trend of a biphasic nature to 
the enhancement, however the concentration that displays the significant enhancement of 
release is in close agreement with the EC50 value described for anatoxin-a against 
reconstituted a7 nAChR in Xenopus oocytes (Thomas etal., 1993).
3.2.6.2 nAChR antagonism of the enhancement of KCI-evoked release of [3H]D- 
aspartate
Mecamylamine inhibition of both epibatidine (1nM) and anatoxin-a (300nM) enhancement 
of KCI-evoked release of [3H]D-aspartate confirmed that the responses are mediated by
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nAChR. However, neither MLA nor a-Conotoxin Iml could convincingly inhibit this 
enhancement. In comparison, Marchi et al. (2002) showed evidence for the participation of 
a7 nAChR in the anatoxin-a enhancement of KCI-evoked [3H]D-aspartate release, with 
inhibition by a-Bgt (100 nM) as well as MLA (100 nM). Recently the specificity of MLA, 
especially at high concentrations of 50 nM above, has come into question; Mogg et al. 
2003; see also Klink et al., 2001), have demonstrated that this compound interacts with a- 
Conotoxin Mil sensitive presynaptic nAChRs in the rat striatum, suggesting that MLA is 
also a potent antagonist for non-a7 nAChR. Interestingly, Marchi et al. (2002), showed that 
mecamylamine displayed no significant inhibition of the anatoxin-a enhancement of KCI- 
evoked [3H]D-aspartate release at 1 and 10 jiM, yet at 100 p,M, release was completely 
abolished; this concentration is almost 10 fold higher than that used by a majority of groups 
who use this antagonist effectively in similar preparations, and could exert non-specific 
effects. However, low sensitivity to mecamylamine is compatible with the lower sensitivity of 
a7 nAChR to this antagonist.
3.2.6.3 Calcium dependency
The high Ca2+ permeability of the a7* nAChR compared to other nAChR subtypes (Seguela 
et al., 1993; Delbono et al., 1997) would suitably explain the Ca2+ dependence of the 
nAChR enhancement of KCI-evoked release demonstrated in Fig 3.2.6 and by Marchi etal. 
2002. However, it is important to highlight that depolarisation-evoked EAA release is 
dependent on Ca2+ entering the presynaptic terminal via the voltage operated calcium 
channels (VOCC’s). VOCC’s are more efficiently coupled to EAA exocytosis than Ca2+ 
entering the terminal non-specifically (Nicholls & Attwell, 1990); non-L type calcium 
channels contribute to the majority of KCI-evoked release of EAA from synaptosomes, 
where on activation they trigger the release via a highly localised pool of calcium within the
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immediate vicinity of the calcium channel (Tibbs et al., 1989; Sanchez-Prieto et al., 1996). 
The reliance for the detection of nAChR enhancement only in depolarising conditions make 
it impossible to ascertain whether the nAChRs contributing to the enhancement of release 
in this study and by Marchi et al. (2002), either depolarise the cell membrane and activate 
VOCC to increase intrasynaptosomal Ca2+ concentration or contribute to intrasynaptosomal 
concentration alone via Ca2+ flux through their ion pore or indeed both mechanisms. In a 
recent report by Dougherty et al. (2003) that examines the effect of soluble Ap peptides on 
nAChR Ca2+ influx into brain synaptosomes, cortical synaptosomes demonstrated both an 
a7 and non-a7 component to nicotine and Ap protein activated rise in intra-terminal Ca2+. 
The a7 component demonstrated a partial activation of VOCC’s, where a7 nAChR 
activation depolarised the synaptosome membrane to activate non-L type VOCC’s that 
contributed to the rise in intra-terminal Ca2+. The non-a7 component of nicotine or Ap 
activated rise in intra-terminal Ca2+ was independent of VOCC activation. The ambiguous 
effect of a7 nAChR specific antagonists on the enhanced release of [3H]D-aspartate 
demonstrated herein does not support the source of intra-terminal Ca2+ coming solely from 
cc7 nAChR activation as stated by Marchi et al. (2002). An important study by Nayak et al. 
(2001) demonstrated that striatal synaptosomes, loaded with fluo-3 (a fluorescent calcium 
indicator dye), displayed only non-a7 nAChR mediated increases in intra-terminal Ca2+ 
when activated by nicotine. It was undetermined whether the synaptosomes examined for 
nAChR-evoked responses in the report by Dougherty et al. (2003) were glutamatergic, 
however, this work is further supported by the contribution of non-L-type Ca2+ channels to 
the anatoxin-a evoked release of [3H]Dopamine from striatal synaptosomes (Soliakov etal., 
1996).
Despite these conflicting reports, presynaptic elevation of Ca2+ has been shown to 
demonstrate a predominantly a7 nAChR component in hippocampal presynaptic terminals
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(Gray et al., 1996; Sharma & Vijaraghavan, 2003) and in the VTA (Mansvelder & McGehee, 
2000) and therefore the nAChR subtype expressed on presynaptic terminals may be 
specific to certain brain regions. With respect to the frontal cortex, as utilised in this 
investigation, reports reveal both the presence of a7 and non-a7 nAChRs on presynaptic 
terminals (Vidal & Changeux., 1989; Vidal & Changeux 1993; Granon et al., 1995; Gioanni 
et al., 1999; Lambe et al., 2003; and chapter 3 section 3 and chapter 4).
Interestingly, a possible association of nAChR with EAAT reversal can be eliminated due to 
the lack of enhancement of KCI-evoked release in the absence of Ca2+; an indirect 
inference made from our results in this section and that from characterising the Ca2+ 
independent component of KCI-evoked release of [3H]D-aspartate (Chapter 3 Sectionl)
3.2.6.4 Electrical-evoked release of [3H]D-aspartate
This component of study for the nAChR enhancement depolarised-evoked release of 
[3H]D-aspartate was carried out on placement at Eli Lilly and Company, Erl Wood, 
Windlesham, Surrey, under the supervision of Dr I.A Pullar. Frontal cortex minces were 
employed instead of synaptosomes for practical reasons due to the nature of the apparatus 
employed and on guidance from Clare Roberts (GlaxoSmithKline, Harrow). Therefore the 
greater degree of synaptic integrity maintained in a slice preparation compared to a 
synaptosome preparation is an important consideration in the assessment of the data 
accumulated.
Initial experiments assessed the electrical stimulus parameters of the electrical evoked 
release of [3H]D-aspartate. These steps were undertaken to determine a suitable level of 
electrical stimulation that would evoke [3H]D-aspartate release to a degree that was neither 
too small to evade detection nor too large to mask any future examination of the nAChR 
enhancement of release. The variability of the release was also taken into consideration as
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another determining factor of control condition choice. Both current intensity and current 
frequency had a positive correlation with the extent of [3H]D-aspartate release. At a set 
frequency of 5Hz, increasing the current intensity evoked release to a maximum of 1.5% of 
total radioactivity released, with further increases in current intensity having no greater 
effect. Only two different frequencies were applied where 10Hz (and a set intensity of 
50mA) gave three times the release of [3H]D-aspartate compared to 5Hz stimulation. From 
Fig. 3.2.8, it was evident that a frequency of 5Hz gave a variability that was less than 10 % 
of the actual response, whereas at 10Hz the variability was obviously larger. The same was 
true for the current intensity of 50mA compared to other current intensities, and so control 
conditions consisted of a 50mA, biphasic square wave pulse at 5HZ for 90 s. In comparison 
to previously cited electrical stimulation experiments in the superfusion paradigm, this value 
is in good agreement with test stimuli used in these experiments (Muzzolini et al., 1996; 
Savage etal., 2000; Sehmisch et al., 2001)
3.2.6.5 Effect of TTX
TTX is an effective antagonist of the spread of an action potential to the terminal regions of 
an axon, by way of blocking Na+ channels. If release of [3H]D-aspartate from the 
presynaptic terminals is solely dependent on this process then we would expect a large 
degree of inhibition of release on application of TTX. However Fig. 3.2.9 displays a 74.0 ± 
8.9% blockade of the electrical evoked release of [3H]D-aspartate in the presence of TTX (1 
jiM). Although not a complete blockade of release was observed, this value falls within 
values given previously of an 80% blockade of endogenous glutamate and 65% blockade 
of [3H]D-aspartate release from hippocampal slices, reported by Muzzolini et al. (1996), as 
well as Sehmisch et al. (2001). This remaining 25% release could be attributed to release 
from the presynaptic terminal that is independent of an action potential terminating in this 
region. An important note to make is that the perfusing buffer and all other perfusing
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solutions contained DL-TBOA (20 îM), a non-transportable blocker of EAAT 1-3, therefore 
it is assumed that this residual release is not due to reversal of the glutamate transporters 
under depolarising conditions. Although no literature exists on the use of this compound in 
rat tissue sections, this concentration was effective at inhibiting the Ca2+-independent 
component of potassium-evoked release from rat frontal cortex synaptosomes (See 
Chapter 3 Section 1, Fig 3.1.9 and 3.1.10).
3.2.6.6 nAChR enhancement of electrically evoked release
Technical limitations did not permit the co-application of both agonist and electrical 
stimulation at the same time (see results section 3.2.5.2) therefore we chose to stimulate 
the frontal cortex minces with a 90 s perfusion of nicotine and then allow for an 
approximate 90 s washout prior to the application of an electrical stimulation. Significant 
enhancement of release was detected at 10 pM nicotine (102.7 ± 34.9% above the effect of 
control conditions; see Fig 3.2.10 A & B). Other concentrations of nicotine examined did 
show an enhancement of release but failed to pass significance (one way ANOVA with post 
hoc Tukeys analysis). No other nAChR agonists were examined in this instance.
These results suggest that the nAChR enhancement of electrical-evoked release of [3H]D- 
aspartate effect lasts greater than a period of 90 s after exposure to nicotine. With respect 
to the chemical depolarising agent stimulation, nAChR enhancement is within the 90 s time 
frame of nAChR agonist + KCI co-application, whereas no enhancement was detected 
when the depolarising stimulus was applied after the nAChR stimulus. This disparity may 
be explained by the temporal differences in agonist application of the two systems; 
synaptosome drug exchange is almost immediate whereas minces are subject to slower 
drug exchange. Because both drug exchange and removal is a lot slower than that 
described for synaptosomes, then the effect of the nAChR enhancement may too be
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sustained over a longer period. The enhancement described for the shorter nAChR agonist 
+ KCI exposure in synaptosomes could simply be a reflection of a larger calcium 
conductance, via both activation of voltage operated calcium channels and through the ion 
channel of the nAChR, whereas the longer exposure of the minces to nicotine could result 
in the priming of vesicles after nAChR activation via phosphorylation of vesicle docking 
proteins or changes in the arrangement of cytoskeleton proteins that increases the 
available pool of synaptic vesicles ready for fusion to the presynaptic membrane and 
thereby evoking a greater quantum of neurotransmitter release.
3.2.6.7 nAChR antagonism of the enhancement of electrical-evoked release of 
[3H]D-aspartate
nAChR specificity of the enhancement of release was confirmed in those experiments by 
blocking the response by the nAChR antagonists a-Bgt and mecamylamine. a-Bgt (40 nM) 
showed a complete block of the enhancement induced by nicotine (10 pM) supporting the 
possibility that the enhancement we see is solely due to activation of the a7 nAChR. The 
lesser effect of mecamylamine (20 pM) compared with a-Bgt may reflect the lower efficacy 
of this antagonist to the a7 nAChR subtype (Papke et al., 2001). However, the degree of 
mecamylamine blockade in these experiments does not correspond to the level of blockade 
seen against nAChR agonist + KCI (where a complete blockade was shown; see Fig.
3.2.6). This could be for a number of reasons: (1) the other nAChR agonists used to 
enhance KCI-evoked release could be activating a subtype of nAChR that is more sensitive 
to mecamylamine. (2) More than one nAChR subtype may be activated by nicotine to 
enhance the electrical-evoked release of [3H]D-aspartate (Beani etal., 2000; see Chapter 3 
section 3). (3) Mecamylamine may be more effective as an antagonist when the membrane
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is depolarised (in concomitant nAChR agonist + KCI application) compared to a membrane 
at resting potential (nAChR + a 90 second delay before electrical stimulus application).
A further point of consideration is nicotine alone fails to evoke release of [3H]D-aspartate. In 
synaptosomes this can be readily demonstrated in both the presence and absence of 
glutamate re-uptake biockers such as DL-TBOA (See Chapter 3 Section 3). in the present 
study, DL-TBOA (10 pM) was present in all perfusing solutions and therefore theoretically 
would prevent any re-uptake of nicotine evoked release of [3H]D-aspartate. It is plausible 
that in slices this concentration is ineffective and that in synaptosomes the marked 
decrease in glial transporter glutamate uptake helps reveal [3H]D-aspartate release even in 
the absence of DL-TBOA, compared to the mince preparation where glial cells are in 
abundance and the effect of DL-TBOA decreased. Secondly, the membrane potential of 
synaptosomes compared to slices, is thought to be less stable and this may be beneficial to 
the nAChR in its ability to evoke release, although methodically this would be hard to 
demonstrate.
3.2.6.9 Summary
In summary, the inherent variability of the KCI-evoked release of [3H]D-aspartate made it 
difficult to ascertain clear concentration dependent effects of nAChR agonist enhancement 
of KCI-evoked release of [3H]D-aspartate, in contrast to that described by Marchi et al. 
(2002). This was also the case with nicotine enhancement of electrical-evoked release, 
although evidence for a7 nAChR mediated enhancement of release was demonstrated in 















Figure 3.2.14 Summary of the nAChR enhancement of depolarisation-evoked EAA release.
(A) a7 nAChR mediated facilitation of depolarisation-evoked release of EAA may directly activate 
EAA vesicles for exocytosis via Ca2+ flux through the receptor and/or contribute to the enhanced 
depolarisation of VOCC’s and the concomitant Ca2+ influx which couples to a localised pool of EAA 
vesicles to trigger release by exocytosis. (B) Non-a7 nAChR mediated facilitation of depolarisation- 
evoked release of EAA may directly activate EAA vesicles for exocytosis via Ca2+ flux through the 
receptor and/or increase the available pool of ‘primed’ vesicles by freeing them from cytoskeletal 
proteins or mediating CICR in the synaptic terminal (Sharma & Vijaraghavan, 2003). (C) Variability 
of KCI-evoked release may be a consequence of EAA transporter reversal depending on the 
viability of the synaptosomes.
nAChR agonists that did significantly enhance KCI-evoked release (epibatidine 1nM and 
anatoxin-a 300 nM) displayed a Ca2+ dependent and non-a7 nAChR facilitation of the 
response, however, the variability of some experiments prevented any clear effects of a l  
antagonists being demonstrated and therefore the involvement of a l  nAChR facilitation of 
KCI-evoked release cannot be ruled out. Figure 3.2.14 represents a schematic of possible 
relationships between the nAChR and the enhancement of depolarised evoked release.
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Chapter 3 Section 3
3.3 nAChR-evoked release of [3H]D-aspartate
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3.3.1 Introduction
A substantial body of evidence, mainly from electrophysiological experiments, 
supports the presynaptic nAChR modulation of glutamate release (see Introduction 
section 1.7.2). This nAChR mediated facilitation has been recorded in a number of 
rodent CNS regions such as the hippocampus (Gray et al., 1996; Alkondon et al., 
1999; Radcliffe & Dani, 1998; Fischer & Dani, 2000; Sharma & Vijaraghavan, 2003), 
prefrontal and frontal cortex (Vidal & Changeux, 1989; Vidal & Changeux, 1993; 
Granon et al., 1995; Gioanni et al., 1999; Lambe et al., 2003), olfactory bulb 
(Alkondon et al., 1996), midbrain (Schilstrom et al., 2000; Nomikos et al., 2000; 
Mansvelder & McGehee, 2000; Girod & Role, 2001) and cerebellum (De Filippe et 
al., 2001). In the majority of these rodent CNS regions, nicotinic agonists provoke an 
increase in frequency and amplitude of glutamate receptor-mediated post-synaptic 
excitatory potentials that are sensitive to a-Bgt, Ca2+-dependant and insensitive to 
tetrodotoxin (TTX) (Alkondon etal., 1996 & 2002; Gray eta!., 1996), consistent with 
stimulation of a7 nAChR located on presynaptic terminals of glutamatergic afferents. 
However, in the frontal cortex, the region of the rat CNS under examination in this 
thesis, the majority of nicotine-evoked postsynaptic events are insensitive to a-Bgt. 
Instead presynaptic non-a7 nAChR have been implicated in the modulation of 
glutamate release in this region, found on thalamo-cortical glutamatergic afferents 
(Vidal & Changeux., 1989; Vidal, 1993; Granon et al., 1995; Gioanni et al., 1999; 
Lambe et al., 2003). Specifically, nicotine-evoked responses in the frontal cortex of 
mouse brain were reported to be sensitive to dihydro-p-erythroidine (DHpE) and 
absent in p2 nAChR subunit null mutant mice (Lambe et al., 2003). Together with 
the loss of [3H]nicotine binding sites in cortical areas after thalamic lesions (Gioanni
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et al., 1999), this pharmacology further supports the presence of high affinity, 02* 
nAChR on these afferents.
3.3.1.1 Direct detection of nAChR-evoked EAA release
As described in Chapter 1 (Introduction), electrophysiological experiments measure 
the postsynaptic response of glutamate release from the nerve terminal and have 
used approaches such as the use of TTX, to deduce that the release of glutamate is 
independent of action potential generation, consistent with presynaptic localisation of 
nAChR. However, few groups have reported a direct detection of glutamate release 
evoked by nAChR stimulation from the presynaptic terminal. Microdialysis studies 
have come the closest to reporting a direct modulation of nAChR-evoked glutamate 
release in cortical and mid brain areas of the rat (Toth et al., 1992; Gioanni et al., 
1999; Reid eta!., 2000; Schilstrom eta!., 2000). However these reports have drawn 
different conclusions to the nAChR subtype specificity of the modulation of 
glutamate release; systemic nicotine elicits glutamate release in the VTA and is 
blocked by local administration of MLA, (Schilstrom et al., 2000) supporting the 
presence of a7* containing nAChR on presynaptic terminals, yet in the prelimbic 
area of the PFC, systemic nicotine elicits glutamate release which was sensitive to 
DH0E and not a-Bgt or MLA, supporting the presence of non-a7, 02*-containing 
nAChR on presynaptic terminals (Gioanni et al., 1999). Together these 
investigations highlight the complexity of those regions of the brain being studied 
and the different anatomical distribution of the subtypes of nAChR in the CNS 
(Alkondon eta!., 1996a; Role and Berg., 1996; Girod etal., 2000).
A robust model for the determination and pharmacological characterisation of the 
nAChR modulation of neurotransmitter release is via superfusion of synaptosomes
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preloaded with radiolabelled neurotransmitter (Raiteri, 1987; Nicholls, 1998; Raiteri 
& Raiteri, 2000). This method has been utilised for the demonstration of nAChR 
modulation of acetylcholine (Wilkie et al., 1996), dopamine (Soliakov et al., 1995; 
Kaiser & Wonnacott, 2000; Mogg et al., 2003), GABA (Maggi et al., 2001; Zhu & 
Chiappinelli, 2002; Frazier et al., 2003), noradrenaline (Clarke & Reuben, 1996; 
Anderson et al., 2000; Lei & Eisenach, 2002; O’Leary & Leslie, 2003) and 5-HT 
release (Li etal., 1998; Kenny et al., 2000; Cordero-Erausquin & Changeux, 2001). 
However, superfusion has been less successful for the examination of nAChR- 
evoked EAA release (see Chapter 1 section 1.7.1). The most common difficulty in 
measuring EAA release in-vitro is the inability to outweigh re-uptake via the highly 
efficient nature of glutamate transporters. As well as this, the poor temporal 
resolution of nAChR agonist delivery to the CNS tissue in this assay may desensitise 
the receptors before any functional activity can be measured (compared to 
electrophysiological experiments; see Kaiser & Wonnacott, 2000). A modified 
superfusion system has achieved sub-second time-scale application of depolarising 
stimuli to synaptosomes loaded with [3H]L-glutamate (Turner & Dunlap, 1995a and 
b), but as of yet, there has been no reports of nAChR agonists applied in this same 
manner. Superfusion per se, by continuously removing any extracellular perfusates, 
should reduce the possibility of neurotransmitter re-uptake (see Raiteri & Raiteri, 
2000), thereby increasing the detectable pool of neurotransmitter that is released via 
activation of the nAChR. It is therefore possible that, in synaptosomes loaded with 
tritium labelled EAA, the superfusion rate employed in previous attempts to detect 
nAChR modulation of EAA release was too slow to avoid the possibility of re-uptake. 
As well as the superfusion rate, the use of a synaptosome preparation itself, 
particularly with respect to the detection of glutamate, should have a reduced
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number of transporter systems (although possible gliosomes contamination of the 
P2 preparation may provide a source of EAAT) compared to an intact synaptic circuit 
such as that found in a slice preparation. Sehmisch et al. (2001) failed to 
demonstrate nAChR modulation of electrical-evoked release of [3H]L-glutamate and 
[3H]D-aspartate, in the presence of EAAT blockers from hippocampal sections. With 
respect to the dopamine assay (Soliakov et al., 1995; Kaiser & Wonnacott, 2000; 
Mogg et al., 2002), and the noradrenaline assay (Clarke & Reuben, 1996; Anderson 
et al., 2000; Lei & Eisenach, 2002; O’Leary & Leslie, 2003) the use of nomifensine 
and desipramine (DMI) is employed to prevent the re-uptake of these 
neurotransmitters respectively, thereby increasing the available neurotransmitter 
pool for detection. Glutamate transporter inhibitors such as PDC and TBOA have yet 
to be fully examined against either different transporters or species transporter 
variation (Waagepetersen etal., 2001), but do provide an opportunity to enhance the 
detection of EAA release as evoked by application of nAChR agonists.
In this chapter we demonstrate that nAChR agonists applied to frontal cortex 
synaptosomes can evoke the release of [3H]D-aspartate in the absence of a 
concomitant depolarisation or EAAT inhibitors. This has enabled characterisation 
with respect to nAChR subtype, using specific agonists and antagonists; an a7 and 




3.3.2.1 nAChR agonist-evoked release of [3H]D-aspartate from rat frontal 
cortex synaptosomes
The nAChR agonists nicotine or anatoxin-a failed to evoke release of [3H]D- 
aspartaie above the effect of basal conditions during early attempts to detect the 
release of [3H]D-aspartate from both rat striatal synaptosomes and rat frontal cortex 
synaptosomes. These initial experiments were carried out using a 6 channel
TM
Brandel superfusion apparatus which resulted in inconsistent results and large 
variability, confounded by the small number of chambers available to assess 
conditions in parallel. However, after obtaining some encouraging results with 
nicotine applied alone using the 12 chamber Brandel™ superfusion apparatus a 
thorough investigation into the effect of nAChR agonists on modulating the release 
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Figure 3.3.1 The effect of 
nicotine (10 nM) on [3H]D- 
aspartate release compared to 
buffer. Rat frontal cortex 
synaptosomes were superfused 
with KB buffer and stimulated for 
90 s with nicotine (10 ^M; closed 
circles) using a 12 channel 
Brandel™ superfusion apparatus. 
A 90 s buffer pulse was also 
applied to a set of chambers run 
in parallel (open circles). Release 
is expressed as a percentage of 
the average baseline release for 
both conditions, taken as 100%. 
Results represent the mean ± 
S.E.M of three independent 
experiments. * Statistical 
significance observed between
0 2 4 6 8 10 nicotine 10 n-M compared to basal
Fraction Number P<0.05, n=3, One way ANOVA 
with post-hoc tukeys analysis.
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The first three experiments re-examining the effect of nicotine alone on the release 
of [3H]D-aspartate from rat frontal cortex synaptosomes, using the 12 channel 
Brandel superfusion apparatus, showed a significant enhancement of release above 
the effect of a comparable buffer pulse within each experiment (Fig. 3.3.1). Nicotine 
(10 piM) evoked [3H]D-aspartate release to 24.87 ± 2.3% above baseline, compared 
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Figure 3.3.2 Calcium dependency and the effect of glutamate transport inhibitors on 
the reiease of [3H]D-aspartate evoked by nicotine (10 ^M) from rat frontal cortex 
synaptosomes. Rat frontal cortex synaptosomes were superfused with KB buffer in the 
presence (control) and absence of Ca2+ or in the presence of DI-TBOA (10 îM) and 
stimulated for 90 s with nicotine (10 |xM) using a 12 channel Brandel™ superfusion 
apparatus. (A) Nicotine-evoked release is expressed as a percentage of the average 
baseline release for all three conditions (control = normal KB buffer (closed circles), KB 
buffer -  Ca2+ (open circles) and KB buffer containing DL-TBOA (10 jxM; closed triangles), 
taken as 100%. Results represent the mean ± S.E.M of three independent experiments. (B) 
Release is expressed as a percentage of control-evoked release (nicotine 10 piM in normal 
KB buffer) with each condition adjusted for buffer evoked release. Results represent the 
mean ± S.E.M of three independent experiments. * Statistical significance between nicotine 
10 (xM in the absence of Ca2+ compared to control P<0.05, n=4, one way ANOVA with post- 
hoc tukeys analysis.______________________________________________________
In order in assess the specificity of the response in terms of Ca2+-dependency and 
the possible effect of glutamate transporter reversal; nicotine-evoked release (10 
jxM) was assessed in the absence of Ca2+ or in the presence of the glutamate
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transporter inhibitor TBOA (10 fxM) (see Fig. 3.3.2 A & B). In the absence of Ca2+, 
nicotine-evoked release of [3H]D-aspartate from rat frontal cortex synaptosomes was 
significantly reduced to 12.8 ± 10.4% of the control response (control; Nicotine 10 
pM in normal KB buffer = 100 ± 23.0%). In the presence of the glutamate transporter 
inhibitor (TBOA; 10 jiM) neither the baseline release of [3H]D-aspartate nor the 
release evoked by nicotine was significantly different to control (139.7 ± 20.5% of 
nicotine control; P>0.05. Fig. 3.3.2 B).
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Figure 3.3.3 Nicotine-evoked release of [3H]D-aspartate from rat frontal cortex 
synaptosomes: a7 nAChR specificity and concentration dependant release. (A) Rat
frontal cortex synaptosomes were superfused with KB buffer in the absence (control) and 
presence of a-Bgt (40 nM). Release is expressed as a percentage of the total radioactivity 
present at the point of nicotine (10 ^M) stimulation (see methods for calculation). Results 
represent the mean ± S.E.M of three independent experiments. (B) Rat frontal cortex 
synaptosomes were superfused with KB buffer and stimulated for 90 s with nicotine (over a 
concentration range of 1-300 îM). Release was calculated as a fraction of the total 
radioactivity remaining in the preparation at the point of stimulation, and expressed as a 
percentage of the response to buffer (taken as 100% ± S.E.M). Results represent the mean 
± S.E.M of at least three independent experiments for each agonist concentration. (A) * 
Statistical significance observed between nicotine 10 îM in the presence of a-Bgt (40 nM) 
compared to control (nicotine 10 ^M alone). (B) * Statistical significance between nicotine 
and buffer evoked release. P<0.05, n=3, one way ANOVA with post-hoc tukeys analysis.
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nAChR specificity of the response, in particular, a7* nAChR subtype specificity, was 
confirmed by examining the effect of a-Bgt (40 nM) on nicotine-evoked release of 
[3H]D-aspartate. Synaptosomes were incubated for 20 min, with or without a-Bgt, 
prior to a 90 s pulse of nicotine (10 pM). After adjusting release for buffer-evoked 
release, nicotine-evoked release was inhibited by 91.4 ± 16.6% in the presence of a- 
Bgt compared to control (100 ± 16.2%; Fig. 3.3.3 A).
Release of [3H]D-aspartate from rat frontal cortex synaptosomes was significantly 
different to buffer-evoked release at nicotine concentrations above 1 pM, whereas 1 
pM nicotine was without effect. Nicotine increased the release of [3H]D-aspartate to 
150-250% above the buffer-evoked release (100 ± 18.9%) between the 
concentration range 3 and 300 pM (Fig. 3.3.3 B). These results prompted the 
investigation of a variety of nAChR agonists and antagonists in an attempt to 
elucidate the nAChR subtype(s) associated with the modulation of EAA release in 
the frontal cortex.
The general nAChR agonists, anatoxin-a and epibatidine were applied over a broad 
concentration range; anatoxin-a and epibatidine (0.1-1000 nM; see Fig. 3.3.4 A & B). 
Significant release of [3H]D-aspartate was observed for anatoxin-a at concentrations 
above 0.1 nM, whereas 0.1 nM anatoxin-a was without effect (Fig. 3.3.4 A). 
Anatoxin-a evoked the release of [3H]D-aspartate to 150-175% above the buffer- 
evoked release (100 ± 16.2%), between the concentration range of 1 and 1000 nM. 
Maximal anatoxin-a-evoked release of [3H]D-aspartate was observed at 300 nM (270 
± 17.6% above buffer evoked release). This value was statistically different to either 
release evoked by 1 nM anatoxin-a or buffer-evoked release when compared using 
one way ANOVA with post hoc tukeys analysis.
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Figure 3.3.4 Concentration dependency anatoxin-a and epibatidine-evoked release of 
[3H]D-aspartate from rat frontal cortex synaptosomes. Rat frontal cortex synaptosomes 
were superfused with KB buffer and stimulated for 90 s with (A) anatoxin-a or (B) epibatidine 
(over a concentration range of 0.1-1000 nM for both agonists) using a 12 channel Brandel™ 
superfusion apparatus. Release was calculated as a fraction of the total radioactivity 
remaining in the preparation at the point of stimulation, and expressed as a percentage of 
the response to buffer. Results represent the mean ± S.E.M of at least three independent 
experiments for each agonist concentration. * Significantly different from buffer-evoked 
release. All values shown for epibatidine release are significantly different to buffer-evoked 
release. P<0.05, n>3, one-Way ANOVA with post-hoc tukeys analysis. ____ ____
Epibatidine also elicited the release of [3H]D-aspartate, and this was concentration 
dependant over the range 0.1 nM to 1 (Fig. 3.3.4 B). All concentrations 
examined in these experiments produced a statistically significant increase in [3H]D- 
aspartate release compared to buffer-evoked release. The maximum release of 
[3H]D-aspartate (359.3 ± 57.4% above buffer-evoked release; 100 ± 12.1%) was 
evoked by 300 nM epibatidine. This value is statistically different to the release 
evoked by 0.1-1nM epibatidine and buffer-evoked release, but not to other 
concentrations of epibatidine-evoked release.
The investigation into the nAChR agonist-evoked release of [3H]D-aspartate was 
extended to the subtype selective agonists choline (a7 selective; Papke et al., 1996 
& 2002; Alkondon et al., 1997;) and 5-I-A-85380 (p2 selective; Mukhin et al., 2000).
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In agreement with reported concentrations of choline that are effective at a l  nAChR 
(Albuquerque et al., 1997), 1 and 10 mM choline increased [3H]D-aspartate release 
to 240.2 ± 59.2% and 258.6 ± 75.8 above the buffer response (100 ± 24.2%) 
respectively (Fig. 3.3.5 A). At 1, 10 and 30 mM, choline-evoked release of [3H]D- 
aspartate was significantly above the effect of buffer-evoked release, whereas 0.3 
mM choline was without significant effect. The |32*selective agonist 5-I-A-85380 
evoked [3H]D-aspartate release to 107-173% of the buffer response, over the 
concentration range of 0.1-300 nM (Fig. 3.3.5 B). All concentrations of 5-I-A-85380 
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Figure 3.3.5. Concentration dependency of choline and 5-l-A-85380-evoked release of 
[3H]D-aspartate from rat frontal cortex synaptosomes. Rat frontal cortex synaptosomes 
were superfused with KB buffer and stimulated for 90 s with choline or 5-I-A-85380 (over a 
concentration range of 0.3-30 mM and 0.1-300 nM respectively) using a 12 channel 
Brandel™ superfusion apparatus. Release was calculated as a fraction of the total 
radioactivity remaining in the preparation at the point of stimulation, and expressed as a 
percentage of the response to buffer. Results represent the mean ± S.E.M of at least three 
independent experiments for each agonist concentration. * Statistical significance observed 
between choline-evoked release (1,10 and 30 mM) and buffer-evoked release. All values 
shown for 5-l-A-85380-evoked release are significantly different to buffer-evoked release. 
P<0.05, n=3, One way ANOVA with post-hoc tukeys analysis.
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The release profile for 5-I-A-85380 is relatively uniform with no specific 5-I-A-85380 
concentration displaying a significantly different amount of release compared to 
other 5-I-A-85380 concentrations.
3.3.2.2 Determination of subtype specificity of the nAChR modulation of 
[3H]D-aspartate release
Nicotine, anatoxin-a and epibatidine all display broad concentration dependant 
release profiles (Fig. 3.3.3 and Fig. 3.3.4 A & B). It is this observation that prompted 
a pharmacological characterisation of [3H]D-aspartate release to ascertain if more 
than one nAChR subtype contributes to the facilitation of release over such a broad 
concentration profile for each agonist.
As described above (Fig. 3.3.3 A & B), nAChR specificity of nicotine-evoked release 
of [3H]D-aspartate demonstrated that nicotine (10 pM) evoked release was inhibited 
in the presence of a-Bgt (40 nM). However when [3H]D-aspartate release was 
evoked by a higher concentration of nicotine (300 pM) the release was not inhibited 












Figure 3.3.6 Concentration 
dependant sensitivity of nicotine- 
evoked release of [3H]D-aspartate to 
a-Bgt. Rat frontal cortex 
synaptosomes were superfused with 
KB buffer and then subject to a 90 s 
pulse of nicotine (either 10 or 300 pM). 
a-Bgt (40 nM) was introduced 20 min 
before agonist stimulation and 
remained throughout the remainder of 
the experiment. Responses are 
expressed as a percentage of the 
corresponding agonist response in the 
absence of antagonist determined in 
parallel. Values are the mean ± S.E.M. 
of at least three independent 
experiments. * Significantly different 
from nicotine control in the absence of 
a-Bgt, P<0.01, one way ANOVA with 
post hoc Tukeys analysis.
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Nicotine-evoked release (300 pM control; 100% ± 10.6) was inhibited by 14.5 ± 9.2 
% in the presence of a-Bgt (40 nM), which is not statistically different to control. In a 
repeat measure of a-Bgt inhibition against 10 pM nicotine-evoked release of [3H]D- 
aspartate, a-Bgt (40 nM) inhibited release by 88.8 ± 11.1%, similar to the initial 
observation (see Fig. 3.3.3). A second a7* selective nAChR antagonist was also 
examined (Fig. 3.3.7). At a low concentration of nicotine, MLA inhibited nicotine- 
evoked release of [3H]D-aspartate by 71.3 ± 8.6 % (nicotine 10 pM control; 100 ± 
25.0%). However, at the higher concentration of nicotine, MLA also displayed a high 
(71.3 ± 9.4%) inhibition of nicotine-evoked [3H]D-aspartate release (nicotine 300 pM 
control; 100 ± 33.0%).
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Figure 3.3.7 Concentration dependant sensitivity of nicotine-evoked [3H]D-aspartate 
release to MLA Rat frontal cortex synaptosomes were superfused with KB buffer and then 
subject to a 90 s pulse of nicotine (either 10 or 300 pM). MLA 50 nM was introduced 10 min 
before agonist stimulation and remained throughout the remainder of the experiment. 
Responses are expressed as a percentage of the corresponding agonist response in the 
absence of antagonist determined in parallel. Values are the mean ± S.E.M. of at least three 
independent experiments. * Significantly different from nicotine control in the absence of 
MLA, P<0.05, one way ANOVA with post hoc Tukeys analysis.
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The effect of a-Bgt against low and high concentrations of epibatidine-evoked 
release of [3H]D-aspartate was also examined.
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Figure 3.3.8 Concentration dependant sensitivity of epibatidine-evoked [3H]D- 
aspartate release to a-Bgt. Rat frontal cortex synaptosomes were superfused with KB 
buffer and then subject to a 90 s pulse of epibatidine (either 1 or 100 nM). a-Bgt (40 nM) 
was introduced 20 min before agonist stimulation and remained throughout the remainder of 
the experiment. Responses are expressed as a percentage of the corresponding agonist 
response in the absence of antagonist determined in parallel. Values are the mean ± S.E.M. 
of at least three independent experiments. * Significantly different from epibatidine control in 
the absence of a-Bgt, P<0.05, one way ANOVA with post hoc Tukeys analysis.
Against low concentrations of epibatidine (1 nM), a-Bgt (40 nM) inhibited release by 
53.3 ± 14.9%, which although was significantly different to the epibatidine 1 nM 
control response, was approximately 30% less inhibition than that observed against 
the release evoked by 100 nM epibatidine (84.1 ± 11.1% inhibition of release in the 
presence of a-Bgt). These results suggest that a7* nAChR account for most of the 
[3H]D-aspartate release evoked by low concentrations of nicotine and high 
concentrations of epibatidine, but that another nAChR subtype(s) contributes to the 
higher and lower ranges, respectively, of the dose response curves of these two 
agonists. To address this hypothesis, the effect of the p2-preferring antagonist DHpE
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was examined (Chavez-Noreiga et al., 1997). In the case of nicotine, 1 pM DHpE 
produced a similar level of blockade of responses to both 10 pM and 300 pM 
nicotine, decreasing evoked release by 38.1 ± 17.8% and 39.5 ± 18.3% respectively 
(see Fig. 3.3.9 A; 100 ± 19.9% for 10 pM nicotine control and 100 ± 13.1% for 300 
pM nicotine control).
Nicotine 1 0 ^  Nicotine 300 iJW EpMnM Epi 100nM
cm  ~om cm  "d^e
1mM 1mM 1mM
Figure 3.3.9 DHpE antagonism of nicotine and epibatidine-evoked release of [3H]D- 
aspartate from rat frontal cortex synaptosomes. Rat frontal cortex synaptosomes were 
superfused with KB buffer and then subject to a 90 s pulse of (A) nicotine (either 10 or 300 
mM) or (B) epibatidine (either 1 or 100 nM). DHpE (1 pM) was introduced 10 min before 
agonist stimulation and remained throughout the remainder of the experiment. Responses 
are expressed as a percentage of the corresponding agonist response in the absence of 
antagonist determined in parallel. Values are the mean ± S.E.M. of at least three 
independent experiments. * Significantly different from epibatidine controls in the absence of 
DHpE, P<0.05, one way ANOVA with post hoc Tukeys analysis.
With respect to epibatidine, DH(3E (1 pM) inhibited [3H]D-aspartate release evoked 
by 1 nM epibatidine by 48.8 ± 13.9% (control = 100 ± 9.8%). When DHpE was 
applied together with a-Bgt, the evoked release of [3H]D-aspartate was abolished 
(see Fig. 3.2.13). At the higher concentration of epibatidine (100 nM) DHpE (1 pM) 
had significantly less effect, inhibiting release by 21.4 ± 1.1% (epibatidine control = 
100 ±16.8 %; see Fig. 3.3.9 B).
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The results obtained from the DHpE antagonism experiments, seem to indicate a 
non-a7 component of the release evoked by low concentrations of epibatidine (the 
concentration of epibatidine that displayed a low sensitivity to a-Bgt). Unfortunately, 
the effect of DH(3E on high and low concentrations of nicotine-evoked release did not 
replicate the same observations made with epibatidine; this could be a reflection of 
the competitive mode of action of DH(3E and will be discussed later.
Mecamylamine, a general nAChR antagonist (with a preference for non-a7 nAChR; 
Papke etal., 2001) was also assessed against low and high concentrations of either 














8 8 ra o>
I I  ao
H  
t o  60
LS 







EpibaHdne 1 nM Eplbabdne 100 nM 
Mec Mec
2 0 20|M
Figure 3.3.10 Mecamylamine antagonism of nicotine and epibatidine-evoked release 
of [3H]D-aspartate from rat frontal cortex synaptosomes. Rat frontal cortex 
synaptosomes were superfused with KB buffer and then subject to a 90 s pulse of (A) 
nicotine (either 10 or 300 piM) or (B) epibatidine (either 1 or 100 nM). Mecamylamine (20 piM 
or 100 piM) was introduced 10 min before agonist stimulation and remained throughout the 
remainder of the experiment. Responses are expressed as a percentage of the 
corresponding agonist response in the absence of antagonist determined in parallel. Values 
are the mean ± S.E.M. of at least three independent experiments. * Significantly different 
from agonist controls in the absence of mecamylamine, P<0.05, one way ANOVA with post 
hoc Tukeys analysis.
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At a concentration expected to block all nAChR subtypes (20 pM), mecamylamine 
inhibited responses by 50-60%: responses to 10 pM and 300 pM nicotine were 
decreased by 57.3±13.1% and 55.6±10.3% respectively, whereas responses to 1 
nM and 100 nM epibatidine were decreased by 51.5±16.1% and 58.4±10.8% 
respectively. Increasing the mecamylamine concentration to 100 pM did not produce 
a significantly greater block of the 300 pM nicotine-evoked release.
To definitively address the contributions of the a7 and p2* nAChR in modulating 
[3H]D-aspartate release we re-assessed the effect of subtype-preferring antagonists 
against the subtype-selective agonists choline (a l selective; Alkondon et al., 1997) 













Figure 3.3.11 a-Bgt and DH(3E antagonism of nAChR subtype specific agonist-evoked 
release of [3H]D-aspartate from rat frontal cortex synaptosomes. Rat frontal cortex 
synaptosomes were superfused with KB buffer and then subject to a 90 s pulse of (A) 
choline (10 mM) or (B) 5-I-A-85380 (10 nM). a-Bgt (40 nM) was introduced 20 min before 
agonist stimulation and remained throughout the remainder of the experiment (DHpE was 
introduced 10 min before). Responses are expressed as a percentage of the corresponding 
agonist response in the absence of antagonist determined in parallel. Values are the mean ± 
S.E.M. of at least three independent experiments. (A)* Significantly different from choline 
control in the absence of a-Bgt, P<0.05, one way ANOVA with post hoc Tukeys analysis.
(B)* Significantly different from 5-I-A-85380 control in the absence of DH0E, P<0.05, one 
way ANOVA with post hoc Tukeys analysis
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Incubation of 40 nM a-Bgt significantly inhibited 10 mM choline-evoked [3H]D- 
aspartate release by 76.4 ± and 16.4%, whereas 1 pM DH|3E was without significant 
effect (Fig. 3.3.11 A). a-Bgt was ineffective at blocking 10 nM 5-l-A-85380-evoked 
release of [3H]D-aspartate, whereas DH|3E (1 îM) completely inhibited the response. 





Figure 3.3.12 nAChR antagonist 
effects on buffer-evoked release 
of [3H]D-aspartate. Rat frontal 
cortex synaptosomes were 
superfused with KB buffer and then 
subject to a 90 s pulse of KB. 
Release is expressed as a 
percentage of the total radioactivity 
in C.P.M, present at the point of 
nicotine stimulation (see methods 
for calculation). Values are the 




To ensure nAChR antagonists had no inherent effect on [3H]D-aspartate release, the 
release evoked by KB was examined in the presence of the range of nAChR 
antagonists used in this study. No nAChR antagonist produced a significant 
difference to KB-evoked release in the absence of antagonist (See Fig. 3.3.12)
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Figure 3.3.13 Summary of the nAChR pharmacology of nicotine and epibatidine 
evoked release of [3H]D-aspartate from rat frontal cortex synaptosomes: a-Bgt, 
mecamylamine and DHpE antagonism. Rat frontal cortex synaptosomes were superfused 
with KB buffer and then subject to a 90 s pulse of (A) nicotine (10 or 300 mM) or (B) 
epibatidine (1 or 100 nM). a-Bgt (40 nM) was introduced 20 min before agonist stimulation 
and remained throughout the remainder of the experiment (DHpE and mecamylamine were 
introduced 10 min before). Responses are expressed as a percentage of the corresponding 
agonist response in the absence of antagonist determined in parallel. Values are the mean ± 
S.E.M. of at least three independent experiments. * Significantly different from nicotine or 
epibatidine control in the absence of antagonist, P<0.05, One way ANOVA with post hoc 
Tukeys analysis.
As possible support for different nAChR subtypes governing the release of [3H]D- 
aspartate, examination of nAChR desensitisation was assessed using high and low 
concentrations of nicotine. In parallel experiments, nicotine was applied twice, with 
each stimulation separated by a 10 min perfusion in KB, for both 10 and 300 pM 
nicotine. The effect of a nicotine (10 pM) stimulation in the presence of a-Bgt and an 
initial buffer-evoked release of [3H]D-aspartate followed by a nicotine (10 pM) 
stimulation were used as controls in each experiment. As displayed in Fig. 3.3.14 A 
B and C, nicotine (10 pM) initially evoked release to 0.41 ± 0.03% of total [3H]D-
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aspartate release, however the second stimulation within the same chamber, 
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Figure 3.3.14 Desensitisation effect of subsequent nicotine (10 and 300 pM) 
applications to rat frontal cortex synaptosomes. Rat frontal cortex synaptosomes were 
superfused with KB buffer and stimulated for 90 s with an initial stimulus of buffer or nicotine 
(10 or 300 pM) in the presence or absence of a-Bgt 40 nM, using a 12 channel Brandel™ 
superfusion apparatus. (A) Nicotine 10 pM. Evoked release is expressed as a percentage 
of the average baseline release for both conditions. Closed circles = 1st stimulation with 
buffer, second stimulation with nicotine 10 pM. Open circles = 1st stimulation with nicotine 10 
pM and 2nd stimulation with nicotine 10 pM. (B) Nicotine 300 pM and a-Bgt sensitivity. 
Evoked release is expressed as a percentage of the average baseline release for both 
conditions. Closed circles = 1st stimulation with nicotine 300 pM, second stimulation with 
nicotine 300 pM. Open circles = 1st stimulation with nicotine 10 pM + a-Bgt 40 nM and 2nd 
stimulation with nicotine 10 pM + a-Bgt 40 nM. Results represent the mean ± S.E.M of at 
least three independent experiments. (C) Summary. Release is expressed as a percentage 
of the total radioactivity in C.P.M, present at the point of nicotine stimulation (see methods 
for calculation). Results represent the mean ± S.E.M of three independent experiments. * 
Statistical significance observed between nicotine 10 pM 2nd stimulation and 1st stimulation.
** Statistical significance observed between nicotine 10 pM 1st stimulation and nicotine 10 
pM 1st stimulation in the presence of a-Bgt. *** Statistical significance observed between 
nicotine 10 |xM 2nd stimulation and 1st buffer-evoked stimulation. P<0.05, n=3, One way 
ANOVA with post-hoc tukeys analysis.
As a control, buffer evoked release of [3H]D-aspartate was applied as the first 
stimulation (0.11 ± 0.01%) whereupon the subsequent stimulation with nicotine (10 
pM) evoked release similar in magnitude (0.40 ± 0.02%) to that evoked by nicotine in 
the first instance. To ensure that the nicotinic effect was specific, nicotine-evoked 
release was also examined in the presence of a-Bgt (40 nM) where on both
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applications of nicotine (10 jxM), release above the effect of buffer was not 
demonstrated (0.13 ± 0.02% and 0.11 ± 0.02%).
Interestingly, nicotine at high concentrations displayed no evidence of 
desensitisation, where the second application of nicotine (300 \M ) showed no 
significant difference to that evoked by the first stimulation within the same set of 
chambers; First nicotine 300 fiM application evoked 0.36 ± 0.03% of total [3H]D- 




The results in this section provide the first direct evidence that activation of 
presynaptic nAChR by nicotinic agonists alone can facilitate the release of [3H]D- 
aspartate from rat frontal cortex P2 synaptosomes. Pharmacological characterisation 
of frontal cortex synaptosomes revealed that both a7* and non-a7 nAChR mediate 
this response.
The general nAChR agonists anatoxin-a, epibatidine and nicotine, as well as the 
subtype specific agonists choline and 5-I-A-85380, evoked the release of [3H]D- 
aspartate from frontal cortex synaptosomes in the absence of KCI. The response to 
10 fxM nicotine was Ca2+-dependant, consistent with exocytotic release of [3H]D- 
aspartate from a vesicular store, but in contrast to KCI-evoked release, reversal of 
the glutamate transporter was not involved (Fig. 3.3.2 A & B). Fig. 3.3.2 B, does 
however show a trend in the increase of nicotine-evoked release of [3H]D-aspartate 
compared to control and this may reflect a prevention of re-uptake within the 
synaptosome chamber, thereby enhancing the evoked release. TBOA was not 
routinely included because of its expense; nAChR agonist-evoked release of [3H]D- 
aspartate was clearly detected in the absence of TBOA.
3.3.3.1 nAChR subtype characterisation
The concentration dependence of nicotine and epibatidine-evoked release of [3H]D- 
aspartate showed a sustained response over a broad concentration range for both 
agonists (see Fig. 3.3.3 B and 3.3.4 B), prompting the notion that different nAChR 
could contribute to these profiles. The differential effects of a-Bgt and DHpE at high 
and low agonist concentrations support this. However, MLA, an a l  nAChR selective 
antagonist, did not display the same functional effects of inhibition of [3H]D-aspartate
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release as described for a-Bgt (see Fig. 3.3.7). This finding could provide support for 
the current trend of data that this compound has a broader pharmacological 
specificity for nAChR subtypes than first predicted (Klink et al., 2001; Mogg et al., 
2002); these authors report the existence of a putative a3/a6p2p3* or an 
a4a6a5p2(2) nAChR subtype the displays sensitivity to low nM concentrations of 
MLA in the rat striatum. In this investigation, MLA is able to inhibit the non-a7 
component of the nicotine (300 fiM) evoked release of [3H]D-aspartate as well as the 
a7 component of low concentrations of nicotine-evoked release. However, the 
pharmacologically described non-a7 (p2* containing nAChR) component to nAChR 
agonist evoked release in the rat frontal cortex is unlikely to incorporate a6 nAChR 
subunit due to its localised expression in catecholaminergic neurons of the rat brain 
such as those found in the mesencephalon and locus coeruleus (Le Novere et al.,
1996).
The concentrations of nicotine and epibatidine that are more sensitive to a-Bgt (10 
jxM and 100 nM respectively (Fig. 3.3.6 and 3.3.8), are in the range predicted to 
activate a7 nAChR (Gerzanich etal., 1994; Alkondon & Albuquerque 1995; Briggs et 
al., 1995; Delbono et al., 1997). The relative insensitivity to mecamylamine of 
responses evoked by these agonist concentrations is compatible with its low efficacy 
at a7 nAChR (see Fig. 3.3.10 A & B; Frazier et al., 1998; Papke et a!., 2001), 
although incomplete blockade of [3H]D-aspartate release by mecamylamine was 
also observed at agonist concentrations insensitive to a-Bgt.
The choice of selective antagonists for non-a7 nAChR is limited. DHpE (0.1-1 jiM) 
has been reported to inhibit predominantly a4p2 nAChR (Alkondon et a!., 1994), 
although it potently inhibits a variety of p2* and a4* nAChR in heterologous
149
expression systems. However, within this concentration range, DHpE is two orders 
of magnitude less potent at a7 nAChR (Harvey et al., 1996; Chavez-Noriega et al.,
1997). DHpE, at a concentration of 1 [iM, was used to define the non-a7 mediated 
component of nicotine and epibatidine-evoked [3H]D-aspartate release. Its limited 
effect against a low concentration of nicotine (10 \M) is consistent with 
predominantly a7 nAChR-mediated facilitation of [3H]D-aspartate release. But DHpE 
was also not very effective at the higher nicotine concentration that was insensitive 
to a-Bgt: its efficacy may be confounded by its competitive mode of antagonism, 
such that its blocking ability is compromised at increasing agonist concentrations 
(see Fig. 3.3.9 A). This is consistent with the pharmacological specificity displayed 
by epibatidine-evoked release of [3H]D-aspartate (Fig. 3.3.9 B): DHpE produced 
greater inhibition at the lower epibatidine concentration and is additive with a-Bgt, 
whereas a-Bgt was more effective at the higher epibatidine concentration. 
Confirmation of the involvement of at least two nAChR subtypes was provided by the 
use of subtype-selective agonists (Fig. 3.3.5 A and B, and Fig. 3.3.11 A & B). 
Choline evoked [3H]D-aspartate release at concentrations reported to activate a7 
nAChR (Papke et al., 1996; Alkondon et al., 1997). The magnitude of the response 
was comparable to that evoked by low and high concentrations of nicotine and 
epibatidine respectively. Blockade of the choline-evoked response by a-Bgt 
confirmed the involvement of the a7 nAChR whereas DHpE had no significant effect. 
The novel agonist 5-I-A-85380 displays over 25000 fold selectivity for a4p2 nAChR, 
compared to a7 nAChR, in binding studies (Mukhin et al., 2000). In functional 
assays it displays a somewhat broader specificity, consistent with it being a potent 
and selective agonist at a4p2 and a6p2* nAChR (A Mogg, F.A.Jones, I.A Pullar,
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C.G.V. Sharpies, and S. Wonnacott. in preparation). Very low concentrations (0.1 
nM) of this agonist evoked [3H]D-aspartate release and this effect was sustained 
over a broad concentration range. The lack of effect of a-Bgt but complete blockade 
of evoked release in the presence of DHpE supports the involvement of non-a7, p2* 
presynaptic nAChR on terminals releasing EAA in the rat frontal cortex.
3.S.3.2 nAChR desensitisation
Homomeric a7 nAChRs and heteromeric non-a7 (p2* containing) nAChRs can also 
be distinguished based on their desensitisation properties; a7 nAChR imparts the 
fastest onset of desensitisation ( « 20 ms described in hippocampal cells) whereas 
p2* containing nAChR slowly desensitise («  300 ms described in hippocampal cells) 
(Alkondon & Alburquerque, 1993; Alkondon et al., 1994; Alburquerque et al., 1997; 
For review see Quick & Lester, 2002). Whole cell currents induced by nAChR 
activation have been categorised into four different types based on their 
pharmacological and kinetic characteristics (Table 3.3.1)
Current Type Desensltlsatlonattribute
Selective
antagonists Affinity to Ach
Possible subunits 
involved
IA Fast MLA, a-Bgt Low a7
IB Fast + slow MLA + DHpE Low and High a7; a402
II Slow DHpE High a4p2
III Slow Mecamylamine High a332
Table 3.1 nAChR pharmacology and kinetic characterisation from currents recorded 
in rat hippocampal cells. Desensitisation currents time constants assigned fast and slow 
when they decayed over <30 ms or >500 ms. The antagonists employed are based on their 
ability to block at specific concentrations that have little effect on other current types. (Table 
adapted from Alkondon & Alburquerque, 1993)
However, superfusion is unable to differentiate nAChR subtype kinetic 
characteristics due to the limited temporal resolution of drug application, but instead
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may be able to differentiate between nAChR subtype recovery times: the ability to 
activate on subsequent agonist exposure. Recovery times for a7 nAChR have been 
reported to be fast, (< 10 s), even after prolonged exposure to nAChR agonist (Dani, 
2000; Kawai & Berg, 2001) whereas in non-a7 nAChR recovery times are more 
diverse dependant upon the subunit combination of nAChR being assessed and the 
expression system/species being used: a4|34 recovery to ACh « 3 hrs, a3p2a5 
recovery to nicotine « 10 min-5hrs, a4p2 recovery to nicotine « 4-60 min (For review 
see Quick & Lester, 2002). With this information it was hoped that by separating low 
and high concentrations of nicotine exposure by a selected time period (10 min; Fig 
3.3.14) we could also define the nAChR subtypes governing [3H]D-aspartate release 
based on recovery times. As demonstrated in Fig. 3.3.14, P2 synaptosomes 
exposed to a second exposure of nicotine (10 p,M; a7 nAChR activating, defined 
pharmacologically) failed to evoke the same extent of [3H]D-aspartate release as 
that evoked by the first nicotine (10 fxM) application 10 minutes earlier during the 
superfusion. Conversely, a second exposure of nicotine (300 fxM; non-a7 nAChR 
activating, defined pharmacologically), evoked [3H]D-aspartate release to the same 
extent as the first nicotine (300 \M) application 10 min earlier. This was a surprising 
result in light of the fact that a7 nAChRs should have recovered from their first 
nicotine exposure. With respect to the non-a7 nAChR result, it appears that these 
receptors have recovered from the first high nicotine exposure within 10 min, in 
agreement with the literature. The a7 component in these studies was confirmed by 
assessing the effect of a-Bgt (40 nM) in parallel, which displayed complete blockade 
of the nicotine (10 p-M) evoked release, however, the recovery rate is not of that 
described for a7 nAChR in the literature. This result could be explained on the
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premise that the a7 nAChR subtype characterised in the frontal cortex, may be 
heteromericallv assembled, rather than homomeric, as assumed in those 
investigations studying recovery rates in the hippocampus, cortical cultures and 
Xenopus ooctyes (Olale et al., 1997; Molinari etal., 1998; Mike etal., 2000; Kawai & 
Berg, 2001). At present, possible heteromeric nAChR subunit combinations with a7 
nAChR subunit have not been defined in terms of recovery rate and therefore 
provides an interesting opportunity for research in defining a7* heteromeric nAChR.
3.3.3.3 Implications of nAChR heterogeneity for regulation of EAA 
release
The role of p2* nAChR in [3H]D-aspartate release is consistent with the inference 
made from microdialysis and electrophysiological experiments that p2* nAChR 
mediate glutamate release in the rat prefrontal cortex (Vidal and Changeux., 1989; 
Vidal, 1993; Granon et al., 1995; Gioanni et al., 1999; Lambe et al., 2003). These 
studies found no evidence for a a7 nAChR-mediated component of glutamate 
release. Possible reasons for this disparity with the present findings include 
methodological differences in temporal characteristics or agonist concentrations, or 
anatomical differences dependant on where recording and stimulating electrodes 
were placed. However, the involvement of presynaptic a7 nAChR is compatible with 
the role of this subtype in the facilitation of glutamate release in other areas of the rat 
brain: hippocampus (Gray etal., 1996; Alkondon etal., 1998; Radcliffe & Dani, 1998; 
Fischer & Dani, 2000; Sharma & Vijaraghavan, 2003), olfactory bulb (Alkondon et 
al., 1996), midbrain (Schilstrom et al., 2000; Nomikos et al., 2000; Mansvelder & 
McGehee, 2000; Girod & Role, 2001;) and cerebellum (De Filippe et al., 2001). It 
has been suggested that a7 nAChRs increase the probability of glutamate release
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by increasing local Ca2+ levels in glutamate terminals (Gray et al., 1996). The Ca2+- 
dependence of [3H]D-aspartate release by 10 pM nicotine, a concentration that 
elicits a predominantly a-Bgt-sensitive response, is consistent with this model. a7 
nAChR can modulate synaptic efficacy at glutamate synapses and promote the 
induction of LTP in the hippocampus (Ji et al., 2001) and VTA (Mansvelder & 
McGehee, 2002), and a comparable role in the frontal cortex could be relevant to the 
positive effects of nicotine on attentional aspects of memory (Levin & Simon, 1998).
This has additional implications in neurological disorders such as schizophrenia and 
Alzheimer’s disease, where reduced glutamatergic and cholinergic transmission in 
the frontal cortex compromises both attentional processes and memory functions 
(Sarter & Bruno, 1999). Here we show that at least two nAChR subtypes are 
involved in the presynaptic regulation of [3H]D-aspartate release in the frontal cortex
02*  nAChR
Figure 3.3.15. Summary of nAChR- 
evoked release of EAA release 
from  frontal cortex term inals. The
release of [3H]D-aspartate from rat 
frontal cortex synaptosomes could be 
evoked by activating
pharmacologically defined a7 nAChR 
and 02* containing nAChRs. The 
release of nicotine-evoked release of 
[3H]D-aspartate was shown to rely on 
Ca2+ and was independent of EAAT 
reversal. The source of the intra­
terminal Ca2+ increase remains to be 
investigated.
* Activated by 10 nicotine and 
100 nM epibatidine
* a7 selective agonist choline 
activation blocked by a-Bgt (40 
f nM) only.
a7 nAChR
* Activated by 300 ^M nicotine and 
1nM epibatidine
•  02*  selective agonist 5-IA-85380 
activation blocked bv DH8E (1 uM)
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(summarised in Fig. 3.3.15), albeit the significance of this heterogeneity is presently 
unclear. The a7 and p2* nAChRs may serve distinct functions through their 
localisation on different glutamatergic afferents (which is examined using 
immunocytochemistry, in the next chapter; Chapter 4), or different domains on the 
same terminals, or they may couple to complementary regulatory mechanisms to 
influence different aspects of synaptic function. This study provides an in vitro model 
that will be useful for exploring this relationship.
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Chapter Four
4.1 Localisation of nAChR in the rat frontal 




4.1.2 Techniques utilised for localising nAChR in the vertebrate CNS
The identification and location of nAChR in the vertebrate CNS relies on an array of 
investigative approaches including autoradiographical analysis, in situ hybridisation, 
immunocytochemistry and PET scanning.
Autoradiographical analysis, using radiolabelled nAChR agonists and antagonists 
such as [3H]nicotine, [3H]ACh (in the presence of excess atropine) and [125l]a-Bgt 
(Yoshida & Imura, 1979; Marks & Collins, 1982; Schwartz et al., 1982: Clarke et al., 
1984 & 1985;) incubated with either brain homogenates or brain sections permits the 
gross identification of nAChR location within the brain. It is generally accepted that 
[3H]nicotine and [125l]bungarotoxin label a402* containing nAChR and a7 nAChR 
respectively. Indeed, it was the comparison of different radioligand labelling patterns 
of [3H]nicotine and [125l]bungarotoxin within the rat brain, that provided the first 
evidence that more than one nAChR may co-exist, confirmed and summarised by 
Wonnacott, (1986); coining the term ‘high’ and ‘low’ affinity nicotine binding 
receptors (see Introduction, section 1.2.3). However the majority of nAChR ligands 
fail to demonstrate specificity against other nAChR subtypes and therefore limits the 
extent of analysis of nAChR heterogeneity in the brain using autoradiography. 
Presently, autoradiographical analysis has been extended to human studies and 
provides a useful gross diagnostic tool for nAChR association with 
neurodegenerative diseases (Nordberg & Windblad, 1986; Marutle et al., 1998) as 
well as the characterisation of novel ligands for nAChRs; the compound [125I]5-I-A- 
85380 is a novel 02 selective binding ligand that may display similar labelling 
patterns to other well characterised ligands (Musachio et al., 1998; Muhkin et al., 
2000). The suitability of this technique is not favoured in this thesis because
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autoradiographical analysis of rat frontal cortex regions, using radiolabel nAChR 
ligands, would give insufficient detail of the neurochemical identity of the cell bodies 
or subcellular components associated with the radiolabel as well as possible 
concerns over the nAChR specificity of the label.
The advent of molecular cloning techniques accelerated the understanding of 
nAChR in the CNS, namely the revelation of a family of genes encoding for the a 
and p subunit proteins that could be manipulated to form functional nAChR in a 
variety of expression systems (Seguela et al., 1993; Leutje et al., 1990; 
Gopalkrishnan et al., 1995). In terms of nAChR localisation studies, this knowledge 
has allowed for the progression of either in situ hybridisation or immunocytochemical 
techniques to identify and localise nAChR subunits by enabling the design of specific 
nAChR subunit riboprobes or specific nAChR antibodies respectively. These 
techniques have essentially corroborated the data provided from autoradiographical 
analysis but have allowed for a greater detail of inspection on the basis of an 
increased specificity and selectivity for the array of a or p subunits of the nAChR that 
nAChR ligands cannot discriminate between, as well as provide greater 
morphological data about the specific cell type and subcellular distribution of the 
nAChR (For review see Heinemann et al., 1991). However the location of nAChR 
gene expression from in situ studies are only defined to those regions where the 
mRNA is expressed, mainly cell bodies and therefore cannot define the location of 
nAChR subunits located away from the soma. As well as this, disparities also exist 
between the quantifiable level of in-situ hybridisation labelling and that of 
autoradiographical or immunocytochemical labelling, demonstrating the point that in 
situ hybridisation cannot reveal any changes of nAChR protein expression at the 
level of the membrane (e.g. Marks et al., 1992). For these reasons and for the fact
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that the majority of this thesis focuses on the presynaptic function of nAChR, in situ 
hybridisation techniques do not serve as a suitable means to corroborate the 
functional data described in Chapter 3 (section 2 and 3), as the a7* or (32* containing 
nAChR transcript would only be detected in the cell bodies within the frontal cortex. 
Immunocytochemistry serves as a useful tool in receptor identification and 
localisation at both the cellular and subcellular level, dependent on the probes being 
used, e.g. fluorescent-labelled antibodies or ligands. Immunocytochemical 
identification of nAChR combined with electron microscopy analysis can reveal the 
micro-architecture of the synapse such as pre and post-synaptic elements, 
alongside immuno-gold labelled receptors. This has been utilised for anatomical 
studies of the nAChR in the dorsal striatum e.g. (32 nAChR-immunogold labelling of 
TH-positive cells (Jones et al., 2001) and a7 nAChR-immunogold labelling of 
synapses within the dentate gyrus, CA1 and CA3 areas of the rat hippocampus 
(Fabien-Fine et al., 2001). Confocal imaging of immunolabelled brain tissue permits 
the differentiation of up to six or seven different components within a sample 
preparation (mainly due to the limitations of confocal system and its use of 
wavelength filtration). This technique provides a large amount of information 
compared to other receptor localisation methods (although not to the resolution of 
EM), namely: the receptor identification, the identification of other proteins 
associated with the receptor (i.e. structural or cell membrane associated proteins or 
other co-localised receptors/transporter/channels) and the neurochemical identity of 
the cell or presynaptic terminal associated with the receptor (via immunolabelling for 
neurotransmitter-specific enzymes or transporters). However confocal microscopy is 
limited with respect to resolution and therefore the interpretation of the pre or 
postsynaptic location of an immunolabelled receptor has to be exercised with
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caution. With respect to our study, this technique is utilised to support the 
association of nAChR with glutamatergic terminals; nAChR localisation and 
association with glutamatergic terminals and cell bodies of the rat frontal cortex are 
examined using fluorescently labelled ligands for the nAChR (Alexa-Fluor488 or 546 
a-Bgt), antibodies directed against 02 nAChR, antibodies directed against the 
vesicular glutamate transporters 1 & 2 (VGluT 1 &2; a marker for glutamatergic 
terminals; Kaneko et al., 2002) and antibodies directed against presynaptic terminal 
proteins (synaptophysin) and cell body proteins (Neun) respectively.
Notably we have utilised fluorescent labelled a-Bgt (Alexa-Fluor® 488 or 546 a- Bgt) 
instead of monoclonal antibodies directed against a7 nAChR such as mAb306 (a 
mouse monoclonal antibody directed against the predicted cytoplasmic domain of 
the a7 nAChR (Schoepfer et al., 1990; Mclane et al., 1992)), on the basis that data 
accumulated in our laboratory has raised grave concerns over antibody specificity 
for a number of ‘supposed’ a7 nAChR specific antibodies. a-Bgt on the other hand is 
a well-characterised selective antagonist for a7 nAChR and the development of a 
fluorescent-labelled a-Bgt serves as an extremely useful tool in confocal microscopy 
analysis of a7 nAChR localisation and identification studies (see Fabien-Fine et al., 
2001; Kawai et al., 2002; Akaaboune et al., 2002). Added advantages of the 
confocal microscope software allow for the investigator to selectively obtain serial 
images through a tissue sample and then generate a 3D image of the tissue as well 
as the use of ‘profiling’, where along a selected axis, the relative fluorescence 
intensities can be assigned for each fluorochrome used. .
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4.1.3 Present understanding of a7* and (32* nAChR localisation in the frontal 
cortex
To date, few studies have specifically examined the rat frontal cortex with respect to 
the a7 * and 02* nAChR localisation and distribution in the rat CNS (the two nAChRs 
defined pharmacologically in Chapter 3 section 3). As described in Chapter 1 (see 
Introduction; see sections 1.3) in situ hybridisation studies have demonstrated a 
wide anatomical distribution for the 02 subunit of the nAChR (Deneris et al., 1988; 
Wada et al., 1989, Goldman et al., 1987) in the rat brain; these corresponded with 
the high affinity nicotine binding sites also described from autoradiographical 
analysis. With respect to the rat a7 nAChR, in situ hybridisation techniques also 
displayed a broad distribution of expression of this receptor across the rat brain 
(Seguela et al. 1993; Broide et al., 1995), and these are in agreement with 
autoradiographical studies using [125l]a-Bgt (Clarke et al., 1985). One specific 
observation, particularly from autoradiographical analysis of nAChR distribution, is 
the differences between [3H]nicotine and [125l]a-Bgt labelling found in the cortical 
layers of the rat brain; [125l]a-Bgt labelling is found predominantly in the superficial 
(layers I and II) and deep layers (layers V and VI) whereas [3H]nicotine labelling is 
found in the intermediate layers. This relatively clear difference may reflect the 
different nAChR subtypes expressed by specific neurons that either innervate these 
layers of the cortex (i.e found on their presynaptic terminals) or of those neurons 
found in these layers (i.e found on their dendritic or somatic membranes).
To definitively assign nAChR subcellular location at the presynaptic locus, electron 
microscopy is required for high-resolution imaging. Again few studies have 
specifically examined the rat frontal cortex with respect to the a7 and 02* subunit 
containing nAChR, but nonetheless, these subunits have been identified at the
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presynaptic terminal: a l  nAChR have been defined using EM analysis of immuno- 
gold labelled tissue sections in the guinea pig pre-frontal cortex, rat hippocampus 
and in the rat sensory cortex (Lubin et al., 1999; Levy & Aoki, 2002; Fabien-Fine et 
al., 2001). p2* containing nAChRs have been located at presynaptic terminals in 
axon terminals of the basal ganglia (Hill et al., 1993; Jones eta l., 2001).
4.1.4 Physiological significance of nAChR in the frontal cortex
A large number of glutamatergic pathways innervate the frontal cortex regions 
particularly from the hippocampus (Thierry et al., 2000; Delatour & Witter, 2002) as 
well as the thalamus (Gigg et al., 1994; Groenewegen, 1988; Pinto et al., 2003). 
Although not experimentally assessed in this chapter, the relevance of glutamatergic 
innervation into the frontal cortex is pertinent to the role the frontal cortex plays in 
cognition, memory and reward (Frith & Dolan, 1996; Mitchell & Laiacon, 1998; 
Trzcinska & Bielajew, 1998; Buckner et al., 1999). Therefore if nAChR is found at 
the terminals of these glutamatergic pathways directed towards the frontal cortex, 
then this may support the notion of how the nAChR may participate in such functions 
(Granon etal., 1995; For review see Levin & Simon, 1998), notably exampled by the 
possible involvement of nAChRs with neurological disorders associated with frontal 
cortex dysfunction such as schizophrenia (Guan et al., 1999; Breese et al., 2000; 
Marutle etal., 2001) and Alzheimer’s disease (Nordberg & Winblad, 1986; Sugaya et 
al., 1990; Nordberg, 1993; Wevers etal., 2000; Engidawork etal., 2001).
The present chapter describes evidence supporting the presence of a7* and p2* 
nAChR associated with glutamatergic terminals in the rat frontal cortex, to 
complement the functional data described in Chapter 3 (sections 2 and 3). The study
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also provides a preliminary investigation into the regional localisation of these 
receptors within the frontal cortex, which could provide an investigative platform for 
future studies into the functional significance of their location with respect to the 
physiological roles of the frontal cortex.
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4.2. Results
4.2.1 Double Immunolabelling in rat frontal cortex synaptosomes
To address the association of a7 nAChR with presynaptic terminals in the rat frontal 
cortex, P2 and Percoll™ purified synaptosomes were initially subjected to double­
label confocal microscopy analysis. From Fig 4.1 it is clear that the P2 synaptosome 
preparation incorporates many non-specific membrane elements compared to the 
Percoll™ purified synaptosomes. Therefore the use of P2 purified synaptosomes for 
the assessment of nAChR labelling of presynaptic terminals was deemed unsuitable, 
all subsequent figures utilise and demonstrate results obtained using Percoll™ 
purified synaptosomes.
Synaptosomes (presynaptic terminals) are identified using an antibody specific to 
the presynaptic terminal marker protein synaptophysin (identified using a secondary 
label, anti-mouse 546). a7 nAChRs were visualised using fluorochrome-conjugated 
a-Bgt (Alexa-Fluor® 488 a-Bgt). The specificity of this toxin conjugate for labelling 
a7 nAChR has been demonstrated previously (Kawai et al., 2002) and was 
confirmed in this study by pre-incubating the samples with a 100-fold molar excess 
of either a-Bgt or MLA, which abolished the toxin labelling.
An average of 180 synaptophysin positive structures were identified per field view. 
Of these synaptophysin positive structures less than 2% were associated with Alexa- 
Fluor® 488 a-Bgt binding (See Table 4.1). Of the fifteen field views analysed, 
approximately 4 individual Alexa-Fluor® 488 a-Bgt labels were not associated with 
synaptic terminals as indicated by lack of synaptophysin fluorescence when 
assessed using fluorescence intensity profiles.
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Figure 4.1. Confocal imaging of a-Bgt AlexaFluor 488 labelling in rat frontal cortex P2 
purified synaptosomes (A) and Percoll™ purified synaptosomes (B). Example confocal 
image of both P2 synaptosomes (A) and Percoll™ purified synaptosomes (B) double 
labelled with a-Bgt (green) and anti-synaptophysin (red). (C) & (E) x3 zoom image of area 
highlighted in (A) and (B) (square). (D) & (E), fluorescence intensity profiling of the a-Bgt 
labelling in the area delineated in A and B (square) reveals that this labelling is associated 













100 ± 1 4 % 1.8 ±0.07% 1.7 ±0.1 %
(Per field view)
Table 4.1. Quantitative analysis of presynaptic terminal immunolabelling w ith anti- 
synaptophysin and Alexa-Fluor® 488 a-Bgt in rat frontal cortex Percoll™ purified 
synaptosomes. Values given are the mean ± S.E.M of positive immunolabelled structures 
per field view under the confocal microscope from an average of five field views from three 
independent experiments. (+VE = positive)
4.2.2 Triple Immunolabelling of rat frontal cortex synaptosomes: 
Identification of a7 nAChR
The association between a-Bgt binding sites and glutamatergic terminals in the 
frontal cortex was investigated by triple labelling of synaptosomes with antibodies to 
the vesicular glutamate transporter types 1 & 2 (identified using secondary label anti­
rat 633 blue), and synaptophysin (identified using secondary label anti-mouse 546 
red), a7 nAChRs were again visualised using fluorochrome-conjugated a-Bgt 
(Alexa-Fluor® 488 a-Bgt). To avoid any incidence of fluorochrome ‘cross-talk’, which 
could result in erroneous examples of co-localisation, samples were analysed using 
sequential fluorochrome excitation (multi-tracking).
Approximately 80% of all synaptophysin positive synaptosomes were also labelled 
for VGluT 1 & 2 (See Figure 4.2 and Table 4.2) indicating that the majority of 
synaptosomes isolated from Percoll™ purified frontal cortex synaptosomes are
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glutamatergic. Fluorescence intensity profile examination of a-Bgt fluorescence 
showed near 85% association with presynaptic terminals (36 out of 44 identified 
Alexa-Fluor® 488 a-Bgt labels). Of these labelled structures, 75% (32 of the 36 
identified Alexa-Fluor® 488 a-Bgt labels that co-associated with anti-synaptophysin 
labelling) were also co-associated with structures positive for VGluT 1 & 2.
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4 0  4.5 5.0
□slance (inn)
»2-T1 CH3-T2 C41-T3
Figure 4.2. Confocal imaging of a-Bgt AlexaFluor 488 labelling in rat frontal cortex 
Percoll™ purified synaptosomes. (A), Example confocal image Percoll™ purified 
synaptosomes triple labelled with a-Bgt (green), anti-synaptophysin (red) and anti-VGluT 1 
& 2. (B) x3 zoom image of area highlighted in (A) (white square). (C) Fluorescence intensity 
profiling of the a-Bgt labelling in the area delineated in A and reveals that this labelling is 
associated with glutamatergic terminals.
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This approximates to less than 1.2% of all synaptophysin positive structures co- 
associated with Alexa-Fluor® 488 a-Bgt labels from an average field view (See 
Table 4.2). These results are consistent with the presence of presynaptic a7 nAChR 
on a minority of glutamatergic axon terminals.
Table 4.2. Quantitative analysis of presynaptic terminal immunolabelling with anti- 
synaptophysin, Alexa-Fluor® 488 a-Bgt and VGluT 1 and 2 in rat frontal cortex 
Percoll™ purified synaptosomes. Values given are the Mean (± S.E.M where indicated) o 
positive immunolabelled structures per field view under the confocal microscope. Results 
are accumulated from an average of five field views from three independent experiments, 15 


















Total number of 
positive 
structures 
(from 15 field 
views)
3208 44 2530 36 2474 32
Average number 
of positive 





181-261 1-5 144-220 1-4 101-215 1-4
%of total 
S’physin positive 
structures 100 ±2.7 1.1 ±0.1 77.1 ± 4.3 0.98 ± 0.1
(Per field view)




100 ±5.1 97.7 ± 5.5 1.3 ±0.1




100 ±0.3 82.7 ± .9 72.4 ± 6.9
From these results it is apparent that a small proportion of Alexa-Fluor® 488 a-Bgt 
binding is associated with non-glutamatergic structures (12 out of 44 Alexa-Fluor® 
488 a-Bgt labels). Of these 12, only 4 Alexa-Fluor® 488 a-Bgt labels are associated
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with synaptophysin positive structures indicating that a7 nAChR may also reside on 
non-glutamatergic terminals. The remainder of Alexa-Fluor® 488 a-Bgt labels 
displayed could be associated with non-presynaptic structures such as post-synaptic 
membranes of neurons or glial cells but this was not investigated further.
4.2.3 Triple Immunolabelling of rat frontal cortex synaptosomes: 
Identification of a7 and (32 nAChR
To corroborate the functional evidence described in Chapter 3 (section 3) for non-a7 
nAChR mediated release of [3H]D-aspartate (presumably (32* nAChR containing), 
Percoll™ purified synaptosomes were triple labelled with antibodies to the vesicular 
glutamate transporters (VGluT; types 1 & 2; secondary label anti-rat 633 blue) anti- 
132 nAChR (mAb 270; anti-rat nAChR- secondary label anti-mouse 546 red) and a7 
nAChRs, were again visualised using fluorochrome-conjugated a-Bgt (Alexa-Fluor® 
488 a-Bgt). Limitation of the confocal microscope prevented the examination of anti- 
synaptophysin positive labelling, indicative of presynaptic terminals. However, 
because the majority of anti-VGluT 1 & 2 labels were identified with the presynaptic 
terminal marker (97.7%; See Fig 4.2 and Table 4.2), this labelling was taken as also 
indicative of presynaptic terminals.
Notably, Alexa-Fluor® 488 a-Bgt labelling is more prominent in experiments where 
anti-synaptophysin is not utilised; there is an increase of Alexa-Fluor® 488 a-Bgt 
labelling (approximately 8 Alexa-Fluor® 488 a-Bgt labels per field view, compare 3 
Alexa-Fluor® 488 a-Bgt labels per field view in table 4.2). Approximately 80% of the 
Alexa-Fluor® 488 a-Bgt binding was associated with anti-VGluT labelling (95 out of
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the 118 Alexa-Fluor® 488 a-Bgt labels from 15 field views) representing less than 
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Figure 4.3. Confocal imaging of a-Bgt AlexaFluor 488 and anti-p2 nAChR 546 labelling 
in rat frontal cortex Percoll™ purified synaptosomes. (A), Example confocal image 
Percoll™ purified synaptosomes triple labelled with a-Bgt (green), anti-p2 nAChR (red) and 
anti-VGluT 1&2 (Blue). (B) x3 zoom image of area highlighted in (A) (white square 1) with 
(C) the fluorescence intensity profiling of the p2 nAChR labelling in the area revealing 
labelling associated with glutamatergic terminals and co-association with Alexa-Fluor® 488 
a-Bgt. (D) x3 zoom image of area highlighted in (A) (white square 2) with (E) the 
fluorescence intensity profiling of the p2 nAChR labelling in the area revealing labelling is 
associated with glutamatergic terminals.
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Table 4.3. Quantitative analysis of presynaptic terminal immunolabelling with anti-p2 
nAChR, Alexa-Fluor® 488 a-Bgt and VGluT 1 and 2 in rat frontal cortex Percoll™ 
purified synaptosomes. Values given are the Mean (± S.E.M where indicated) of positive 
immunolabelled structures per field view under the confocal microscope. Results are 
accumulated from an average of five field views from three independent experiments, 15 
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(from 15 field 
views)
2895 118 65 45 95 10
Average number 




(from 15 field 
views)
139-239 3-14 1-7 1-6 2-11 1-3
% of total VGluT 1 
& 2 positive 
structures 
(Per field view)
100 - - 1.6 ±0.2 3.3 ± 0.1 0.3 ± 0.02




- 100 - - 80.5 ± 2.5 8.5 ±1 .4




- - 100 69.2 ±1.9 - 15.3 ± 0.8
Approximately 9% of the Alexa-Fluor® 488 a-Bgt binding was also co-associated 
with VGluT 1 & 2 and p2 nAChR labelling. The remaining 11% of Alexa-Fluor® 488 
a-Bgt was either co-associated with p2 nAChR labelling alone (6%) or found on its 
own with no co-association (5%).
P2 nAChR labelling was identified with an average of 4 p2 nAChR immunolabels per 
field view. Almost 70% of this labelling was associated with anti-VGluT 1 & 2 
labelling, representing less than 2% of all VGluT 1 & 2-labelled synaptic terminals. A 
further 15% of this p2 nAChR binding was co-associated with VGluT 1 & 2 and 
Alexa-Fluor® 488 a-Bgt labelling indicating that two different nAChR receptors may
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reside on the same terminal. The remaining 15% of p2 nAChR binding was either 
associated with Alexa-Fluor® 488 a-Bgt fluorescence (11%) alone with no co­
association with anti-VGluT 1 & 2, or found on its own with no co-association with 
any other label (4%).
4.3 Immunocytochemical labelling of rat frontal cortex sections
4.3.1 Triple Immunolabelling in rat frontal cortex sections: Identification of a7 
nAChR
Detergent permeabilised sections of rat frontal cortex were immunolabelled for 
VGluT 1 & 2 and NeuN. a7 nAChRs were again visualised using fluorochrome- 
conjugated a-Bgt (Alexa-Fluor® 488 a-Bgt). This allows the assessment of a l  
nAChR association with glutamatergic terminals and cell bodies respectively. Both 
Alexa-Fluor® 488 a-Bgt (green) and Alexa-Fluor® 546 a-Bgt (red) were assessed 
for their ability to label a l  nAChR in rat frontal sections that were either co-labelled 
with anti-NeuN (secondary 546 red) and VGlutl and 2 (Secondary 633 blue) or anti- 
NeuN (secondary 488 green) and VGlutl and 2 (Secondary 633 blue) respectively 
(see Fig 4.4). Both approaches to immunolabelling gave similar results. Sections 
were initially analysed under the confocal microscope by selection of a-Bgt positive 
field views. On obtaining a-Bgt positive field views, images were recorded and 
assessed using the fluorescence intensity software provided with the confocal 
microscope.
Fluorescence intensity profile lines were used to delineate a-Bgt (either Alexa- 
Fluor® 488 a-Bgt (green) or Alexa-Fluor® 546 a-Bgt (red)) and its association with 
any other immunolabels, either anti-NeuN or anti-VGIut1 & 2 or both. Association of 
a-Bgt fluorescence with either anti-NeuN or anti-VGIut1 & 2 or both (indicative of
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a7nAChR association with either cell bodies or glutamatergic terminals respectively) 
was taken when fluorescence intensity (arbitrary units) of each of the labels was 
100% above baseline fluorescence for each of the labels and within l^m  of each
Figure 4.4. Comparison of confocal imaging of a-Bgt AlexaFluor® 488 or 546, anti- 
Neun and anti-vGluT1 and 2 labelling in rat frontal cortex sections. Example confocal 
image field view of frontal cortex section triple labelled with a-Bgt AlexaFluor 546 (red) anti- 
Neun (green) and anti-VGluT 1 and 2 (Blue) (A). Example confocal image field view of 
frontal cortex section triple labelled with a-Bgt AlexaFluor 488 (green), anti-Neun (red) and 
anti-VGluT 1 and 2 (Blue) (B). a-Bgt fluorescence can be seen in glutamatergic terminal 
fields (white square) or cell bodies (yellow square) of rat frontal cortex sections using both 
immunolabelling methods.
Alexa-Fluor® 488 a-Bgt labelling in frontal cortex sections was observed in the 
terminal fields as labelled by anti-VGluT 1 & 2 antibodies as well as in association 
with neuronal cell bodies labelled with anti-NeuN. A small proportion of Alexa-Fluor® 
488 a-Bgt binding (less than 11 %; 11 out of a total 103 Alexa-Fluor® 488 a-Bgt 
binding sites) was observed in the absence of either VGluT 1 & 2 or Neun labelling,
other.
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indicating that a7 nAChR associates with non-glutamatergic terminals or non­
neuronal cell bodies.
Figure 4.5. Confocal imaging of a-Bgt AlexaFluor 488, anti-Neun and anti-vGluT1 and 
2 labelling in rat frontal cortex sections. Example confocal image field view of frontal 
cortex section triple labelled with a-Bgt AlexaFluor 488 (green), anti-Neun (red) and anti- 
VGluT 1 and 2 (Blue) (A). (B) x3 zoom image of area highlighted in (A) (white square 1) with 
(C) the fluorescence intensity profiling of the Alexa-Fluor® 488 a-Bgt labelling in the area 
revealing co-association with VGluT 1 and 2 (glutamatergic terminals). (D) x3 zoom image of 
area highlighted in (A) (white square 2) with (E) the fluorescence intensity profiling of the 
Alexa-Fluor® 488 a-Bgt labelling in the area revealing co-association with Neun (cell 
bodies).
174
The largest population of Alexa-Fluor® 488 a-Bgt binding was observed in the 
glutamatergic terminal fields of rat frontal cortex sections (44.6%; 46 out of a total 
103 Alexa-Fluor® 488 a-Bgt binding sites) with a further 20% associated with both 
glutamatergic terminals and neuronal cell bodies (20.4%; 22 out of a total 103 Alexa- 
F luo® 488 a-Bgt binding sites). As previously mentioned it is not possible to 
discriminate at the resolution of the confocal microscope whether these Alexa- 
Fluo® 488 a-Bgt binding sites are singly associated with glutamatergic terminals or 
with the neuronal cell body and therefore have been classed as associated with 
both. Approximately 25% of the total Alexa-Fluor® 488 a-Bgt binding sites were 
associated with cell bodies alone (25.2%; 28 out of a total 103 Alexa-Fluo® 488 a- 
Bgt binding sites).
Table 4.4. Field View quantitative analysis of frontal cortex section immunolabelling 
with anti-Neun, Alexa-Fluor® 488 a-Bgt and VGluT 1 & 2 in rat frontal cortex sections.
Values given are the Mean ± S.E.M of positive immunolabelled structures per field view 
under the confocal microscope. Results are accumulated from an average of five field views 
from three independent experiments. (+VE = positive)














(from 15 field 
views)




1.8 ±0.2 3.1 ±0.3 1.4 ±0.09 0.7 ±0.01 7 ±0.9
Range of a-Bgt 
+VE structures 
(from 15 field 1-4 1-5 1-4 0-3 3-12
views)
% of total a-Bgt 
(Per field view) 25.2 ± 2.4 44.6 ± 3.9 20.4 ± 4.1 10.6 ±1.2 100%
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In these instances the Alexa-Fluor® 488 a-Bgt binding sites were either inside the 
neuronal cell body or within close proximity to the outer perimeter of the neuronal 
cell body membrane.
4.3.2 Triple Immunolabelling in rat frontal cortex sections: Identification of a7 
nAChR and 02 nAChR
In order to assess the presence of a7 nAChR and 02 nAChR in rat frontal cortex, 
coronal sections were triple labelled for Alexa-Fluor® 488 a-Bgt, anti-02 nAChR and 
anti-VGluT 1 & 2. By labelling for two nAChR receptors it became methodologically 
impossible to also immunolabel for cell bodies due to the limitations of the confocal 
microscope; it was decided that by omitting neuronal cell body labelling, more 
information could be obtained with respect to examining the presence of both the a7 
and 02 nAChR together in the frontal cortex, since the confocal microscope cannot 
discriminate between the pre or postsynaptic labelling of the nAChR anyway. 
Therefore in this instance the two nAChRs being examined can only be clearly 
assessed for the co-association with glutamatergic terminals. As shown in Fig 4.6 it 
is clear from the dark spaces displayed within the field views where neuronal cell 
bodies or glial cells might be. In many cases the Alexa-Fluo® 488 a-Bgt and anti-02 
nAChR labelling surround the perimeter of these spaces. Those labels that are 
found in these areas and are not co-associated with the anti-VGluT 1 & 2 labels 
have been grouped into ‘non-glutamatergic structure co-associations’ (non-VGluT 
1& 2 associated), as described in Table 4.5. However, more importantly, those 
nAChRs labelled for either Alexa-Fluo® 488 a-Bgt or anti-02 nAChR that are 
associated with VGluT 1 and 2 labels could also be associated with neuronal cell 
bodies or glial cell membranes, as seen with the a7nAChR labelling described in 
section 4.2.3. Therefore caution must be taken in the interpretation.
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Figure 4.6. Confocal imaging of a-Bgt AlexaFluor 488, anti-(32 nAChR and anti-vGluT1 
and 2 labelling in rat frontal cortex section. Example confocal image field view of frontal 
cortex coronal section triple labelled with a-Bgt AlexaFluor 488 (green), anti-f52 nAChR (red) 
and anti-VGluT 1 & 2 (Blue) (A). (B) x3 zoom image of area highlighted in (A) (white square 
1) with (C) the fluorescence intensity profiling of the anti-p2 nAChR labelling in the area 
revealing co-association with VGluT 1 and 2 (glutamatergic terminals). (D) x3 zoom image of 
area highlighted in (A) (white square 2) with (E) the fluorescence intensity profiling of the 
anti-p2 nAChR labelling in the area revealing no co-association with VGluT 1 & 2. (F) x3 
zoom image of area highlighted in (A) (white square 3) with (G) the fluorescence intensity 
profiling of the a-Bgt AlexaFluor 488 labelling in the area revealing co-association with 
VGluT 1 and 2
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Table 4.5. Field View quantitative analysis of frontal cortex section immunolabelling 
with Alexa-Fluor® 488 a-Bgt, anti-p2 nAChR and VGluT 1 and 2 in rat frontal cortex 
sections. Values given are the Mean ± S.E.M of positive immunolabelled structures per field 
view under the confocal microscope. Results are accumulated from an average of five field 
views from three independent experiments. (+VE = postiVE)
Association of a-Bgt and anti 02 nAChR binding with VGluT
1& 2 in rat frontal cortex sections











Range of a-Bgt 
+VE structures 
(from 15 field 
views)
3-11 3-8 5-18
% of total a-Bgt 
(Per field view) 50 50 100
Anti-p2 nAChR
positive binding 





binding (Per field 
view)
4.9 3.5 8.4
Range of Anti-|32 
nAChR +VE 
structures (from 15 
field views)
2-9 0-8 4-15
% of total Anti-02 
(Per field view) 58.3 41.7 100
Again, fluorescence intensity profile lines were used to delineate a-Bgt (either Alexa- 
Fluor® 488 (green) and anti-p2 nAChR (red) and its association with anti-VGluT 1 & 
2. This co-association was taken when fluorescence intensity (arbitrary units) of 
each of the labels was 100% above baseline fluorescence for each of the labels and 
within 1 jLtm of each other. Equal proportions of Alexa-Fluor® 488 a-Bgt binding was 
found in co-association with VGluT 1 & 2 structures or on its own (see Table 4.5).
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The majority of Alexa-Fluor® 488 a-Bgt observed in co-association with anti-VGluT 1 
& 2 antibodies was found in the terminal fields of frontal cortex sections as well as 
around the perimeter of dark spaces that likely represent either neuronal cell bodies 
or glial cells. The Alexa-Fluor 488 a-Bgt found with no co-association with anti- 
VGluT 1 & 2 was found either around the perimeter of dark spaces or in the centre of 
these dark spaces. With respect to the anti-02 nAChR binding, approximately 60% 
was associated with VGluT 1 & 2 structures, similarly found in either the terminal 
fields or around the perimeter of dark spaces that likely represent neuronal cell 
bodies or glial cells. The remaining 40% of anti-02 nAChR binding was found on its 
own, either around the perimeter of dark spaces that may represent neuronal cell 
bodies or glial cells, or within the central regions of the dark spaces, perhaps 
indicating an intracellular localisation of the subunit.
Interestingly, in frontal cortex sections, no co-association was observed for Alexa­
Fluor® 488 a-Bgt and anti-02 nAChR together, in contrast to that described in a 
small number of observations in the Percoll™ purified synaptosome preparation.
4.3.3 Preliminary investigation into a-Bgt labelling and regional localisation in 
the rat frontal cortex
The location of a-Bgt labelling within the frontal cortex was assessed in both coronal 
and sagital rat frontal cortex sections. Rat frontal cortex coronal sections were triple 
labelled for cell bodies (anti-NeuN), glutamatergic terminals (anti-VGIuT1 & 2) and 
a7 nAChR (either Alexa-Fluo® 488 or 546 a-Bgt). Frontal cortex sections were cut 
in 30 urn sections between
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Table 4.6. Number of a-Bgt binding sites in layers l-VI of a rat frontal cortex coronal 
section. Rat frontal cortex coronal sections were triple labelled for identification of neuronal 
cell bodies, glutamatergic terminals and a7 nAChR. Along a defined axis (see figure XX), a- 
Bgt binding sites were counted from three field views per layer of the frontal cortex section 
(n=3 individual experiments). Results are expressed as the total number of a-Bgt binding 
sites counted in each of the field views per layer of the frontal cortex and also as Mean ± 
S.E.M of the average number of a-Bgt binding sites per field view within each layer.
Frontal cortex iayers
1 !l IN IV V VI
Total number of a- 
Bgt binding sites 
(Taken from 9 field 
views per layer)
37 23 6 1 22 34
Average number of 
a-Bgt binding sites 
(per field view of 
each layer)
4.1 ± 0.4 2.6 ± 0.5 0.7 ± 0.2 0.1 ± 0.1 2.4 ± 0.3 3.8 ± 0.4
Figure 4.7. Confocal imaging of a-Bgt AlexaFluor 488, anti-NeuN and anti-vGluT1 and 
2 labelling in rat frontal cortex coronal sections. Example field view confocal image of 
layer I from a rat frontal cortex coronal section triple labelled with a-Bgt AlexaFluor 488 
(green), anti-NeuN (red) and anti-VGluT 1 and 2 (Blue) (A). Example field view confocal 
image of layer VI (and part of layer V) from a rat frontal cortex coronal section also triple 
labelled with a-Bgt AlexaFluor 488 (green), anti-NeuN (red) and anti-VGluT 1 and 2 (Blue) 
(B). White squares within field view images (A) and (B) highlight the presence of fluorescent 
a-Bgt binding.___________________________________________________________
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approximate 2.0 and 3.0 Bregma. Along a defined axis (from the dorsal-lateral 
region of the coronal section to the midpoint of the medial-ventral axis), these 
sections were then assessed for Alexa-Fluor® 488 a-Bgt binding by examination of 
three individual field views for each layer (Layers I through to VI) of the frontal cortex 
section.
a-Bgt binding sites were consistently found in Layers I and II and layers V and VI 
(average of 3 or 4 Alexa-Fluor® 488 a-Bgt binding sites per field view in each of 
these layers; see Fig 4.7) whereas layers III and IV displayed almost negligible a-Bgt 
binding (average of less than 1 a-Bgt binding site per field view; See Table 4.6).
Figure 4.8. Mid-sagital section of rat frontal cortex. Low power magnification (x10) of mid 
sagital section (approximate Bregma 1-1.5; see insert) triple labelled for a-Bgt AlexaFluor 
488 (green), anti-NeuN (red) and anti-VGluT 1 and 2 (Blue) (A). Rat frontal cortex map 
(Bregma 1.3) illustrating brain regions: 1-Lateral orbital cortex. 2-Frontal association cortex. 
3-Secondary motor cortex. 4-Primary motor cortex. 5-forceps minor corpus callosum. 6- 
Striatum. + denotes approximate areas of the frontal cortex where 5 or more a-Bgt binding 
sites are found per field view in that area. n=2 independent experiments.
Mid-sagital sections (30nm sections taken between Bregma 1-1.5; see insert Fig 4.8 
A) of rat frontal cortex were triple labelled for cell bodies (anti-NeuN), glutamatergic 
terminals (anti-VGIuT1 and 2) and a l  nAChR (either Alexa-Fluor® 488 or 546 a-
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Bgt). The sequential analysis of each field view from a whole mid-sagital section 
revealed that in certain regions of the sagital section, a-Bgt binding was more 
prominent than others (typically 5 or more Alexa-Fluor® 488 or 546 a-Bgt binding 
sites per field view) These areas included the rostral-ventral regions of the frontal 
association cortex, the caudal-ventral regions of the lateral orbital cortex and the 
rostral-dorsal regions of the primary motor cortex (See Fig 4.8 B).
Regions of the mid-sagital section outside of those areas described above were 
relatively devoid of a-Bgt binding sites, typically presenting either 0 or a maximum of 
2 binding sites per field view. The results represented in Fig 4.8 show only the 
regions of the mid-sagital section where a large density of a-Bgt binding sites are 
present.
In those regions of the sagital section where a-Bgt binding was most prominent, a- 
Bgt binding was increased in the Layers I, II, V and VI, compared to the intermediate 
layers, as described for coronal sections above.
4.4 Discussion
Immunolabelled rat frontal cortex Percoll™ purified synaptosomes were examined to 
determine the association of a7 nAChR (identified by labelling with fluorescent 
labelled a-Bgt; Alexa-Fluor 488 a-Bgt) or 02 nAChR (identified by immunolabelling 
with anti-02 nAChR antibody, mAb 270) with glutamatergic terminals, in support of 
functional the data described in Chapter 3 (sections 2 and 3), where these subunit 
containing receptors appear to modulate the release of [3H]D-aspartate.
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4.4.1 a7 nAChR association with glutamatergic terminals
Of the two synaptosome preparations initially used to investigate the association of 
nAChR with presynaptic terminals, Percoll™ purified synaptosomes, demonstrated a 
substantially lower degree of non-specific membrane elements labelled with anti- 
synaptophysin compared to P2 purified synaptosomes. These non-specific 
membrane elements could represent a number of membrane structures from 
presynaptic membranes that have failed to re-seal to form a ‘closed’ synaptic 
terminal (i.e. a synaptosome) to axonal or postsynaptic membrane elements. Anti- 
synaptophysin labelling in Percoll™ purified synaptosomes were more homogenous 
in shape, with the majority of the synaptophysin labelled structures displaying a 
‘spherical’ like shape indicative of a synaptosome, in agreement with the EM 
observations of Dunkley etal. (1988).
When these synaptosomes were double labelled for identification of synaptophysin 
protein and a-Bgt binding receptors (i.e. a7 nAChR) approximately 2% of the total 
number of synaptophysin positive structures were labelled for a-Bgt. The same 
percentage of synaptosomes with a-Bgt bound per field view was observed when 
synaptosomes were triple labelled with markers for glutamatergic terminals (anti- 
VGIuTI & 2). The majority of synaptosomes (80%) were labelled for VGIutl & 2, 
suggesting that this preparation of synaptosomes from the frontal cortex of rat brain 
is high in glutamatergic terminals, conversely, almost all VGluT 1 & 2 labelled 
structures were co-labelled with anti-synaptophysin. Observations made by Dunkley 
et al. (1986) and (1988) using cerebral cortex synaptosomes, and Robinson & 
Lovenberg. (1986) using striatal synaptosomes, proposed that fractions 3 and 4 of 
the Percoll™ purified gradient are generally enriched with serotonergic and 
dopaminergic synaptosomes respectively. These authors did not provide any
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evidence for glutamatergic identity in the synaptosomes used, perhaps due to lack of 
specific tools, and it therefore remains an interesting observation that such a large 
majority of synaptosomes labelled in this study with anti-synaptophysin also co-label 
for VGIuH and 2, raising the question of whether presynaptic terminals contain and 
release multiple neurotransmitters or that the morphology/density of glutamatergic 
terminals specifically, is highly favourable for their acquisition from the particular 
layers of the Percoll™ gradients.
Almost 100% of the a-Bgt fluorescence coincided with VGIutl & 2 fluorescence in 
the triple label assessment, indicating that all a7 nAChRs identified in a frontal 
cortex synaptosome preparation co-localise within the vicinity of glutamatergic 
terminals. As mentioned in the Introduction (Section 4.1.2), the interpretation that 
these results are indicative of a7 nAChR residing on glutamatergic terminals has to 
be exercised with caution. It has been described that synaptosomes (review; 
Whittaker, 1993), obtained from Percoll™ purification, have elements of the post- 
synaptic terminal membrane bound to their surface membrane that it made contact 
with in the intact synapse, prior to homogenisation. It is therefore possible that a-Bgt 
nAChR could bind to these post-svnaptic membranes that are attached to the 
synaptosome. However as mentioned previously, this cannot be resolved at the level 
of the confocal microscope and would require EM analysis. In support of a 
presynaptic association for the nAChR identified herein, synaptosomes prepared in 
a similar manner as described in this section (Diaz-Hernandez et a!., 2002), showed 
no evidence for labelling with a post synaptic membrane protein PSD-95, 
demonstrating the absence post synaptic density contamination in the synaptic 
terminal preparation.
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4.4.2 02 nAChR association with glutamatergic terminals
AlexaFluor 488 a-Bgt was also included with the labelling of frontal cortex 
synaptosomes during the assessment of anti-02 nAChR labelling. This was carried 
out on the basis from previous findings that almost 100% of anti-VGluT 1 & 2 
labelling in Percoll purified synaptosomes is in co-association with anti- 
synaptophysin labelling, therefore anti-synaptophysin could be omitted and replaced 
with anti-02 nAChR (mAb 270). This allowed for the examination of both a7 nAChR 
and P2* nAChR in the same preparation and provides supportive evidence for the 
functional superfusion experiments described in chapter 3 section 3, where the 
nAChR pharmacology is consistent with the presence of at least two nAChR 
subtypes in frontal cortex synaptosomes.
Examination of p2 nAChR labelling of frontal cortex synaptosomes demonstrated 
analogous findings to that described for a7 nAChR labelling, that is, the majority of 
P2 nAChR labelling (approximately 70%) was in co-association with VGluT 1 & 2 
labelling, indicative of co-association with glutamatergic terminals and therefore in 
support of the functional data described in chapter 3 section 3, as well as the 
electrophysiological evidence described by Gioanni et al, (1999) and Lambe et al, 
(2003). The same proportions of AlexaFluor-488 a-Bgt labels were identified with 
anti-VGluT 1 & 2 labelling as previously described (see sections 4.2.2), however the 
presence of a-Bgt binding per field view was almost twice that of anti-p2 nAChR 
(see Table 4.3) and twice that described in sections 4.2.2, where a-Bgt was 
incorporated with the anti-synaptophysin and anti-VGluT 1 & 2 immunolabels. For 
the former observation it appears that the a7 nAChR is the predominant nAChR 
associated with glutamatergic terminals over 02* nAChR in the frontal cortex and
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also supports the notion that this nAChR is associated with glutamatergic 
transmission. The reasons for the latter are unknown; the use of ‘multi-tracking’ (see 
Chapter 2 section 2.7.3) should prevent the incidence of fluorochrome ‘crosstalk’ 
and therefore enable sequential identification of each fluorochrome, it is therefore 
unlikely that the presence of anti-synaptophysin and its attached secondary label 
fluorochrome would prevent the identification of AlexaFluor 488 a-Bgt binding. Other 
plausible reasons are perhaps an increase in the efficiency of the experiment over 
time and repeat experiments that improve the binding and identification of 
AlexaFluor 488 a-Bgt.
The most interesting observation from the examination of both a-Bgt and mAb270 
immunolabelling within the same synaptosome preparation was that a proportion of 
the VGluT 1 & 2 labelling (0.3% per field view; see Table 4.3) was found in co­
association with both AlexaFluor 488 a-Bgt and anti-02 nAChR binding. This triple 
co-association (two receptors and glutamatergic terminal labels) represented 15 and 
9 % of the total 02 and a7 nAChR labelling respectively (gathered from the fifteen 
field views used for analysis; Table 4.2 and 4.3). Two possible explanations for this 
finding are: (1) More than one nAChR subtype at the glutamatergic terminal or (2) 
the nAChR at the glutamatergic terminal binds both a-Bgt and anti-02 nAChR 
antibody (i.e. is made up of both a7 and 02 nAChR subunits). With respect to the 
first possibility, the resolution of the confocal microscope limits the assessment of 
the pre or postsynaptic location of the two different nAChR labels, therefore it is not 
possible to ascertain at this level whether the triple label described is either 
representative of two different nAChR attached to the presynaptic membrane of a 
glutamatergic terminal or attached to postsynaptic elements that remain in contact 
with the synaptosome membrane from the homogenisation procedures. Another
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possibility is that one of each of the labels for a7 and (32 nAChR are on each of the 
two synaptic membrane components (pre and post). Electron microscopy analysis 
may provide a clearer definition of the pre or post-synaptic location of the nAChR 
labelling to discriminate between different types of nAChR using different sized 
metal particles attached to either ligands or antibodies specific to the nAChR. 
Secondly, a very interesting possibility is that perhaps the two nAChR labels used 
actually label one individual nAChR that contains both a l  and (32 nAChR subunits 
(i.e. a7|32* nAChR). In fact, a7 and P2 nAChR subunits have been heterologously 
co-expressed in Xenopus oocytes to form a functional nAChR (Khiroug etal., 2002), 
distinguished from homomeric a7 nAChR on the basis that native nAChRs that 
contain the a7 subunit in rat hippocampal interneurons express functional properties 
that differ from observed properties of recombinant homomeric a7 nAChRs (Shao & 
Yakel, 2000; Sudweeks & Yakel, 2000). This has been a consistent observation 
even from early electrophysiological studies that first examined the presence of a7 
nAChR in the hippocampus (Gray et al., 1996) and to present date an a7p2 
heteromeric nAChR has been put forward as a novel subtype of nAChR found in 
cholinergic cell groups that project to the hippocampus and cortex that are 
associated with the regulation of cognitive processes (Azam et al., 2003). However, 
the one underlying report in contrast to these possibilities is that only a7 nAChR 
subunits compose the a7 nAChR, determined using Western blot analysis of a-Bgt 
binding proteins from purified rat brains (Chen & Patrick, 1997).
4.4.3 a7* and |32* nAChR in rat frontal cortex sections
Where identified, AlexaFluor 488 (or 546 a-Bgt) and anti-(32 nAChR labels were 
associated with glutamatergic terminals (as labelled for using anti-VGluT 1 & 2) in
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the terminal fields of rat frontal cortex sections as well as around the perimeter of 
neuronal cell bodies. As mentioned before, the exact location of the latter nAChR 
labelling cannot be ascribed definitively to a pre or postsynaptic location due to the 
resolution limitations of the confocal microscope.
With respect to AlexaFluor 488 (or 546) a-Bgt binding, the two types of a-Bgt 
binding with glutamatergic terminal associations (with or without cell body 
association) combined make up the majority of a-Bgt binding (60%) in rat frontal 
cortex sections. This binding supports either the presence of a7 nAChR on 
glutamatergic terminals, as demonstrated with the a-Bgt binding found in association 
with frontal cortex synaptosomes labelled for VGluT 1 & 2 or a7 nAChR on either 
glutamatergic terminals that are located in close proximity to the cell membrane or 
indeed on the cell membrane itself that is in close proximity to a glutamatergic 
terminal. The remaining 40% identified was either found in association with cell 
bodies alone (30%) or found on its own (10%). The first of these two observations 
could represent the internalisation of a-Bgt binding sites within cell bodies, an 
observation which has been previously described for immunogold labelled a-Bgt 
binding inside the pre and postsynaptic membranes of neurons of the stratum 
radiatum of the CA1 area of the rat hippocampus (Fabien-Fine et al., 2001) and in 
the rat sensory cortex (Levy & Aoki, 2002). These authors report that this type of 
‘internalisation’ of the receptor may represent a-Bgt binding receptors that are 
localised to vesicles inside the pre and post synaptic terminals, which allow for the 
efficient cycling and dynamic regulation of a7 nAChRs to their respective membrane 
surface, consistent with the role of mediating and/or modulating synaptic 
transmission. For the latter type of binding, where fluorescent a-Bgt binding was 
found on its own, is slightly harder to define. Efforts are made to ensure complete
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washing of sections to prevent non-specific a-Bgt binding, as well as the fact that a- 
Bgt is completely absent when sections are pre-incubated with excess a l  
antagonists (either a-Bgt or MLA). Most, if not all of this type of fluorescent a-Bgt 
binding was localised within the vicinity of ‘dark spaces’ that may represent 
astyrocytes or blood vessels, but as described in the results this represents the 
smallest proportion of a-Bgt binding in rat frontal cortex sections (See Sharma & 
Vijayaraghavan, (2002), for review of nAChR expression and function in non- 
excitable cells in the CNS). It is also possible that this a-Bgt binding may represent 
association with non-glutamatergic terminals, such as terminals from GABAergic 
interneurons, demonstrated in the rat hippocampus (Fabien-Fine etal., 2001) but as 
of yet not in the rat frontal cortex, which does display immunoreactivity for 
GABAergic interneurons (Retaux etal., 1993).
Anti-02 nAChR labelling was found in association with glutamatergic terminals in 
similar proportions to that described for fluorescent a-Bgt labelling (approximately 
60%). Of this 60% it is unknown what proportion are also in association with cell 
bodies as markers for cell bodies (anti-NeuN) was not utilised in this investigation; 
fluorescent a-Bgt labelling was also incorporated into the assessment, thereby 
limiting the number of available fluorochromes available to detect using the confocal 
microscope system. Nonetheless, anti-02 nAChR labelling was found either in the 
terminal fields or in and around the perimeter of dark spaces that presumably 
represent cell bodies (or astrocytes and blood vessels). The remaining 40% of anti- 
02 nAChR labelling was found in areas with no co-association with glutamatergic 
terminals, nor a-Bgt labelling, the latter only being observed in frontal cortex 
synaptosomes labelled for both a7 and 02 nAChR. This non-glutamatergic anti-02
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nAChR labelling could again represent the similar findings demonstrated for 
fluorescent a-Bgt labelling, where anti-02 nAChR labels ‘internalised’ nAChR; in 
many cases anti-02 nAChR binding was found inside the ‘dark spaces’ 
representative of internalisation or in close proximity to the perimeter of these 
spaces but in sufficient distance away from any anti-VGluT 1 & 2 labelling that 
appears to terminate on the cell body. The fluorescent a-Bgt labelling carried out 
within these experiments mirrored the observations displayed in previous 
experiments in terms of its localisation (i.e. in both the glutamatergic terminal fields 
and in and around the perimeters of the dark spaces that presumably represent 
neuronal or glial cells). Its incorporation into these experiments that also co-label for 
02 nAChR was hoped to reveal co-expression of the two receptors within the vicinity 
of each other, as exemplified in a small proportion of labelled synaptosomes (see 
above) therefore implying that in an intact synaptic circuit, the two different nAChR 
may have similar or supportive roles in glutamatergic transmission at the same 
synapse. Unfortunately, this was not demonstrated in frontal cortex sections. This 
may be a consequence of steric hindrance factors exhibited in labelling fixed 
sections with the labels used; the large molecular weight of a-Bgt and anti-02 
nAChR antibody may prevent a second immunolabel, (or fluorescent ligand) to bind 
within close proximity of the other. This may not be a limiting factor in dissociated 
synaptosomes.
4.4.4 Regional localisation of a7 nAChR in rat frontal cortex sections
Rat frontal cortex sections were assessed for fluorescent a-Bgt binding in specific 
regions of coronal and mid-sagital sections. In agreement with autoradiographical 
analysis of the rat frontal cortex using [125l]a-Bgt (Clarke et al., 1985), fluorescent a-
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Bgt was found in the majority of the superficial layers I and II and the deeper layers 
V and VI along a defined axis (see results Fig 4.7), the principal input and output 
layers respectively to this area of the rat brain (Groenewegen, 1988). The 
localisation of a l  nAChR in these regions is consistent with the recording of nicotine 
or ACh-induced glutamate release demonstrated in electrophysiological preparations 
examining these areas (Vidal & Changeux, 1993; Gioanni etal., 1999*; Lambe etal., 
2003), however these authors fail to report clear a7-like physiology and 
pharmacology which may represent the difficulties in recording a7-like phenomena, 
due to fast desensitisation properties of the receptor. (* only Gioanni et al., 1999 
report inhibition of mEPSC’s induced by nicotine in the presence of MLA (100 nM)). 
Nonetheless, the cells mediating synaptic transmission in this area are 
predominantly glutamatergic (e.g. pyramidal cells; See Carr & Cesack, (1996), 
therefore the presence of a7 nAChR may mediate/modulate glutamatergic 
transmission in these regional layers at both the presynaptic and postsynaptic level, 
the former also being supported by the inferences made in chapter 3 section 3.
In the mid-sagital section, a-Bgt binding was diffuse across layers I, II and V and VI 
in the whole plain, however, there existed certain regions within the plane that 
displayed more prominent a-Bgt binding (defined in Results section 4.4), namely the 
rostroventral regions of the frontal association cortex, the caudal-ventral regions of 
the lateral orbital cortex and the rostrodorsal regions of the primary motor cortex. 
The source of the glutamatergic innervation to these areas was not examined in this 
study, but all regions receive prominent afferent input from the mediodorsal thalamic 
nucleus (MD). The immunocytochemical detection of 62 nAChR in rat frontal cortex 
sections and synaptosomes supports the presynaptic modulation of glutamate 
release in this area as recorded in the electrophysiological paradigm (Vidal &
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Changeux, 1993; Gioanni et al., 1999; Lambe et al., 2003). These authors provide, 
in the majority, evidence for a 02* nAChR modulation of release, however, the a7 
nAChR modulation of release is not completely ruled out (See Gioanni et al., 1999). 
mRNA transcripts for the a7 subunit are relatively low in the thalamus (Seguela et 
al., 1993) and therefore it is plausible that the thalamocortical terminals originating 
from the medial dorsal thalamus do not bind a-Bgt in the frontal cortex (Gioanni et 
al., 1999). In contrast the hippocampus and parahippocampal regions express high 
levels of a7 mRNA transcript (Seguela et al., 1993) and these regions have been 
shown to send afferent projections to the frontal cortex (Theirry et al., 2000; Delatour 
& Witter, 2002). A detailed study by Delatour & Witter (2002) who employ 
anterograde-tracing methods demonstrate that projections from parahippocampal 
regions of the rat brain were found to terminate in regions of the frontal cortex 
analogous to the regions where a-Bgt labelling is described in our study (in particular 
the frontal association and lateral orbital cortex areas). Thierry et al, (2000), in a 
review of the hippocampal-frontal cortex pathways, describe prominent innervation 
of prelimbic/medial orbital areas (corresponding to frontal cortex association areas 
and lateral orbital areas displayed in Fig 4.8) that originate from the CA1/subiculum 
fields. By deduction, it is therefore possible that the a7 nAChRs found on the 
glutamatergic terminals in the frontal cortex may originate from the hippocampal and 
parahippocampal regions of the brain. It therefore appears from these initial 
observations that the presence of a7 nAChR at these specific locations is an integral 




The identification of a7 and 02 immunolabelling found within the vicinity of 
glutamatergic terminals in both synaptosomes and sections supports the nAChR- 
enhancement of glutamatergic transmission in the rat frontal cortex.
cx7 nAChR p2 nAChR cx7 nAChR &  p2 
nAChR
Detected by AlexaFluor 488 (or 
546) a-Bgt
Detected by mAb270 (anti- 02 
nAChR) and secondary labelled 
with anti-rat 546 IgG
Detected by AlexaFluor 488 (or 
546) a-Bgt and mAb270 (anti- 
02 nAChR) secondary labelled 
with anti-rat 546 IgG 
respectively
Found in approximately 2% of 
glutamatergic terminals per field 
of frontal cortex synaptosomes
Found in approximately 2% of 
glutamatergic terminals per field 
of frontal cortex synaptosomes
Found co-localised in 
approximately less than 0.5% of 
glutamatergic terminals per field 
of frontal cortex synaptosomes
Hippocampal-cortical afferents? Thalamocortical afferents? Unknown
Figure 4.9 Summary diagram and table of the immunocytochemical analysis of frontal 
cortex synaptosomes. All possible locations of nAChR subtypes co-associated with 
glutamatergic terminals from immunocytochemical analysis; (A) a7 nAChR detected using 
fluorescent a-Bgt, (B) (32* nAChR detected using mAb270 and (C) a7 and 02* nAChR using 
both probes. Diagram (C) also depicts the possible existence of a a702* heteromeric 
nAChR as postulated from the co-localisation of both probes.
The location of a l  and 02 nAChR in the terminal fields of the rat frontal cortex is 
consistent with a role in facilitating EAA release, as demonstrated from the release 
of [3H]D-aspartate evoked from frontal cortex P2 synaptosomes using nAChR 
agonists in this thesis as well as from electrophysiological observations (Vidal & 
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Figure 4.10 Hypothetical diagram of nAChR location and its integration with 
excitatory neurotransmission. a7 nAChR and (32 nAChR (and possibly a7|32* nAChR) are 
co-localised with glutamatergic terminals and postsynaptic cell membranes. Evidence also 
exists for an ‘internalised’ source of nAChR that may be bound to intracellular vesicles for 
their insertion into the postsynaptic membrane. nAChR activation is also coupled with AMPA 
activity and the exact relationship, via investigation of calcium and secondary messenger- 
mediated events is currently being defined. The presence of both pre and postsynaptic 
membrane nAChR may be an important criterion for the nAChR modulation of excitatory 
neurotransmission.
The exact location of nAChRs found in association with glutamatergic terminals and 
cell bodies is not clear from our immunocytochemical analysis and therefore requires 
electron microscopy to ascertain their exact location, as deciphered from 
investigations in the rat hippocampus and sensory cortex (Fabien-fine et al., 2001; 
Levy & Aoki, 2002). Nonetheless, in accordance with the original hypothesis put 
forward by Gray et al. (1996), both the presence of pre and post-synaptic nAChRs 
may increase synaptic efficacy of glutamatergic connections as described in the
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hippocampus (Gray et al., (1996), Dani et al., 2001; McGehee, 2002; Sharma & 
Vijayaraghavan, 2003). The exact secondary messenger systems and calcium 
mediated events that improve synaptic efficacy are still the subject of debate; it is 
presently understood that the up-regulation of AMPA receptors, via the integration of 
both calcium and secondary messenger mediated events, to the postsynaptic 
membrane are crucial for the strengthening of synaptic communication in excitatory 
synapses (for review see Isaac, 2003). nAChR activation combined with co­
activation of AMPA receptors may indeed work together to mediate post-synaptic 
excitation (Levy & Aoki, 2002; Alkondon et al., 2003). Further to these interactions, 
nAChR activation, during heightened cholinergic activity, may up-regulate its own 
expression via insertion of vesicles containing nAChR constructs to the pre or 
postsynaptic membrane, hinted at from the existence of nAChR labelling defined 
inside cellular membranes (section 4.3.2 & 4.4.3. see Fabien-Fine etal., 2001).
In summary, this chapter, in particular, has raised a number of undefined issues with 
respect to nAChR function in the frontal cortex and hence serves as a platform for a 
number of future studies, namely: (1) determination of the origination of 
glutamatergic afferents containing nAChR in the frontal cortex (hippocampal 
afferents and/or thalamocortical afferents), (2) an anatomical assessment of the 
cholinergic pathways that may serve these projections, (3) precise definition of pre 
and postsynaptic location of nAChR using electron microscopy, (4) 
immunocytochemical analysis of cell types (GABAergic etc) that express nAChR in 
the frontal cortex, (5) exploration of other intracellular events that may regulate 
nAChR expression in and out of the cell membrane in accordance with heightened
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cholinergic and glutamatergic activity and (6) determination of the possible existence 
of an a7P2* heteromer.
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Chapter 5
5.1 Summary, Conclusions and Future
Perspectives
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5.1.1 Summary of the nAChR and modulation of EAA release
Over a number of decades it has emerged that the cholinergic system serves as the 
major constituent for the execution of cognitive functions such as attention, learning 
and memory, manifested by the loss of cholinergic-cortical projections common 
theme to a number of neurological disorders in which cognition is compromised (for 
review see Sarter et al., 2003).
Because nAChRs mediate cholinergic activity in the form of their activation by ACh 
and exogenous ligands such as nicotine, nicotinic therapy could serve as a 
treatment strategy for cognitive disorders in the future. However, the development of 
future compounds for such a treatment strategy relies on the broad integration of 
studies that examine nAChR structure, function, and location within the CNS. One of 
the most interesting facets to nAChR research is the finding that activation of 
nAChRs can evoke the release of a number of neurotransmitters, including 
glutamate. Glutamate serves as the major excitatory amino acid in the CNS, and its 
controlled release and uptake is essential for synaptic efficacy. It is therefore likely 
that the loss of nAChR function, subsequent to the loss of cholinergic innervation in 
particular cognitive disorders, is one, of a number of factors, which may affect 
synaptic efficacy in the form of glutamatergic transmission between synapses. The 
resultant inefficiency of information flow through the CNS would then culminate in 
poor execution of tasks that require attention, learning and memory processes. 
Indeed the stimulation of nAChR in synaptic circuits of hippocampal slices and 
cultured neurones, as well as in circuits of midbrain areas, has displayed an 
increased synaptic efficacy (See Introduction Section 1.7.3), where the modulation 
of glutamate release from the presynaptic terminal is considered as a contributing 
factor (For review see McGehee, 2002). These particular inferences have been
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made from electrophysiological based experiments and have provided intricate detail 
of the nAChR modulation of excitatory and inhibitory currents dependant on where 
the recording and stimulating probes are placed. However, the means of inferring 
presynaptic modulation of EAA release in electrophysiological investigations are 
indirect (by recording excitatory currents on postsynaptic neurons) and until now, no 
direct means of inferring nAChR modulation of EAA reiease has been described. 
Therefore the work presented in this thesis represents the gross response of 
superfused presynaptic terminals (synaptosomes) from the rat frontal cortex, a 
region of the brain heavily implicated with cognitive functions such as working 
memory, but with regard to nAChR function and location has been minimally 
explored (see Chapter 1). Synaptosomes were pre-loaded with radiolabelled D- 
aspartate and subjected to stimulation with nAChR agonists. Superfusion per se 
prevents any possible interference of the nAChR-mediated event by continually 
removing any other neurotransmitter-receptor auto-regulatory events that may affect 
EAA release. Second to this, superfusion is particularly advantageous for the 
examination of EAA release in that, if set at a high flow rate, will prevent the re­
uptake of EAA by the highly efficient membrane glutamate transporters, without the 
need of EAAT blockers.
[3H]D-aspartate was utilised as the preferred choice of EAA analogue in place of 
glutamate with regard to its limited involvement in other cellular metabolic activities, 
thereby increasing the available ‘neurotransmitter pool’ available for release and 
detection (see Chapter 3 Section 3.1.2). In the first results chapter (Chapter 3 
Section 1) we provide evidence in support of the use of [3H]D-aspartate as an 
analogue for glutamate by revealing both exocytotic and glutamate transporter 
reversal mechanisms of KCI-evoked release of [3H]D-aspartate from presynaptic
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terminals, analogous to that described in previous investigations examining 
endogenous glutamate release.
Previous attempts to measure the direct detection of nAChR-evoked EAA release 
have only been recognised when nAChR agonists are combined with a depolarising 
stimulus (Beani et al., 2000; Marchi et al., 2002). We emulated these findings in 
Chapter 3 Section 2, by providing evidence of nAChR enhancement of KCI-evoked 
[3H]D-aspartate release from synaptosomes and nAChR enhancement of electrical- 
evoked release of [3H]D-aspartate from frontal cortex minces. The results from this 
chapter demonstrate that the nAChR enhancement of depolarisation-evoked release 
was Ca2+-dependant and sensitive to mecamylamine. However, only the nAChR 
enhancement of electrical-evoked release of [3H]D-aspartate displayed sensitivity to 
a7 nAChR selective antagonists, implying that the pharmacological detection of 
specific nAChR subtypes may be affected by the type and degree of depolarisation, 
as well as the effect of synaptic communication i.e. minces versus synaptosomes 
and the possibility that certain nAChR subtypes may be desensitised. The 
experimental assessment of nAChR enhancement of depolarisation-evoked release 
of [3H]D-aspartate was subject to persistent variability and consequently was not 
explored any further. At the same time, evidence was accumulating in our studies for 
the release of [3H]D-aspartate evoked by nAChR agonists alone, and subsequently 
the work in this thesis was directed towards the pharmacological characterisation of 
this response (Chapter 3 Section 3).
nAChR-evoked release of [3H]D-aspartate from synaptosomes (Chapter 3 Section 3) 
was Ca2+-dependant, reflecting an exocytotic mechanism of release, but 
independent of glutamate transporter reversal, in contrast to KCI-evoked release. 
Pharmacological characterisation of the nAChR-evoked release demonstrated a
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broad concentration dependency by a number of nAChR agonists. This inferred that 
possibly more than one nAChR subtype was associated with EAA release; made 
evident from differences of a-Bgt blockade (a7 nAChR specific) on low and high 
concentrations of nAChR agonist-evoked release. This possibility was 
pharmacologically defined using nAChR specific agonists and antagonists which 
revealed that both the a7 and 02* containing nAChR mediate the release of EAA 
from presynaptic terminals of the frontal cortex (See Chapter 3 Section 3.3.2.2).
The second body of direct evidence for presynaptic association with EAA release 
was inferred from our immunocytochemical investigation of rat frontal cortex 
synaptosomes. Using fluorescent a-Bgt probes and/or secondary labelled antibodies 
to the (32 nAChR subunit (mAb270), both a7 nAChR and 02* containing nAChR 
were found co-localised with glutamatergic terminals (identified by the antibodies 
directed towards vesicular glutamate transporters). This labelling represented 
approximately less than 2% of all glutamatergic synaptosomes per field view of the 
confocal microscope for each nAChR (See Chapter 4 Section 4.2). Although of very 
small proportion, evidence also existed for the presence of a7 and 02* nAChR co­
localised together on glutamatergic terminals; this could infer the existence of more 
than one nAChR subtype on the same glutamatergic terminal or even the possible 
existence of a native a702* heteromer, however only electron microscopy would 
confirm this interpretation due to the limitations of the confocal microscope 
resolution.
Rat frontal cortex sections (both coronal and sagital), displayed labelling for a7 and 
02* nAChR using the same probes as for the synaptosome investigation. Both labels 
were found in association with cell membranes and in glutamatergic terminal fields, 
but for the former, a precise pre or postsynaptic location could not be defined, again
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due to resolution limitations. Interestingly we observed the presence of a l  and (32* 
labelling inside cells, near to the membrane, corroborative with electron microscopy 
reports of nAChR found within cells of the hippocampus and rat sensory cortex 
(Fabien-Fine et al., 2001; Levy & Aoki, 2002). These authors report that this type of 
‘internalisation’ of the receptor may represent nAChRs that are localised to vesicles 
inside the pre and post synaptic terminals, which may allow for the efficient cycling 
and dynamic regulation of nAChRs to their respective membrane surface, consistent 
with the role of mediating and/or modulating synaptic transmission.
With respect to the regional distribution of a7 nAChR in the different layers of the 
frontal cortex, we demonstrated that both superficial and deeper layers of the frontal 
cortex (layers I, II and V, VI) are prominently labelled for a7 nAChR compared to 
intermediate layers, consistent with autoradiographical experiments using 
radiolabelled a-Bgt (Clarke et al., 1985). In particular, when mid sagital sections of 
rat frontal cortex were analysed there appeared to be a7 nAChR ‘hotspots’ which 
displayed slightly higher levels of a-Bgt fluorescence than in other regions within the 
same layer of the frontal cortex. Although not experimentally assessed in the 
chapter, it is inferred from distribution studies of glutamatergic projections to the 
frontal cortex, that these a7 nAChRs may reside on glutamatergic terminals 
originating from hippocampal regions of the rat CNS (See Chapter 4 section 4.4.4).
5.1.2 Future perspectives
By direct examination, this thesis has demonstrated certain aspects of nAChR 
function and subtype specificity in the rat frontal cortex. This work has supported 
particular elements of previous electrophysiological findings of nAChR modulation of 
glutamate release in this region, but has also furthered our understanding by
2 0 2
revealing the existence of multiple nAChR subtypes associated with excitatory 
amino acid release as well as their regional and cellular distribution. However, as a 
result of the inferences made from this thesis there are a number of specific 
questions that remain unanswered and would benefit from further experimentation. 
With respect to understanding the role nAChRs play in cognitive processes of the 
frontal cortex, those experiments that are relevant are outlined below.
• Determining specific nAChR subtypes mediating EAA release in the 
frontal cortex
Although this thesis ascertained that both a l  and 02* containing nAChR modulate 
the release of [3H]D-aspartate, the full subunit composition of these nAChRs was not 
ascertained. Presently, a-Bgt serves as the most specific tool for identifying 
homomeric a7 nAChRs in expression systems. Yet in native preparations, such as 
hippocampal slices, there are consistent (yet subtle) indications that although a l  
nAChR responses are blocked by a-Bgt, certain aspects of a l  nAChR function 
(such as desensitisation times and recovery times) do not coorelate with those 
displayed by homomeric a l  nAChR (Shao & Yakel, 2000; Sudweeks & Yakel, 2000) 
and therefore indicate the possible existence of a native heteromeric a T  containing 
nAChR. Heteromeric a702* nAChRs have been expressed in Xenopus oocytes and 
although the effects of a l  specific antagonists were not demonstrated, these 
receptors did demonstrate altered kinetic responses to choline compared to 
homomeric a l  nAChRs (Khiroug etal., 2002).
Pharmacological definition of the 02* containing nAChR modulating EAA release 
was determined in this thesis using the novel 02 selective agonist 5-IA-85380, in
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which release evoked by this agonist was completely blocked by DHpE; an a4p2* 
preferring antagonist, depending on the concentration used (Chavez-Noreiga et al., 
1997). Other nAChR ligands, such as Conotoxins from the marine snail of the genus 
Conus, display specificity for P2* containing nAChR that also contain other nAChR 
subunits, but have only been implicated in nAChR modulation of other 
neurotransmitters (see Mogg etal., 2002). It remains to be determined if these toxins 
inhibit the release of [3H]D-aspartate from rat frontal cortex synaptosomes and 
therefore provide more detail to the full subunit composition of nAChR mediating 
EAA release.
Both the expansion of the nicotinic pharmacopoeia and the expression of specific 
nAChR subunit combinations in expression systems (to ascertain ligand specificity) 
will help define the nAChR specificity of function in native systems. Over the past 50 
years of nicotinic research this effort has been a slow and arduous task, exampled 
by the development of only a handful of nAChR subtype specific pharmacological 
tools. However, one particular facet of nAChR drug design is the emergence of 
nAChR ‘potentiator’ ligands, nAChR specific tools that appear to potentiate the 
action of nAChR agonists by altering kinetic properties of the receptor.
An alternative option to drug design is the ability to induce specific nAChR subunit 
gene mutations or specific nAChR subunit knockouts in experimental animals. By 
comparison of altered functional responses to nAChR agonists or antagonists in 
mutant and wild-type animals this approach may provide useful information 
regarding the subunit composition of native nAChR in the specific regions of the 
brain examined. Similar to drug design efforts, this would be a difficult and time 
consuming process, further complicated by possible nAChR subunit compensatory 
mechanisms that exist to replace lost nAChR subunit expression.
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• nAChR and calcium
It has been recently made evident that the a7 nAChR-evoked presynaptic release of 
glutamate from presynaptic terminals innervating the CA3 region of the 
hippocampus relies heavily on the mobilisation of calcium from internal stores via a 
calcium-induced-calcium release (CICR) mechanism (Sharma & Vijaraghvan, 2003; 
see also Dajas-Bailador et al., 2002 for nAChR association with VOCC and CICR in 
SH-SY5Y cells). As described in Chapter 1 Section 1.5, nAChRs, in particular a7 
nAChR, are permeable to calcium and this may serve as the source of calcium 
mediating CICR. However, at present no evidence exists for the co-operation of 
nAChR with specific calcium channels in the modulation of EAA release (see Gray et 
al., 1996), although with respect to nAChR modulation of dopamine release, an 
association between nAChR and non-L-type calcium channels has been described 
(Soliakov et al., 1996). It is likely that nAChR activation may increase the 
presynaptic membrane potential sufficiently to activate VOCC’s and therefore further 
augment the influx of calcium into the presynaptic terminal to evoke the release of 
EAA. To examine this, the present superfusion system utilised in this thesis should 
be of sufficient means to explore the effect of nAChR-agonist evoked release of 
[3H]D-aspartate release from synaptosomes in the presence of calcium channel 
inhibitors as well as assess the contribution of internal calcium stores using 
ryanodine and lnsP3 receptor blockers.
• Anatomical studies of nAChR distribution
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Although the results presented in Chapter 4 support the presence of a l  and 02* 
nAChR on glutamatergic terminals and cell bodies of the rat frontal cortex, a number 
of questions, outside the scope of this thesis, remain unanswered (See Chapter 4 
Section 4.4.5 for overall summary of future perspectives in this area of nAChR 
research). In particular, the anatomical origination of glutamatergic afferents 
terminating in the frontal cortex is only inferred from the literature, but strong 
evidence supports the possibility that the difference in distribution of a l  and 02* 
nAChRs may be the result of glutamatergic afferents (expressing specific nAChR 
subtypes) originating from different areas of the rat CNS (See Chapter 4 Section 
4.4.4). Retrograde-tracer labelling experiments could provide the means to answer 
these questions; injection of fluorescent labelled retrograde tracer beads into specific 
regions of the frontal cortex where either a l  or 02* nAChR have been identified 
should reveal the cell bodies to which glutamatergic afferents originate from. It may 
even be possible to ascertain specific differences of nAChR subunit expression 
between the cells that are identified from retrograde-tracer labelling via single cell 
PCR experiments.
Other future perspectives for nAChR distribution experiments include electron 
microscopy studies that can reveal the specific location of nAChR subunits at pre 
and postsynaptic loci in the frontal cortex. Electron microscopy analysis of a l  
nAChR distribution has recently been aided by the development of gold-labelled a- 
Bgt, intricately detailing the presence of pre and postsynaptic a l  nAChR in the rat 
VTA and dorsal striatum (see I Jones, J Barik, MJ O’Neill and S Wonnacott. in 
preparation) and therefore the use of this tool could be extended to future studies of 
the frontal cortex.
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• Development of high-throughput assays for nAChR modulation of EAA
release?
The superfusion methodology used in this thesis certainly provides a direct and 
more expedient means of ascertaining presynaptic release of EAA evoked by 
nAChR than the indirect means employed by electrophysiological experiments. By 
increasing the number of chambers in standard superfusion systems, the ability to 
assess more conditions per experiment can be utilised. However, the number of 
conditions (and replicates of) can be exploited even further with the recent 
development of a 96 well plate-based superfusion system. 96 well-filtered plates 
have been utilised to demonstrate the nAChR modulation of noradrenaline release 
from a number of brain regions that show comparable results to standard 
superfusion systems (Anderson et al., 2000). It remains to be determined if this 
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